<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet xmlns="http://www.openarchives.org/OAI/2.0/">
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1422-0067</Issn>
      <Volume>27</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Aerobic Exercise Attenuates Epidermal Hyperplasia in an Obesity-Associated Psoriasiform Dermatitis Model</ArticleTitle>
    <FirstPage LZero="delete">2308</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin</FirstName>
        <LastName>Morizane</LastName>
        <Affiliation>Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daiki</FirstName>
        <LastName>Takezaki</LastName>
        <Affiliation>Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuma</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Immunology and Molecular Genetics, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuyasu</FirstName>
        <LastName>Baba</LastName>
        <Affiliation>Department of Immunology and Molecular Genetics, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Iseki</LastName>
        <Affiliation>Department of Immunology and Molecular Genetics, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshio</FirstName>
        <LastName>Kawakami</LastName>
        <Affiliation>Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Shiomi</LastName>
        <Affiliation>Department of Pathology, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyuki</FirstName>
        <LastName>Mukai</LastName>
        <Affiliation>Department of Immunology and Molecular Genetics, Kawasaki Medical School</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Obesity is an important risk factor for psoriasis, and clinical studies indicate that exercise interventions can improve disease severity. However, the mechanisms by which exercise influences psoriatic pathogenesis remain insufficiently understood. To investigate the effects of aerobic exercise on obesity-associated psoriasis, wild-type mice were fed a high-fat diet (HFD) for 7 weeks to induce obesity and subsequently underwent moderate-intensity treadmill running for 3 weeks. Psoriasiform dermatitis was induced by daily topical application of imiquimod (IMQ) to the skin for five consecutive days. HFD increased body weight, epididymal fat mass, and serum cholesterol. HFD-fed mice developed more severe IMQ-induced psoriatic skin changes compared with normal diet-fed mice. Treadmill exercise modestly reduced body weight gain and attenuated epidermal hyperplasia in HFD-fed mice. In contrast, inflammatory cytokine expression, including Tnfa, Il17a, and Il23a, showed modest increases in the skin of HFD-fed exercised mice, which did not parallel the improvement in epidermal hyperplasia. Overall, these findings indicate that while obesity exacerbates psoriasiform dermatitis, aerobic exercise ameliorates epidermal hyperplasia in obese mice without corresponding changes in inflammatory cytokine expression in the skin, suggesting that exercise may influence psoriatic skin changes through multiple metabolic and immunological pathways.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">psoriasis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">obesity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">aerobic exercise</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">imiquimod</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">high-fat diet</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2073-4360</Issn>
      <Volume>18</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effect of Universal Adhesives on Resin Cement–Fiber Post–Core Materials</ArticleTitle>
    <FirstPage LZero="delete">810</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masao</FirstName>
        <LastName>Irie</LastName>
        <Affiliation>Department of Biomaterials, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Department of Dental Biomaterials, Graduate School of Dentistry, Tohoku University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukinori</FirstName>
        <LastName>Maruo</LastName>
        <Affiliation>Department of Prosthodontics, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenraro</FirstName>
        <LastName>Akiyama</LastName>
        <Affiliation>Department of Occlusal and Oral Functional Rehabilitation, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kumiko</FirstName>
        <LastName>Yoshihara</LastName>
        <Affiliation>Health Research Institute, National Institute of Advanced Industrial Science and Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akimasa</FirstName>
        <LastName>Tsujimoto</LastName>
        <Affiliation>Department of Operative Dentistry, School of Dentistry, Aichi Gakuin University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Biomaterials, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>This study evaluated eleven resin cements used as core build-up materials by examining the following properties: (a) push-out force between root dentin and the fiber post; (b) pull-out force between the fiber post and the core build-up material; (c) shear bond strength of the resin cement to root dentin; (d) flexural strength of the resin cement; and (e) flexural modulus of elasticity of the resin cement. The purpose of this investigation was to clarify the relationships between recently available universal adhesives, core build-up materials, resin cements, and fiber posts. All experiments were performed at two evaluation periods: after 1 day of water storage (Base) and after 20,000 thermocycles (TC 20k). For the push-out test, simulated post spaces were prepared in single-rooted human premolars. The specimens were sectioned perpendicular to the long axis into 2 mm-thick slices and then subjected to push-out testing to assess the bond strength of the dentin–resin cement–fiber post complex. No significant differences in bonding performance were found between Base and TC 20k. These findings suggest that universal adhesives used for pretreatment of multiple substrates in fiber post cementation can provide not only strong but also durable adhesion over time.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">bonding performance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">universal adhesive</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fiber post</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">luting materials</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">root dentin</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1422-0067</Issn>
      <Volume>27</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Porphyromonas gingivalis Vesicles Control Osteoclast–Macrophage Lineage Fate</ArticleTitle>
    <FirstPage LZero="delete">831</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Elizabeth</FirstName>
        <LastName>Leon</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Periodontics and Endodontics, Division of Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Shindo</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maria Rita</FirstName>
        <LastName>Pastore</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoki</FirstName>
        <LastName>Kumagai</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Alireza</FirstName>
        <LastName>Heidari</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Elaheh Dalir</FirstName>
        <LastName>Abdolahinia</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoya</FirstName>
        <LastName>Ueda</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takumi</FirstName>
        <LastName>Memida</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ana</FirstName>
        <LastName>Duran-Pinedo</LastName>
        <Affiliation>Department of Oral Biology, College of Dentistry, University of Florida</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jorge</FirstName>
        <LastName>Frias-Lopez</LastName>
        <Affiliation>Department of Oral Biology, College of Dentistry, University of Florida</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xiaozhe</FirstName>
        <LastName>Han</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xin</FirstName>
        <LastName>Chen</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shengyuan</FirstName>
        <LastName>Huang</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Guoqin</FirstName>
        <LastName>Cao</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sunniva</FirstName>
        <LastName>Ruiz</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jan</FirstName>
        <LastName>Potempa</LastName>
        <Affiliation>Department of Oral Immunology and Infectious Diseases, School of Dentistry, University of Louisville</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihisa</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University, Fort Lauderdale, FL 33314, USA</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Porphyromonas gingivalis (Pg), a keystone pathogen of chronic periodontitis, releases outer membrane vesicles (OMVs) that act as nanoscale vehicles to disseminate virulence factors within periodontal tissues and systemically beyond the oral cavity. Although Pg-OMVs are increasingly recognized as critical mediators of host–pathogen interactions, their effects on the differentiation and function of monocyte–macrophage/osteoclast lineage cells remain unclear. Here, we examined the impact of Pg-OMVs on the differentiation of RAW264.7 monocyte/macrophage-like cells into osteoclasts (OC) and/or macrophages (MΦ) in the presence of receptor activator of nuclear factor-κB ligand (RANKL). OMVs were isolated from Pg W83 and applied to RANKL-primed RAW264.7 cells using three distinct stimulation schedules: (1) simultaneous treatment with Pg-OMVs and RANKL at Day 0; (2) RANKL priming at Day 0 followed by Pg-OMV stimulation at Day 1; and (3) RANKL priming at Day 0 followed by Pg-OMV stimulation at Day 3. In all schedules, cells were cultured for 7 days from the initial RANKL exposure. Remarkably, simultaneous exposure to Pg-OMVs and RANKL (Schedule 1) markedly suppressed osteoclastogenesis (OC-genesis) while promoting M1 macrophage polarization. In contrast, delayed Pg-OMV stimulation of RANKL-primed cells (Schedules 2 and 3) significantly enhanced OC-genesis while reducing M1 polarization. These schedule-dependent effects were consistent with altered expression of osteoclastogenic markers, including dc-stamp, oc-stamp, nfatc1, and acp5. Importantly, a monoclonal antibody against OC-STAMP counteracted the Pg-OMV-induced upregulation of OC-genesis in Schedules 2 and 3. Furthermore, levels of Pg-OMV phagocytosis were inversely correlated with osteoclast formation. Finally, co-stimulation with RANKL and Pg-OMVs (Schedule 1) enhanced macrophage migratory capacity, whereas delayed stimulation with Pg-OMVs (Schedules 2 and 3) did not. Collectively, these findings indicate that Pg-OMVs exert stage-specific effects on the OC/MΦ lineage: stimulation at early stages of RANKL priming suppresses OC-genesis and promotes M1 polarization, whereas stimulation at later stages enhances OC-genesis without inducing M1 differentiation. Thus, Pg-OMVs may critically influence the fate of the OC/MΦ unit in periodontal lesions, contributing to disease progression and tissue destruction.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Porphyromonas gingivalis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">outer membrane vesicle</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">periodontitis pathogenesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">macrophage polarization</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">osteoclastogenesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">OC/MΦ unit</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1422-0067</Issn>
      <Volume>27</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>CXCR2-Dependent Infiltration of Tumor-Associated Neutrophils Is Linked to Enhanced CD8+ T Cell Effector Function and Reduced Lung Metastasis in 4T1 Breast Cancer</ArticleTitle>
    <FirstPage LZero="delete">3143</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tiantian</FirstName>
        <LastName>Li</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teizo</FirstName>
        <LastName>Yoshimura</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miao</FirstName>
        <LastName>Tian</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Gakushi</FirstName>
        <LastName>Nishida</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chunning</FirstName>
        <LastName>Li</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayoshi</FirstName>
        <LastName>Fujisawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Triple-negative breast cancer (TNBC) is characterized by prominent neutrophil infiltration; however, its significance remains controversial. Here, we investigated the role of neutrophil chemoattractant receptors in TNBC progression and metastasis. In contrast to wild-type (WT), Fpr1−/−, and Fpr2−/− mice, neutrophils were almost completely absent in 4T1 tumors from Cxcr2−/− mice, indicating a dominant role for CXCR2 in the recruitment of tumor-associated neutrophils, leading us to use Cxcr2−/− mice for further studies. Primary tumor growth was comparable between WT and Cxcr2−/− mice, whereas lung metastasis was significantly increased in Cxcr2−/− mice, with reduced expression of inflammatory cytokines, chemokines and cytotoxic molecules, including granzyme B and perforin, in primary tumors and metastatic lungs of Cxcr2−/− mice. In vitro, WT, but not Cxcr2−/−, neutrophils enhanced CD8+ T cell activation, partly via ICAM-1, and directly induced tumor cell death, supporting their anti-tumor function. To assess clinical relevance, transcriptomic data were analyzed. High neutrophil infiltration combined with elevated CXCR2 expression, and to a lesser extent CXCR1 expression, was associated with improved prognosis in patients with basal-like BC that largely overlaps with TNBC. Collectively, these findings suggest that CXCR2-mediated neutrophil recruitment exerts protective, anti-tumor effects and may represent a new prognostic marker for TNBC patients.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">breast cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">neutrophils</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CD8+ T cells</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">chemokines</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">chemokine receptors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tumor microenvironment</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0971-5894|0974-0430</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Suppression of salt-enhanced apoplastic flow by salicylic acid in rice</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Md. Asadulla Al</FirstName>
        <LastName>Galib</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maoxiang</FirstName>
        <LastName>Zhao</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshimasa</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiko</FirstName>
        <LastName>Hirai</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshitaka</FirstName>
        <LastName>Nakashima</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shintaro</FirstName>
        <LastName>Munemasa</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Izumi C.</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiyuki</FirstName>
        <LastName>Murata</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Salinity enhances apoplastic flow, resulting in an increment of Na+ uptake and a lower K+/Na+ ratio. Salicylic acid (SA) plays an important role in improving salinity tolerance in plants. The effect of exogenous SA on apoplastic flow in salt-treated rice seedlings was studied using an apoplastic tracer, 8-hydroxy-1,3,6-pyrenetrisulphonic acid (PTS) in light. Application of NaCl at 25 mM to the hydroponic solution significantly increased PTS uptake, while 25 mM NaCl did not affect seedling growth. Application of 25 mM NaNO3 increased PTS uptake to the same degree. Salinity significantly increased sodium (Na+) content but had no significant effect on potassium (K+) content, resulting in a lower K+/Na+ ratio. The application of SA at 0.05 mM and 0.1 mM to the hydroponic solution reduced Na-enhanced PTS uptake. Salicylic acid at 0.05 mM and 0.1 mM significantly reduced Na+ content and slightly increased K+ content in the shoots of rice seedlings, resulting in a higher K+/Na+ ratio. However, SA at up to 0.1 mM did not increase SA contents in shoots under salt stress. These results suggest that exogenous SA reduces Na+ uptake by suppressing Na+-enhanced apoplastic flow in rice seedlings. These findings provide insight into modulation of Na+ transport pathways from roots to shoots by SA and may allow us to utilize brackish water for rice cultivation and to improve salt-tolerant rice through suppression of salt-enhanced apoplastic flow by chemicals such as salicylic acid.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Apoplastic flow</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Salicylic acid</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Rice</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Salinity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Trisodium-8-hydroxy-1,3,6-pyrenetrisulphonic acid</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Institute of Electrical and Electronics Engineers (IEEE)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2169-3536</Issn>
      <Volume>14</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Self-Adaptive Framework for Deploying Machine Learning Systems Without Ground-Truth Data at Runtime</ArticleTitle>
    <FirstPage LZero="delete">30309</FirstPage>
    <LastPage>30326</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kento</FirstName>
        <LastName>Furukawa</LastName>
        <Affiliation>Graduate School of Information Science and Technology, Osaka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Nakagawa</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuhiro</FirstName>
        <LastName>Tsuchiya</LastName>
        <Affiliation>Graduate School of Information Science and Technology, Osaka University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>In recent years, the practical application of machine learning technology has rapidly progressed, accelerating its adoption across various fields. In this context, studies into the effective operation of machine learning systems in real-world environments have become essential. In actual operational settings, the distribution of input data often changes over time, leading to a significant decline in the predictive performance of models. Additionally, the lack of ground-truth data for test data during operation can sometimes make adaptation through retraining difficult. This study proposes a framework that autonomously adapts to changes in input data distribution, even in environments where ground-truth data for test data is unavailable during operation. This framework analyzes the distribution of input data and selects the appropriate predictive model based on the state of the distribution. To ensure optimal model selection, the framework employs two complementary approaches: 1) dynamically switching between multiple pre-trained models with different feature sets according to environmental changes and 2) building ensemble models based on the distribution of the test data. These approaches enable the framework to autonomously adapt to shifts in data distribution, even in operational settings where ground-truth data is unavailable. Evaluation experiments using both simulated and real-world data assessed the predictive performance of the proposed method through metrics such as R2, RMSE, and MAE. Compared to conventional single model predictions, the proposed method consistently demonstrated higher accuracy. These results indicate that the proposed approach effectively adapts to data distribution shifts in operational environments where ground-truth data is unavailable.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Self-adaptive systems</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">frameworks</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">machine learning</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山大学法学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-3050</Issn>
      <Volume>75</Volume>
      <Issue>3-4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>自殺関与と同意殺人</ArticleTitle>
    <FirstPage LZero="delete">456</FirstPage>
    <LastPage>439</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Shiotani</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山大学法学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-3050</Issn>
      <Volume>75</Volume>
      <Issue>3-4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>2024 Irish Dáil Éireann Election: An Analysis of NEDS 2024 Data</ArticleTitle>
    <FirstPage LZero="delete">494</FirstPage>
    <LastPage>457</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Narihiro</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山大学法学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-3050</Issn>
      <Volume>75</Volume>
      <Issue>3-4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>日本独自の違憲審査基準論の可能性</ArticleTitle>
    <FirstPage LZero="delete">586</FirstPage>
    <LastPage>496</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Ito</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山大学教育推進機構 教師教育開発センター</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2186-1323</Issn>
      <Volume>16</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>説明的文章の指導における「内省」を促す批判的読み ―高等学校１年生を対象として―</ArticleTitle>
    <FirstPage LZero="delete">15</FirstPage>
    <LastPage>29</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yumi</FirstName>
        <LastName>SAISHO</LastName>
        <Affiliation>Graduate School of Education (Professional Degree Corse), Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masafumi</FirstName>
        <LastName>IKEDA</LastName>
        <Affiliation>Faculty of Education, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/CTED/70357</ArticleId>
    </ArticleIdList>
    <Abstract>　批判的読みは，現代では欠かせない能力であり，学習指導要領にも明記されている。近年，批判的読みの指導に関する研究がなされているものの，内容的な価値の検討や社会的な文脈のなかで捉えることが希薄だとする指摘や，「反省性」という観点に着目した批判的読みを求める声もある。そこで，本稿では，文章そのものを批判的に読むだけでなく，自身の持っている考えをも批判的に捉える（内省する）ことを促す授業を開発した。その手立てとして，複数の社会認識が存在する二つの教材の読み比べたうえで，対立する立場からの意見交換を行うことや，教材に対する評価の記述，その記述（自己の読み）を学習者自身が評価するといった活動を取り入れた。学習者の記述の分析からは，意識的な内省に至らなかった学習者も見受けられたものの，約６割の学習者の記述には変容が見られ，用いた手立ては効果があったと推測できることを指摘した。</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">反省性 (reflectiveness)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">情意的性向 (affective disposition)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">複数テクスト (multiple texts)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">「現代の国語」 (“Contemporary Japanese Language”)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">生物多様性 (biodiversity)</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1432-0851</Issn>
      <Volume>75</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium</ArticleTitle>
    <FirstPage LZero="delete">84</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Yanagisawa</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Kawada</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Tsujino</LastName>
        <Affiliation>Department of Urology, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoichi</FirstName>
        <LastName>Maenosono</LastName>
        <Affiliation>Department of Urology, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shingo</FirstName>
        <LastName>Toyoda</LastName>
        <Affiliation>Department of Urology, Faculty of Medicine, Kindai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuhisa</FirstName>
        <LastName>Nukaya</LastName>
        <Affiliation>Department of Urology, Fujita-Health University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Morinaka</LastName>
        <Affiliation>Department of Urology, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keita</FirstName>
        <LastName>Tamura</LastName>
        <Affiliation>Department of Urology, Hamamatsu Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wataru</FirstName>
        <LastName>Fukuokaya</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumihiko</FirstName>
        <LastName>Urabe</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Murakami</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Bekku</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyoshi</FirstName>
        <LastName>Takahara</LastName>
        <Affiliation>Department of Urology, Fujita-Health University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazutoshi</FirstName>
        <LastName>Fujita</LastName>
        <Affiliation>Department of Urology, Faculty of Medicine, Kindai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruhito</FirstName>
        <LastName>Azuma</LastName>
        <Affiliation>Department of Urology, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoo</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teruo</FirstName>
        <LastName>Inamoto</LastName>
        <Affiliation>Department of Urology, Hamamatsu Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazumasa</FirstName>
        <LastName>Komura</LastName>
        <Affiliation>Department of Urology, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose Immune checkpoint inhibitor (ICI)-based combination therapy is a standard first-line treatment for metastatic renal cell carcinoma (mRCC), with combinations such as nivolumab plus cabozantinib (Nivo + Cabo) and pembrolizumab plus lenvatinib (Pem + Len) demonstrating favorable oncologic outcomes. However, no direct comparisons between these two regimens have been conducted. This study aimed to compare the safety and oncologic outcomes of Nivo + Cabo and Pem + Len in patients with mRCC.&lt;br&gt;
Methods This retrospective study included 185 patients with mRCC treated with Nivo + Cabo (n = 81) or Pem + Len (n = 104) between January 2018 and June 2025 across multiple institutions. The primary outcome was a comparison of treatment-related adverse events (TrAEs). Oncologic outcomes, including objective response rate (ORR), progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS), were compared using one-to-one propensity score matching.&lt;br&gt;
Results Any-grade TrAEs occurred in 90% of patients in the Nivo + Cabo group and 92% in the Pem + Len group (p = 0.6). Severe TrAEs (grade ≥ 3) were more frequent in the Pem + Len group (44%) than in the Nivo + Cabo group (30%, p = 0.048). Tyrosine kinase inhibitor dose reduction and treatment discontinuation rates were similar between groups. In the matched cohort (Nivo + Cabo: n = 74; Pem + Len: n = 74), ORRs were comparable (66% vs. 71%, p = 0.6). With a median follow-up of 17 months, no significant differences were observed in PFS (p = 0.4), CSS (p = 0.9), or OS (p = 0.5).&lt;br&gt;
Conclusions Nivo + Cabo and Pem + Len demonstrated similar oncologic efficacy as first-line treatments for mRCC. However, Pem + Len was associated with more severe TrAEs. Careful toxicity management and shared decision-making are essential when selecting ICI-based combinations.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Metastatic renal cell carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Immune checkpoint inhibitor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pembrolizumab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Lenvatinib</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nivolumab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cabozantinib</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2192-4449</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A case of tubulointerstitial nephritis with infiltration of neutrophils and interleukin-17-positive cells associated with Behçet’s disease</ArticleTitle>
    <FirstPage LZero="delete">35</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Naruhiko</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Natsuki</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Katsuyama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Tanabe</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruhito A.</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Behçet’s disease (BD) is a non-infectious inflammatory condition characterized by neutrophilic infiltration. In addition to primary symptoms, including oral and genital ulcers, ocular involvement, and skin lesions, BD can also affect various organs. However, renal involvement, particularly in tubulointerstitial nephritis, has rarely been described. Herein, a rare case of acute tubulointerstitial nephritis in a patient clinically diagnosed with BD is reported. The renal lesion presented with other symptoms of BD and fever, and was considered to be BD-related due to the presence of neutrophilic infiltration and its responsiveness to BD-directed therapy. Alterations in T-helper (Th) 1, Th2, and Th17 cytokine profiles are associated with BD activity. Interleukin (IL)-17 plays a central role in neutrophil activation, and recent studies have demonstrated a strong correlation between IL-17A levels and BD activity. In the present case, elevated serum IL-17A levels and infiltration of IL-17A-positive cells into the renal tissue reflected an active phase of BD and a BD-associated renal lesion.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Tubulointerstitial nephritis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Behçet’s disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Neutrophils</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Interleukin-17</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">T-helper (Th) 1/Th2/Th17  cytokines</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>16</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Tribolium castaneum with longer duration of tonic immobility have more variations corresponding to the human Parkinson’s disease genomic region</ArticleTitle>
    <FirstPage LZero="delete">8840</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>NODAI Genome Research Center, Tokyo University of Agriculture</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Sasaki</LastName>
        <Affiliation>Graduate School of Agriculture, Tamagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Yajima</LastName>
        <Affiliation>NODAI Genome Research Center, Tokyo University of Agriculture</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahisa</FirstName>
        <LastName>Miyatake</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Parkinson’s disease (PD) is a common neurodegenerative syndrome characterized by the loss of dopaminergic neurons and is also a progressive neurodegenerative disorder that is characterized by dopamine deficiency. We established strains artificially selected for longer and shorter durations of tonic immobility, an antipredator behavior that has received much attention recently, in the red flour beetle, Tribolium castaneum, a model insect species for molecular analyses different from Drosophila melanogaster. Previous studies have shown that the long strains (L-strain) have significantly lower levels of dopamine expression in the brain than the short strains (S-strain) and that they have an abnormal pattern of locomotor activity. Furthermore, previous studies have shown that administering dopamine to L-strain beetles reduces the duration of tonic immobility. Transcriptome analysis of brain and thorax of the L- and S-strains also showed differences in mRNA expression of genes involved in dopamine synthesis and tyrosine metabolism. These results indicate that the phenotype and molecular basis of the L-strain are similar to those of Parkinson’s syndrome symptoms. In order to establish a link between T. castaneum and PD, we compared the DNA sequences of the L- and S-strains to human genes affecting dopaminergic pathways. The DNA comparison revealed many mutated regions in these genes in the L-strain. We discuss the relationship between dopaminergic pathway genes and PD-like phenotypes across humans, Drosophila, and the red flour beetle.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2398-8835</Issn>
      <Volume>9</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effects of Overload on Imiquimod‐Induced Psoriasis Model Mice: A Basic Experimental Study</ArticleTitle>
    <FirstPage LZero="delete">e72040</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tomoki</FirstName>
        <LastName>Furutani</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Section of Medicine, Division of Medicine, Dentistry, and Pharmaceutical Sciences, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taichi</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Asahi</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Okayama University Medical School Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Mashima</LastName>
        <Affiliation>Okayama University Medical School Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Natsumi</FirstName>
        <LastName>Yukihiro</LastName>
        <Affiliation>Okayama University Medical School Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoki</FirstName>
        <LastName>Kusakabe</LastName>
        <Affiliation>Okayama University Medical School Faculty of Medicine Okayama Japan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Nakamichi</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aki</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Nishida</LastName>
        <Affiliation>Locomotive Pain Center, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background and Aim: Psoriasis is a skin disorder complicated by arthritis and enthesitis. The cytokines interleukin (IL)-17, IL-23, and tumor necrosis factor (TNF)-α are reportedly key effectors of psoriasis. Additionally, gamma delta (γδ) T cells exacerbate inflammation by producing inflammatory cytokines such as IL-17 and TNF-α. However, details regarding the mechanisms linking pathogenesis and mechanical stress remain unclear. This study aimed to investigate the effect of strenuous exercise on the pathology of psoriasis using mouse models of imiquimod (IMQ)-induced psoriasis.&lt;br&gt;
Methods: Twenty mice were randomly assigned to four groups: IMQ − TRED− (control), IMQ − TRED+ (treadmill running mice), IMQ + TRED− group (IMQ treated mice), and IMQ + TRED+ group (IMQ treated and treadmill running mice). The tissue sections from back skin and thymus were immunostained with antibodies against IL-17, IL-23, and γδ T cells. Shoulder sections were stained using hematoxylin and eosin, and Toluidine Blue and Picrosirius Red. Additionally, the shoulder tissue sections were immunostained with antibodies against TNF-α and matrix metalloproteinase (MMP)-13. Serum cytokine level was measured to evaluate systemic inflammation.&lt;br&gt;
Results: Strenuous exercise exacerbated pathological changes associated with psoriasis, including increased γδ T cell infiltration and upregulated IL-17 and IL-23 expression in the skin, as well as enhanced γδ T cell development and IL-17 expression in the thymus. Although strenuous exercise did not further worsen the modified PASI scores, histological and immunological markers of inflammation were significantly enhanced. Serum levels of TNF-α and IL-17 were significantly elevated in IMQ-induced psoriasis model mice. Moreover, pathological changes induced by strenuous exercise were observed in the enthesis, including angiogenesis and upregulated expression of TNF-α and MMP-13.&lt;br&gt;
Conclusion: This study revealed that strenuous exercise exacerbates pathological changes in IMQ-induced psoriasis model mice.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">enthesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">psoriasis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">strenuous exercise</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1478-811X</Issn>
      <Volume>24</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>MMP-3 cleavage of Lamin A induces pro-migratory nuclear deformity, nucleophagy, and their autophagic secretion with extracellular vesicles in metastatic cancer</ArticleTitle>
    <FirstPage LZero="delete">146</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takanori</FirstName>
        <LastName>Eguchi</LastName>
        <Affiliation>Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eman A.</FirstName>
        <LastName>Taha</LastName>
        <Affiliation>Department of Biochemistry, Faculty of Science, Ain Shams University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Vikas</FirstName>
        <LastName>Tiwari</LastName>
        <Affiliation>Council of Scientific &amp; Industrial Research-Indian Institute of Toxicological Research</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuki</FirstName>
        <LastName>Takebe</LastName>
        <Affiliation>Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Lizi</FirstName>
        <LastName>Xing</LastName>
        <Affiliation>Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chiharu</FirstName>
        <LastName>Sogawa</LastName>
        <Affiliation>Department of Food and Health Sciences, Faculty of Environmental Studies, Hiroshima Institute of Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kuniaki</FirstName>
        <LastName>Okamoto</LastName>
        <Affiliation>Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Stuart K.</FirstName>
        <LastName>Calderwood</LastName>
        <Affiliation>Division of Molecular and Cellular Biology, Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases that cleave a plethora of substrates, including components of the extracellular matrix and cell-surface-associated proteins, as well as intracellular targets. MMPs have also been found in extracellular vesicles (EVs), such as exosomes. MMP-3 promotes tumor growth, epithelial-to-mesenchymal transition, genome instability, migration, invasion, and metastasis of cancer cells, and nuclear MMP-3 controls gene transcription. Intranuclear proteolysis by MMPs may significantly alter cancer progression. However, the nuclear substrates of MMP-3 have not been well investigated. In this study, we performed proteomic analyses to identify the nuclear substrates and EV proteins regulated by MMP-3. While rabidly metastatic colon cancer (LuM1) three-dimensionally cultured tumoroids secreted EVs containing 30 protein types, including Lamin A (LMNA), MMP-3, fibronectin (FN1), HSPA8 (Hsc70), β-actin (ACTB), and vimentin (VIM), CRISPR/Cas9-based knockout of MMP-3 reduced the secretion of these proteins in EVs. Notably, EV-bound cleaved Lamin secretion was confirmed by immunoelectron microscopy. Also, MMP-3 formed proteolytic dimers via its hemopexin-like repeat domains in nuclei. Many nuclear MMP-3-binding proteins, including Lamin A/C, histones, topoisomerases, and hnRNPs, were screened by co-immunoprecipitation followed by proteomics. Proteolytic MMP-3 overexpression generated a C-terminal 30-kDa fragment of Lamin A, whose cleavage site was defined via structural analysis. MMP-3 digestion of Lamin A induced nuclear deformity (atypia) required for cell migration in confined space. The cleaved Lamin A and MMP-3 were transported with autophagosomes (LC3B+), nucleophagosomes, and amphisomes (CD63 + LC3B+) and co-secreted with EVs. Proteolytic MMP-3 also induced nuclear speckles of Lamin A, suggesting their roles in transcription and splicing. Clinical analysis revealed that high expressions of MMP3 and LMNA were significantly seen in head and neck squamous cell carcinoma (HNSC) than in the other 16 cancer types, and predicted poor prognosis of patients suffering from HNSC, pancreatic, rectum and lung adenocarcinomas at specific stages. Immunohistochemistry revealed that nuclear MMP-3 and cleaved Lamin were significantly higher expressed in stage IV metastatic HNSC cases than in stage I non-metastatic cases. Taken together, MMP3-cleavage of Lamin A induces nuclear deformity, nucleophagy, and their autophagic co-secretion with EVs in metastatic cancer. Also, high expression of MMP-3 and secretion of Lamin A can predict poor prognosis in multiple cancer types at specific stages.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Lamin A (LMNA)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Matrix metalloprotease (MMP)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Proteolysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Extracellular vesicle (EV)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Exosome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Autophagy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Amphisome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Proteome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nuclear deformity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Migration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Metastatic cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Head and neck squamous cell carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Colorectal cancer</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2055-0294</Issn>
      <Volume>12</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Association between the incidence of infusion-related reactions by obinutuzumab and the dose of corticosteroid as premedication: a multicenter retrospective cohort study</ArticleTitle>
    <FirstPage LZero="delete">27</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Ohtsubo</LastName>
        <Affiliation>Department of Pharmacy, Japanese Red Cross Kyoto Daini Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Integrated Clinical and Basic Pharmaceutical Sciences, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Saori</FirstName>
        <LastName>Matumoto</LastName>
        <Affiliation>Department of Pharmacy, Japanese Red Cross Osaka Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaori</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Faculty of Pharmacy, Meijo University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuzuka</FirstName>
        <LastName>Sasa</LastName>
        <Affiliation>Department of Pharmacy, Kindai University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosuke</FirstName>
        <LastName>Tomishima</LastName>
        <Affiliation>Department of Pharmacy, Japanese Red Cross Kyoto Daiichi Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Dote</LastName>
        <Affiliation>Department of Pharmacy, Kyoto-Katsura Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katuya</FirstName>
        <LastName>Makihara</LastName>
        <Affiliation>Department of Pharmacy, Yodogawa Christian Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Wakasugi</LastName>
        <Affiliation>Department of Pharmacy, Shiga University of Medical Science Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsutomu</FirstName>
        <LastName>Mitsuie</LastName>
        <Affiliation>Department of Pharmacy, Japanese Red Cross Otsu Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kouhei</FirstName>
        <LastName>Yamagiwa</LastName>
        <Affiliation>Department of Pharmacy, Saiseikai Shiga Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuo</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Pharmacy, Japan Baptist Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Hasegawa</LastName>
        <Affiliation>Department of Pharmacy, Rakuwakai Otowa Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuhiko</FirstName>
        <LastName>Uoshima</LastName>
        <Affiliation>Department of Hematology, Japanese Red Cross Kyoto Daini Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yumi</FirstName>
        <LastName>Kitahiro</LastName>
        <Affiliation>Department of Pharmacy, Kobe University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kanji</FirstName>
        <LastName>Tomogane</LastName>
        <Affiliation>Department of Pharmacy, Japanese Red Cross Kyoto Daini Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Premedication with corticosteroids is recommended for prophylaxis against infusion-related reactions (IRRs) caused by obinutuzumab despite a lack of solid evidence regarding the dose of corticosteroids.&lt;br&gt;
Methods The incidence rates of IRR in the high-dose and low-dose corticosteroid groups were investigated and compared using Student’s t-test.Univariable and multivariable logistic regression analyses were performed on patients to explore the risk of developing IRRs with obinutuzumab.&lt;br&gt;
Results The incidence of IRRs in the high-dose and low-dose corticosteroid groups at the initial administration of obinutuzumab was 27.0% (41/152) and 48.4% (31/64), respectively, indicating that the high-dose group had a lower incidence of IRRs (p = 0.002). The incidence of IRRs at the initial administration of obinutuzumab was significantly associated with the administration of first-generation histamine 1 receptor antagonist (OR = 3.31, 95% CI: 1.16–9.47; reference: second-generation histamine 1 receptor antagonist), hydrocortisone (OR = 7.21, 95% CI: 1.57–33.15; reference: dexamethasone), and methylprednisolone (OR = 3.99, 95% CI :1.13–14.10; reference: dexamethasone), although no association was found with the lower dose of corticosteroids.&lt;br&gt;
Conclusions Although no association was found between corticosteroid dosage and IRR when considering multiple factors, dexamethasone may be a better option than hydrocortisone or methylprednisolone for preventing IRR. Additionally, second-generation H1-receptor antagonists may be a better option than first-generation drugs. Certain combinations of premedications may influence infusion reaction incidence.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Obinutuzumab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Infusion-related reaction</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Premedication</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Corticosteroids</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Histamine 1 receptor antagonists</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1478-6362</Issn>
      <Volume>28</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Real-world comparative effectiveness of sarilumab versus Janus kinase inhibitors as monotherapy in rheumatoid arthritis</ArticleTitle>
    <FirstPage LZero="delete">32</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuji</FirstName>
        <LastName>Nozaki</LastName>
        <Affiliation>Department of Hematology and Rheumatology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Kishimoto</LastName>
        <Affiliation>Department of Hematology and Rheumatology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsu</FirstName>
        <LastName>Itami</LastName>
        <Affiliation>Department of Hematology and Rheumatology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Tomita</LastName>
        <Affiliation>Department of Hematology and Rheumatology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yumiko</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Kotani</LastName>
        <Affiliation>Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tohru</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Hidaka</LastName>
        <Affiliation>Rheumatology Center, Miyazaki Zenjinkai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoichi</FirstName>
        <LastName>Hino</LastName>
        <Affiliation>Department of Rheumatology and Clinical Immunology, Izumi City General Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Miyamoto</LastName>
        <Affiliation>Miyamoto Internal Medicine and Rheumatology Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Miyake</LastName>
        <Affiliation>Department of General Internal Medicine, Tenri Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazunari</FirstName>
        <LastName>Hatta</LastName>
        <Affiliation>Department of General Internal Medicine, Tenri Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Mamoto</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Graduate School of Medicine, Osaka Metropolitan University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yutaro</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Center for Senile Degenerative Disorders (CSDD), Osaka Metropolitan University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Okano</LastName>
        <Affiliation>Center for Senile Degenerative Disorders (CSDD), Osaka Metropolitan University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takaichi</FirstName>
        <LastName>Okano</LastName>
        <Affiliation>Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Saegusa</LastName>
        <Affiliation>Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Horita</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Nishida</LastName>
        <Affiliation>Locomotive Pain Center, Faculty of Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Kinoshita</LastName>
        <Affiliation>Department of Hematology and Rheumatology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinya</FirstName>
        <LastName>Rai</LastName>
        <Affiliation>Department of Hematology and Rheumatology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Sarilumab (SAR), an interleukin-6 receptor inhibitor (IL-6Ri), and Janus kinase inhibitors (JAKi) are approved options for rheumatoid arthritis (RA) when methotrexate (MTX) cannot be used. Real-world evidence for MTX-free monotherapy remains limited.&lt;br&gt;
Methods: We conducted a multicenter retrospective cohort study of RA patients receiving SAR or JAKi as MTX-free monotherapy. To reduce confounding, 1:1 propensity score matching was performed in the overall cohort (n = 252, 126 per group) and separately within treatment-line strata: Phase 2 first-line biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs: 45 per group), Phase 3 second-line b/tsDMARDs (53 per group), and Phase 3 ≥ third-line b/tsDMARDs (47 per group). Outcomes over 12 months included drug retention, change in Clinical Disease Activity Index (CDAI), glucocorticoid (GC) tapering and discontinuation, low disease activity (LDA, CDAI ≤ 10), and safety profiles. Predictors of LDA were evaluated with logistic regression. This multicenter real-world.&lt;br&gt;
Results: Across matched strata by prior b/tsDMARDs, retention and CDAI change did not differ significantly between SAR and JAKi through 12 months. When classified by cause, adverse events (AEs)-related discontinuation was higher with JAKi, yielding lower AE-specific retention. Both groups demonstrated GC sparing overtime, with a greater increase in GC discontinuation for SAR than for JAKi in Phase 2. Baseline predictors of achieving LDA at 12 months included higher C-reactive protein (CRP) and platelet count (Plt) in both groups, with additional associations of younger age and lower hemoglobin (Hb) in the SAR. In safety analyses, overall AEs were less frequent with SAR than with JAKi, driven by lower risks of infection including herpes zoster, while other categories were similarly infrequent.&lt;br&gt;
Conclusion: SAR and JAKi showed no statistically significant differences in 12-month retention or disease control in MTX-free monotherapy settings. Higher CRP and Plt with lower Hb, particularly in younger patients, identified better response to SAR and support biomarker guided selection between IL-6Ri and JAKi. In Phase 2, GC discontinuation with SAR suggests a practical strategy to reduce AEs while maintaining efficacy. Prospective studies should validate these findings and define actionable thresholds.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Rheumatoid arthritis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Methotrexate</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Biological DMARDs</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>BMJ</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2056-5933</Issn>
      <Volume>12</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Dental infection is associated with early relapse in patients with ANCA-associated vasculitis</ArticleTitle>
    <FirstPage LZero="delete">e006392</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shoichi</FirstName>
        <LastName>Nawachi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Katsuyama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshia</FirstName>
        <LastName>Miyawaki</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Moe</FirstName>
        <LastName>Sakamoto-Tokunaga</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Natsuki</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuya</FirstName>
        <LastName>Terajima</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kei</FirstName>
        <LastName>Hirose</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takato</FirstName>
        <LastName>Nakadoi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manami</FirstName>
        <LastName>Hirata-Watanabe</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keigo</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruki</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eri</FirstName>
        <LastName>Katsuyama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mariko</FirstName>
        <LastName>Takano-Narazaki</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigetomo</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken-Ei</FirstName>
        <LastName>Sada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a systemic autoimmune disease where infections can trigger relapses. Dental infections, being common and associated with systemic inflammation, may play a role in AAV relapse, though their impact remains unclear. We aimed to evaluate the association between severe dental infections and early relapse in patients with AAV.&lt;br&gt;
Methods This retrospective cohort study included patients newly diagnosed with AAV between January 2011 and July 2022. Patients with severe dental infections requiring tooth extraction were placed in the dental infection group, while the remaining patients were assigned to the control group. The primary outcome was defined as either vasculitis relapse or all-cause mortality within 1 year of treatment initiation. Adjusted HRs (aHRs) and 95% CIs were estimated using Cox proportional hazards models.&lt;br&gt;
Results A total of 93 patients were enrolled with a median age of 74 years. 41 patients (44.1%) had severe dental infections in this cohort. Over the 1-year follow-up period, 13 patients experienced a relapse and two died, resulting in a composite event rate of 20.9 per 100 person-years. Dental infection was independently associated with the composite outcome (aHR, 3.78 (95% CI 1.13 to 12.66); p=0.031). Exploratory analysis indicated that composite outcome rates were similar regardless of tooth extraction among patients with dental infections.&lt;br&gt;
Conclusions Severe dental infections were associated with increased risk of early relapse or mortality in AAV. These findings highlight the importance of early dental evaluation in AAV management.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>JMIR Publications Inc.</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2369-3762</Issn>
      <Volume>12</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Prescription Support Practice for Pharmacy Students: Pre-Post Educational Intervention Study</ArticleTitle>
    <FirstPage LZero="delete">e79545</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Fuka</FirstName>
        <LastName>Aizawa</LastName>
        <Affiliation>Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Yagi</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsukasa</FirstName>
        <LastName>Higashionna</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Hamano</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shimon</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshito</FirstName>
        <LastName>Zamami</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuaki</FirstName>
        <LastName>Shinomiya</LastName>
        <Affiliation>Department of Pharmaceutical Care and Clinical Pharmacy, Tokushima Bunri University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Niimura</LastName>
        <Affiliation>Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuhiro</FirstName>
        <LastName>Goda</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kei</FirstName>
        <LastName>Kawada</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Ishizawa</LastName>
        <Affiliation>Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: In the field of team-based care, pharmacists are vital for optimizing medication therapy. However, many medical professionals lack the opportunity to learn how to propose prescription changes with precision.&lt;br&gt;
Objective: This study aimed to address this knowledge gap by developing and assessing a new educational program for pharmacy students focused on prescription support and interprofessional collaboration.&lt;br&gt;
Methods: We recruited 191 fifth-year pharmaceutical students during the 2022‐2024 academic years. The program featured a 7-day intensive curriculum that included learning how to assist with prescriptions, analyzing clinical data, and engaging in role-playing exercises. A web-based questionnaire and a paper test were used to evaluate students’ awareness and knowledge both before and after the program. Statistical analyses were performed to verify the significance of changes; we utilized the Wilcoxon signed-rank test for the ordinal data derived from the specific behavioral objectives and 2-tailed paired t tests for the interval data from the knowledge tests. The magnitude of change was quantified using r for Wilcoxon tests and Cohen dz for 2-tailed t tests, with 95% CI calculated to ensure the stability and reliability of the observed results.&lt;br&gt;
Results: Analysis of the primary outcome specific behavioral objectives revealed statistically significant effects across all items (Wilcoxon signed-rank test; P&lt;.001). Effect sizes (r=0.505‐0.835) ranged from moderate to large, with particularly large effects observed in identifying contents issue (r=0.835, 95% CI 0.126-0.330; P&lt;.001). Knowledge test scores showed significant improvement in the following 3 subjects: pharmacology (r=−0.504, 95% CI –0.215 to 0.127; P&lt;.001), organic chemistry (r=0.254, 95% CI –0.148 to –0.193; P=.004), and communication (r=0.221, 95% CI –0.151 to –0.190; P=.01). No significant changes were observed in pathology or pharmacokinetics.&lt;br&gt;
Conclusions: This program provides strong evidence that practical, hands-on learning with hospital pharmacists helps improve pharmacy students’ professional skills and optimize pharmaceutical therapies in interprofessional care. By teaching pharmacists to effectively propose prescription changes, the program equips them to become integral members of interprofessional care, ultimately leading to optimized pharmaceutical care for patients.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">academic detailing</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pharmaceutical clinical practice</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">prescription support</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">professional education</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Interprofessional care</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2218-273X</Issn>
      <Volume>16</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Targeting the Gut in Sepsis: Therapeutic Potential of Medical Gases</ArticleTitle>
    <FirstPage LZero="delete">199</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Yumoto</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Obara</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromichi</FirstName>
        <LastName>Naito</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsunori</FirstName>
        <LastName>Nakao</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Sepsis is a life-threatening condition characterized by a dysregulated host response to infection, often resulting in multiorgan dysfunction. Among affected systems, the gastrointestinal tract plays a central role in sepsis progression by promoting systemic inflammation through impaired barrier function, immune imbalance, and microbiome alterations. Recent research has identified selected medical gases and gasotransmitters as promising therapeutic candidates for preserving gut integrity in sepsis. In particular, hydrogen, carbon monoxide, and hydrogen sulfide exhibit antioxidative, anti-inflammatory, and cytoprotective properties. These gases act through defined molecular pathways, including activation of Nrf2, inhibition of NF-κB, and preservation of tight junction integrity, thereby supporting intestinal barrier function. In addition, they influence immune cell phenotypes and autophagy, with indirect effects on the gut microbiome. Although most supporting evidence derives from preclinical models, translational findings and emerging safety data highlight the potential of gut-targeted gas-based strategies. This review summarizes current mechanistic and translational evidence for gut-protective medical gases in sepsis and discusses their integration into future organ-specific and mechanism-based therapeutic approaches.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">carbon monoxide</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gastrointestinal tract</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gut</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hydrogen</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hydrogen sulfide</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">sepsis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">septic shock</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1435-2451</Issn>
      <Volume>411</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The impact of liver transection depth on surgical difficulty in robotic versus laparoscopic limited liver resection (TAKUMI-5)</ArticleTitle>
    <FirstPage LZero="delete">22</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tomokazu</FirstName>
        <LastName>Fuji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosei</FirstName>
        <LastName>Takagi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Yasui</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atene</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeyoshi</FirstName>
        <LastName>Nishiyama</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuo</FirstName>
        <LastName>Nagai</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shohei</FirstName>
        <LastName>Yokoyama</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose Although robotic liver resection (RLR) has gained popularity worldwide, limited liver resection remains the mainstay of RLR. This study aimed to investigate the effect of parameters, including liver transection depth (LTD), on surgical difficulty in limited RLR compared with limited laparoscopic liver resection (LLR).&lt;br&gt;
Methods This retrospective study included 105 patients who underwent limited RLR (n = 56) or LLR (n = 49) at our institution between January 2018 and December 2024. After comparing outcomes of RLR and LLR, multivariate analyses were performed to examine effect of LTD on surgical difficulty (defined as prolonged operative time). Moreover, outcomes stratified by LTD cut-off values were compared between the groups.&lt;br&gt;
Results Median LTD was similar between groups (RLR vs. LLR: 2.6 vs. 2.6 cm, P = 0.77). LTD was significantly correlated with operative time for both procedures (RLR, R² = 0.07, P = 0.042; LLR, R² = 0.08, P = 0.046). Multivariate analyses demonstrated that LLR (odds ratio, 6.9; P &lt; 0.001) and LTD (odds ratio, 2.0; P = 0.004) were significant risk factors of surgical difficulty. Among patients with deeper LTD (&gt; 2.5 cm), the RLR group had significantly shorter operative time (145 vs. 231 min, P &lt; 0.001), less blood loss (nil vs. 100 mL, P = 0.006), and a higher rate of textbook outcomes (76.7% vs. 42.3%, P = 0.01).&lt;br&gt;
Conclusion This study investigated impact of LTD on surgical outcomes in patients who underwent limited RLR compared to those who underwent limited LLR. LTD may be a useful parameter for estimating surgical difficulty in limited RLR. Moreover, robotic surgery may be favorable for deeper and limited liver resections.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Robotic surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Laparoscopic surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Limited liver resection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Textbook outcome</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1462-8910</Issn>
      <Volume>27</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>D3 lymph node dissection in colon cancer patients aged 90 years and over: Is it justified? A multi‐institutional retrospective study</ArticleTitle>
    <FirstPage LZero="delete">e70269</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Fuminori</FirstName>
        <LastName>Teraishi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoe</FirstName>
        <LastName>Takanaga</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Inada</LastName>
        <Affiliation>Department of Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiharu</FirstName>
        <LastName>Mitsuhashi</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Toshima</LastName>
        <Affiliation>Department of Surgery, Kagawa Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Ohtani</LastName>
        <Affiliation>Department of Surgery, Saiseikai Okayama Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryosuke</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Surgery, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryohei</FirstName>
        <LastName>Shoji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>Setouchi Colorectal Neoplasm Registration study group collaborators</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Aim: The oncological benefit of D3 lymph node dissection (D3 LND) for colon cancer in patients aged ≥90 years remains unclear. This study aimed to evaluate the impact of D3 LND on outcomes in this specific, vulnerable population.&lt;br&gt;
Method: This retrospective cohort study evaluated 166 patients aged ≥90 years with pathological Stages II–III colon cancer undergoing non-D3 or D3 LND from a multicentre database (2011–2022). Postoperative complications, overall survival and cancer-specific survival were compared between LND groups using propensity score-weighted analyses.&lt;br&gt;
Results: D3 LND group had significantly more females and laparoscopic procedures. Operation time was longer, and blood loss was lower in the D3 LND group. Postoperative complications and severe complications were significantly fewer, and postoperative hospital stay was shorter in the D3 LND group. The number of harvested lymph nodes and distal margin was significantly higher in the D3 group. While unadjusted analysis showed better overall survival with D3 LND (p &lt; 0.001), adjusted cancer-specific survival showed no significant difference (p = 0.10). Adjusted mortality risk was significantly higher in the non-D3 group (p = 0.001).&lt;br&gt;
Conclusion: In nonagenarian colon cancer patients, D3 LND is safe and feasible without increasing complications, but lacks survival benefit. Careful consideration is warranted, and high-quality D2 LND must be consistently ensured when limited surgery is chosen.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">colon cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lymph node dissection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">nonagenarian</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">postoperative complication</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">survival benefit</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0964-2633</Issn>
      <Volume>70</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Prevalence and Modifiable Risk Factors of Dementia in People With Down Syndrome: Cross‐Sectional Study of Japan in Collaboration With the Intellectual Diversity for Goodness Research Consortium (INDIGO‐2019)</ArticleTitle>
    <FirstPage LZero="delete">329</FirstPage>
    <LastPage>336</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shintaro</FirstName>
        <LastName>Takenoshita</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seishi</FirstName>
        <LastName>Terada</LastName>
        <Affiliation>Department of Neuropsychiatry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomokazu</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Asahigawaso Research Institute, Social Welfare Corporation Asahigawaso</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taku</FirstName>
        <LastName>Kurozumi</LastName>
        <Affiliation>Asahigawaso Research Institute, Social Welfare Corporation Asahigawaso</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manabu</FirstName>
        <LastName>Takaki</LastName>
        <Affiliation>Department of Neuropsychiatry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryozo</FirstName>
        <LastName>Kuwano</LastName>
        <Affiliation>Asahigawaso Research Institute, Social Welfare Corporation Asahigawaso</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeru</FirstName>
        <LastName>Suemitsu</LastName>
        <Affiliation>Asahigawaso Research Institute, Social Welfare Corporation Asahigawaso</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: People with Down syndrome (DS) have a strong genetic predisposition to Alzheimer's disease (AD). However, the clinical burden and associated risk factors in diverse, non-Western populations remain less understood. This study aimed to investigate the prevalence of dementia in Japanese adults with DS and to identify modifiable clinical factors associated with dementia.&lt;br&gt;
Methods: This cross-sectional multicentre study surveyed 133 adults with DS (mean age 50.1 years) residing in 45 welfare facilities across Japan in 2019. Dementia was diagnosed by a consensus panel of physicians using established criteria (DSM-5, ICD-10, DC-LD) after comprehensive assessments, including the Japanese version of the Dementia Screening Questionnaire for Individuals with Intellectual Disabilities (DSQIID-J). Logistic regression analysis was performed to identify factors independently associated with dementia.&lt;br&gt;
Results: Forty-six participants (34.6%) were diagnosed with dementia. The prevalence rose sharply with age: 0% in their 30s, 30.8% in their 40s, 31.6% in their 50s and 65.5% in their 60s. After adjusting for covariates, older age, female sex, dyslipidaemia and visual impairment were independently associated with dementia.&lt;br&gt;
Conclusions: This study, the largest of its kind in Asia, confirms a high prevalence of dementia in institutionalized Japanese adults with DS. Crucially, this study is the first to identify dyslipidaemia and visual impairment as independent and potentially modifiable risk factors in this population. These findings highlight tangible targets for clinical interventions aimed at mitigating dementia risk in people with DS.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1863-9941</Issn>
      <Volume>52</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Preferential sacral fracture sites in fragility fractures of the pelvis type IVb and comparison of internal fixation methods: CT-based morphological mapping and finite element analysis</ArticleTitle>
    <FirstPage LZero="delete">72</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shuichi</FirstName>
        <LastName>Naniwa</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Section of Medicine, Division of Medicine, Dentistry and Pharmaceutical Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Yorimitsu</LastName>
        <Affiliation>Department of Musculoskeletal Traumatology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University,</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsubasa</FirstName>
        <LastName>Hasegawa</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Section of Medicine, Division of Medicine, Dentistry and Pharmaceutical Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teruhiko</FirstName>
        <LastName>Ando</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Section of Medicine, Division of Medicine, Dentistry and Pharmaceutical Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuichiro</FirstName>
        <LastName>Okuda</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Section of Medicine, Division of Medicine, Dentistry and Pharmaceutical Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shiro</FirstName>
        <LastName>Fukuoka</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kagawa Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Mochizuki</LastName>
        <Affiliation>Department of Emergency Health Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuaki</FirstName>
        <LastName>Yamakawa</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuichi</FirstName>
        <LastName>Nakahara</LastName>
        <Affiliation>Department of Musculoskeletal Health Promotion, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shiro</FirstName>
        <LastName>Hanakawa</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama Saidaiji Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose Fragility fractures of the pelvis (FFP) classified as Rommens-Hoffman type IVb are associated with spinopelvic dissociation and are generally considered to require surgical intervention. This study aimed to clarify the localization patterns of FFP type IVb and compare the biomechanical stability of different internal fixation techniques.&lt;br&gt;
Methods In this retrospective study, morphologic mapping of sacral fracture lines was performed in 36 patients with FFP type IVb. Based on the mapping results, a finite element (FE) model of FFP type IVb was developed to evaluate the biomechanical stability of ilio-sacral screw (ISS) fixation, trans-sacral screw (TSS) fixation, spinopelvic fixation (SPF; On each side, L5 pedicle screw was connected to two iliac screws with a rod, and the bilateral constructs were linked using a cross-connector.), and bilateral triangular fixation (one TSS at S1 combined with SPF mentioned above) using finite element analysis (FEA).&lt;br&gt;
Results Morphologic mapping showed that the sacrum fracture transverse line tended to pass between the S1-2 transverse lines. Although bilateral triangular fixation and SPF provided the highest stability in both U-type and H-type fractures, a TSS for U-type and two TSSs for H-type also demonstrated comparable levels of stability. ISS-based methods showed greater displacements.&lt;br&gt;
Conclusion TSS-based fixation may provide stability comparable to bilateral triangular fixation and SPF in FFP type IVb, with less invasiveness when anatomy permits. Further studies are needed to optimize treatment strategies for this complex injury.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Fragility fractures of the pelvis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Spinopelvic dissociation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Finite element analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Internal fixation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1364-6753</Issn>
      <Volume>27</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Compound heterozygosity of a novel missense variant and exonic deletion in hypomyelinating leukodystrophy 15</ArticleTitle>
    <FirstPage LZero="delete">16</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Mitsutake</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan Department of Neurology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan Department of Neurology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Orimo</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan Department of Neurology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunihiro</FirstName>
        <LastName>Ueda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan Department of Neurology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomonari</FirstName>
        <LastName>Seki</LastName>
        <Affiliation>Department of Neurology, Tokyo Teishin Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Shiio</LastName>
        <Affiliation>Department of Neurology, Tokyo Teishin Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Precision Medicine Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Harushi</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Radiology, School of Medicine, Jichi Medical University,</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Institute of Medical Genomics, International University of Health and Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Toda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan Department of Neurology</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Hypomyelinating leukodystrophy 15 (HLD15) results from biallelic pathogenic variants in EPRS1, but exonic deletions have not been reported. We describe a 40-year-old woman with mild intellectual disability, ataxia, dystonia, and MRI showing hypomyelination. Whole-exome sequencing identified a heterozygous missense variant in the prolyl-tRNA synthetase domain of EPRS1 (c.3430 C &gt; G; p.Leu1144Val, NM_004446.3), without second variant. Whole-genome sequencing revealed a heterozygous 220-bp deletion spanning exon 15 (c.1743-30_1932del), and segregation analysis confirmed compound heterozygosity. RT-PCR from lymphoblastoid cells demonstrated exon-15 skipping leading to a frameshift (p.Asn582Serfs*10) and nonsense-mediated decay, leaving predominant expression of the paternally inherited missense allele. These findings support loss-of-function for the deletion and classify c.3430 C &gt; G as likely pathogenic under ACMG/AMP criteria (PM1, PM2, PM3, PP3). This case represents the first exonic deletion reported in EPRS1. The relatively mild, adult-onset phenotype broadens both mutational and clinical spectra of HLD15 and highlights the importance of structural-variant anal</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Hypomyelinating leukodystrophy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">EPRS1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Structural variant</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Exon deletion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nonsense‑mediated decay</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Whole‑genome sequencing</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0165-5728</Issn>
      <Volume>414</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Immuno-deficient features of thymoma-associated myasthenia gravis patients with hypogammaglobulinemia: A condition comparable to Good's syndrome</ArticleTitle>
    <FirstPage LZero="delete">578885</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Saki</FirstName>
        <LastName>Nakashima</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, the University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaori</FirstName>
        <LastName>Sakuishi</LastName>
        <Affiliation>Department of Neurology, Teikyo University Chiba Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manato</FirstName>
        <LastName>Hara</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, the University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Reiko</FirstName>
        <LastName>Kawasaki</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, the University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Kakumoto</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, the University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Toda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, the University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Good's syndrome (GS) is a rare immunodeficiency disorder associated with thymoma, characterized by hypogammaglobulinemia and recurrent infections; however, its clinical significance in thymoma-associated myasthenia gravis (TAMG) remains unclear. We retrospectively reviewed 30 patients with TAMG admitted to our center between January 2010 and March 2022. We defined GS-like immunodeficiency as serum IgG below the institutional cutoff of 861 mg/dL and a history of two or more infections requiring antimicrobial treatment; 11 patients (36.7%) met this definition. Compared with the remaining patients, the GS-like group had higher incidences of malignancy (45.5% vs. 5.3%, p = 0.016) and autoimmune diseases other than MG (36.4% vs. 5.3%, p = 0.047), lower peripheral lymphocyte counts (median 1100/μL vs. 2200/μL, p = 0.0051), and more frequent airflow obstruction defined by one second to forced vital capacity ratio of less than 70% (60.0% vs. 5.3%, p = 0.0026). Five deaths occurred in the GS-like group, and none in the other; median survival from the first antimicrobial-treated infection was 5.0 years. These findings imply that TAMG patients with GS-like immunodeficiency have a worse prognosis, underscoring the need for close monitoring and timely adjustments of MG management. (189 words).</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Good's syndrome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Thymoma-associated myasthenia gravis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hypogammaglobulinemia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Immunodeficiency</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Prognosis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1546-0096</Issn>
      <Volume>23</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Comparison of clinical practices during the transitional and young adult phases between patients with oligoarticular/polyarticular juvenile idiopathic arthritis and those with rheumatoid arthritis in Japan</ArticleTitle>
    <FirstPage LZero="delete">120</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sho</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosuke</FirstName>
        <LastName>Shabana</LastName>
        <Affiliation>Department of Pediatrics, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiro</FirstName>
        <LastName>Matsui</LastName>
        <Affiliation>Department of Rheumatology Research, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomo</FirstName>
        <LastName>Nozawa</LastName>
        <Affiliation>Department of Pediatrics, Graduate School of Medicine, Yokohama City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuko</FirstName>
        <LastName>Sugita</LastName>
        <Affiliation>Department of Pediatrics, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Minako</FirstName>
        <LastName>Tomiita</LastName>
        <Affiliation>Department of Allergy and Rheumatology, Chiba Children’s Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuo</FirstName>
        <LastName>Nakagishi</LastName>
        <Affiliation>Department of Pediatric Rheumatology, Hyogo Prefectural Kobe Children’s Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichi</FirstName>
        <LastName>Yamasaki</LastName>
        <Affiliation>Department of Pediatrics, Kagoshima University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroaki</FirstName>
        <LastName>Umebayashi</LastName>
        <Affiliation>Department of General Pediatrics, Miyagi Children’s Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masato</FirstName>
        <LastName>Yashiro</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naomi</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Infection and Immunology, Allergy and Immunology Center, Aichi Children’s Health and Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Yasumura</LastName>
        <Affiliation>Department of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Wakiguchi</LastName>
        <Affiliation>Department of Pediatrics, Yamaguchi University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Pediatrics, Chiba University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunichiro</FirstName>
        <LastName>Takezaki</LastName>
        <Affiliation>Department of Pediatrics, Faculty of Medicinea and Graduate School of Medicine, Hokkaido University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Okura</LastName>
        <Affiliation>Center for Pediatric Allergy and Rheumatology, KKR Sapporo Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadafumi</FirstName>
        <LastName>Yokoyama</LastName>
        <Affiliation>Department of Pediatrics, Kanazawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Shimizu</LastName>
        <Affiliation>Department of Pediatrics, Perinatal and Maternal Medicine, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Hirayama</LastName>
        <Affiliation>Department of Pediatrics, Mie University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeto</FirstName>
        <LastName>Tohma</LastName>
        <Affiliation>Department of Rheumatology, National Hospital Organization Tokyo National Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nami</FirstName>
        <LastName>Okamoto</LastName>
        <Affiliation>Department of Pediatrics, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaaki</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Juvenile idiopathic arthritis (JIA) is a chronic inflammatory condition that frequently persists into adulthood, posing long-term challenges in disease control and quality of life. However, clinical management during the transitional and young adult phases remains insufficiently characterized, especially in comparison with adult-onset rheumatoid arthritis (RA). This study aimed to compare disease activity, medication use, and treatment practices between patients with oligoarticular/polyarticular JIA and those with RA, focusing on individuals aged 16–30 years.&lt;br&gt;
Methods Data were derived from two nationwide multicenter databases in Japan—NinJa (National Database of Rheumatic Diseases in Japan) for RA and CoNinJa (a pediatric counterpart of NinJa) for JIA. A total of 176 JIA and 152 RA patients, all aged 16–30 years, were analyzed. Clinical parameters, disease activity indices, and medication profiles were compared using the Mann–Whitney U test and Fisher’s exact test.&lt;br&gt;
Results Compared to RA patients, JIA patients demonstrated significantly lower disease activity (median SDAI 0.6 vs. 2.4) and higher remission rates, particularly Boolean remission (70% vs. 44%) (p &lt; 0.001). MTX usage was less frequent in JIA (49% vs. 68%, p &lt; 0.001), whereas biologic use was notably more common (69% vs. 38%, p &lt; 0.001), with 31% involving off-label prescriptions. Among patients in CDAI remission, biologic monotherapy was observed more frequently in JIA (29% vs. 7%, p &lt; 0.001). Discontinuation of MTX was most commonly attributed to disease improvement (58%) or gastrointestinal intolerance (nausea, 29%). Subcutaneous tocilizumab, though unapproved for JIA in Japan, had the lowest discontinuation rate (4%), suggesting favorable tolerability.&lt;br&gt;
Conclusions Despite an overlap in age, patients with JIA and RA exhibit distinct disease characteristics and therapeutic patterns. These differences underscore the need to expand approved treatment options for JIA, promote equitable access to biologics, and strengthen transitional care frameworks. Further research is warranted to explore long-term outcomes, reproductive health considerations, and socioeconomic barriers that influence treatment continuity in young adults with childhood-onset arthritis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Juvenile idiopathic arthritis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Rheumatoid arthritis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Disease activity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Biologics</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Methotrexate</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2688-4526</Issn>
      <Volume>7</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Safety and efficacy of Rezūm water vapour energy therapy in BPH patients receiving antithrombotic therapy: A Japanese single‐centre experience</ArticleTitle>
    <FirstPage LZero="delete">e70170</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takatoshi</FirstName>
        <LastName>Moriwake</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Tominaga</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruki</FirstName>
        <LastName>Kaku</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ichiro</FirstName>
        <LastName>Tsuboi</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kasumi</FirstName>
        <LastName>Yoshinaga</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Yamanoi</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Kawada</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Sadahira</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shingo</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Bekku</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Urology, Okamura Isshindo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoo</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives: The objective of this study is to evaluate the safety and efficacy of Rezūm water vapour energy therapy (WAVE) in Japanese patients with benign prostatic hyperplasia (BPH) continuing antithrombotic therapy and to validate the Okayama University Modified Clavien-Dindo classification (OU-mCD) for perioperative hematuria.&lt;br&gt;
Patients and Methods: We retrospectively analysed 80 consecutive patients who underwent WAVE from August 2023 to July 2024, including 37 (46.2%) continuing antithrombotic therapy perioperatively. Hematuria within 30 days was graded using conventional Clavien-Dindo classification and the OU-mCD, a novel classification focusing on intervention necessity. We assessed clinically significant hematuria (Grade ≥ Ib), catheter-free rate, prostate volume reduction and haemoglobin change.&lt;br&gt;
Results: Clinically significant hematuria occurred in 21.6% (8/37) of patients continuing antithrombotic therapy versus 4.7% (2/43) without (p = 0.038). All 10 Grade ≥ Ib cases occurred during hospitalization with the catheter in place and were managed conservatively with continuous bladder irrigation (median 1 day); none required transfusion or surgical reintervention. Only one patient required temporary drug discontinuation. Treatment efficacy did not differ by antithrombotic status: 86.2% achieved PVR &lt; 50 ml with 44% mean prostate volume reduction. Multivariate analysis identified antithrombotic therapy as the sole independent risk factor for Grade ≥ Ib hematuria (OR 5.46, 95% CI 1.06–28.16, p = 0.042).&lt;br&gt;
Conclusion: WAVE can be safely performed with continued antithrombotic therapy. Whereas Grade ≥Ib hematuria occurred in 25% of antiplatelet/anticoagulant users (vs. 5% without), 75% had no significant bleeding, and all complications were managed conservatively without transfusion. The OU-mCD provides precise complication stratification. These findings suggest outpatient procedures may be feasible with appropriate patient selection.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">benign prostatic hyperplasia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hematuriaantithrombotic therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Japanese</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">OU-mCD</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">water vapour energy therapy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Medical Association (AMA)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2574-3805</Issn>
      <Volume>8</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non–Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials</ArticleTitle>
    <FirstPage LZero="delete">e2543107</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Pasi A.</FirstName>
        <LastName>Jänne</LastName>
        <Affiliation>Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">David</FirstName>
        <LastName>Planchard</LastName>
        <Affiliation>Department of Medical Oncology, Thoracic Cancer Group, Gustave Roussy, Medical Oncology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>Department of Thoracic Oncology, Nation Cancer Center Hospital East</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Egbert F.</FirstName>
        <LastName>Smit</LastName>
        <Affiliation>Department of Pulmonary Diseases, Leiden University Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Adrianus Johannes</FirstName>
        <LastName>de Langen</LastName>
        <Affiliation>Department of Thoracic Oncology, Netherlands Cancer Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>Department of Thoracic Oncology, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiichiro</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshio</FirstName>
        <LastName>Kubo</LastName>
        <Affiliation>Center for Clinical Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maurice</FirstName>
        <LastName>Pérol</LastName>
        <Affiliation>Department of Medical Oncology, Centre Léon Bérard</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Enriqueta</FirstName>
        <LastName>Felip</LastName>
        <Affiliation>Department of Medical Oncology, Vall d’Hebron University and Vall d’Hebron Institute of Oncology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetoshi</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of Medical Oncology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Nakagawa</LastName>
        <Affiliation>Department of Medical Oncology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junichi</FirstName>
        <LastName>Shimizu</LastName>
        <Affiliation>Department of Thoracic Oncology, Aichi Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Misako</FirstName>
        <LastName>Nagasaka</LastName>
        <Affiliation>Division of Hematology-Oncology, Department of Medicine, University of California Irvine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaline</FirstName>
        <LastName>Pereira</LastName>
        <Affiliation>Daiichi Sankyo Inc</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayumi</FirstName>
        <LastName>Taguchi</LastName>
        <Affiliation>Daiichi Sankyo Co Ltd</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ahmed</FirstName>
        <LastName>Ali</LastName>
        <Affiliation>Daiichi Sankyo Europe GmbH</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maha</FirstName>
        <LastName>Karnoub</LastName>
        <Affiliation>Daiichi Sankyo Inc</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rie</FirstName>
        <LastName>Yonemochi</LastName>
        <Affiliation>Daiichi Sankyo Inc</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">David</FirstName>
        <LastName>Leung</LastName>
        <Affiliation>Daiichi Sankyo Inc</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Bob T.</FirstName>
        <LastName>Li</LastName>
        <Affiliation>Thoracic Oncology and Early Drug Development Service, Global Research Program, Memorial Sloan Kettering Cancer Center</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Importance  Brain metastases reduce overall survival rates of patients with non–small cell lung cancer (NSCLC); patients with epidermal growth factor receptor 2 (ERBB2 [formerly HER2])–mutant NSCLC are more likely to have baseline brain metastases. Trastuzumab deruxtecan (T-DXd) is an approved ERBB2-directed treatment for previously treated unresectable or metastatic ERBB2-mutant NSCLC.&lt;br&gt;
Objective  To assess the clinical effectiveness and safety of T-DXd 5.4 mg/kg and 6.4 mg/kg doses in patients with previously treated ERBB2-mutant metastatic NSCLC with or without untreated or previously treated stable brain metastases.&lt;br&gt;
Design, Setting, and Participants  This post hoc secondary analysis pooled patients from the DESTINY-Lung01 (data cutoff date: December 3, 2021) and DESTINY-Lung02 (data cutoff date: December 23, 2022) clinical trials by T-DXd dose (5.4 mg/kg and 6.4 mg/kg). DESTINY-Lung01 was a multicenter, open-label, 2-cohort, nonrandomized phase 2 study, while DESTINY-Lung02 was a dose-blinded, multicenter, 2-cohort, randomized phase 2 study. Participants had a previously treated ERBB2-mutant metastatic NSCLC with or without untreated or previously treated stable brain metastases at baseline. All statistical analyses were performed from April 2023 to October 2024.&lt;br&gt;
Intervention  Patients received a T-DXd dose of either 5.4 mg/kg or 6.4 mg/kg intravenously every 3 weeks.&lt;br&gt;
Main Outcome and Measure  Systemic and intracranial effectiveness by blinded independent central review using RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1, sites of progression, and safety.&lt;br&gt;
Results  This analysis included 102 patients in the T-DXd 5.4-mg/kg dose group (65 females [64%]; median [range] age, 57.5 [37.0-83.0] years and 59.5 [30.0-79.0] years in patients with and without brain metastases, respectively) and 141 patients in the T-DXd 6.4-mg/kg dose group (94 females [67%]; median [range] age, 62.5 [29.0-88.0] years and 59.0 [27.0-83.0] years in patients with and without brain metastases, respectively). In each group, 31% (32 of 102) and 38% (54 of 141) of patients, respectively, had baseline brain metastases and 53% (17 of 32) and 44% (24 of 54), respectively, received prior brain metastasis treatment. In patients with and without brain metastases, systemic confirmed objective response rates (ORRs) were 47% (15 of 32; 95% CI, 29%-65%) and 50% (35 of 70; 95% CI, 38%-62%), respectively, with the T-DXd 5.4-mg/kg dose, and 50% (27 of 54; 95% CI, 36%-64%) and 59% (51 of 87; 95% CI, 48%-69%) with the T-DXd 6.4-mg/kg dose. Median progression-free survival was 7.1 (95% CI, 5.5-9.7) months in the T-DXd 5.4-mg/kg dose group and 7.1 (95% CI, 4.5-9.6) months in the T-DXd 6.4-mg/kg dose group of patients with baseline brain metastases. Among patients with measurable baseline brain metastases, intracranial confirmed ORRs were 50% (7 of 14; 95% CI, 23%-77%) with the T-DXd 5.4-mg/kg dose and 30% (9 of 30; 95% CI, 15%-49%) with the T-DXd 6.4-mg/kg dose. At both doses, the safety profile of T-DXd was generally manageable, regardless of baseline brain metastases, favoring the T-DXd 5.4 mg/kg dose.&lt;br&gt;
Conclusions and Relevance  In this secondary analysis, T-DXd at the approved dose of 5.4 mg/kg showed antitumor activity in patients with previously treated ERBB2-mutant metastatic NSCLC with or without brain metastases. This finding supports T-DXd 5.4 mg/kg use in this population.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1556-0864</Issn>
      <Volume>20</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02—A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC</ArticleTitle>
    <FirstPage LZero="delete">1814</FirstPage>
    <LastPage>1828</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Pasi A.</FirstName>
        <LastName>Jänne</LastName>
        <Affiliation>Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>Department of Thoracic Oncology, National Cancer Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshio</FirstName>
        <LastName>Kubo</LastName>
        <Affiliation>Center for Clinical Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiichiro</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sang-We</FirstName>
        <LastName>Kim</LastName>
        <Affiliation>Oncology Department, Asan Medical Center, Seoul, and University of Ulsan College of Medicine, Ulsan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">David</FirstName>
        <LastName>Planchard</LastName>
        <Affiliation>Department of Medical Oncology, Thoracic Cancer Group, Gustave Roussy, and Faculty of Medicine, Paris-Saclay University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Myung-Ju</FirstName>
        <LastName>Ahn</LastName>
        <Affiliation>Department of Hematology and Oncology, Samsung Medical Center Sungkyunkwan, and University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Egbert</FirstName>
        <LastName>Smit</LastName>
        <Affiliation>Department of Pulmonary Diseases, Leiden University Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Adrianus</FirstName>
        <LastName>Johannes de Langen</LastName>
        <Affiliation>Department of Thoracic Oncology, Netherlands Cancer Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maurice</FirstName>
        <LastName>Pérol</LastName>
        <Affiliation>Department of Medical Oncology, Léon Berard Centre</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Elvire</FirstName>
        <LastName>Pons-Tostivint</LastName>
        <Affiliation>Centre Hospitalier Universitaire Nantes, Nantes University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Silvia</FirstName>
        <LastName>Novello</LastName>
        <Affiliation>Department of Oncology, University of Turin, Turin, and Azienda Ospedaliero-Universitaria San Luigi Gonzaga</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetoshi</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of Medical Oncology, Kindai University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junichi</FirstName>
        <LastName>Shimizu</LastName>
        <Affiliation>Department of Thoracic Oncology, Aichi Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Dong-Wan</FirstName>
        <LastName>Kim</LastName>
        <Affiliation>Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaline</FirstName>
        <LastName>Pereira</LastName>
        <Affiliation>Daiichi Sankyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fu-Chih</FirstName>
        <LastName>Cheng</LastName>
        <Affiliation>Daiichi Sankyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayumi</FirstName>
        <LastName>Taguchi</LastName>
        <Affiliation>Daiichi Sankyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yingkai</FirstName>
        <LastName>Cheng</LastName>
        <Affiliation>Daiichi Sankyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kyle</FirstName>
        <LastName>Dunton</LastName>
        <Affiliation>Daiichi Sankyo UK</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ahmed</FirstName>
        <LastName>Ali</LastName>
        <Affiliation>Daiichi Sankyo Europe GmbH</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>Department of Thoracic Oncology, National Cancer Center Hospital East</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: Trastuzumab deruxtecan (T-DXd) demonstrated strong and durable responses in patients with previously treated HER2 (ERBB2) mutant (HER2m) metastatic NSCLC (mNSCLC) in the DESTINY-Lung02 primary analysis (December 23, 2022, data cutoff). This final analysis evaluated T-DXd efficacy and safety after 8 additional months of follow-up, including clinically relevant subgroups and patient-reported outcomes.&lt;br&gt;
Methods: DESTINY-Lung02 was a randomized, dose-blinded, multicenter, phase 2 trial. Patients with previously treated HER2m mNSCLC were randomized 2:1 to receive T-DXd 5.4 or 6.4 mg/kg once every 3 weeks. Primary end point was confirmed objective response rate by blinded independent central review.&lt;br&gt;
Results: As of August 25, 2023, 102 and 50 patients had received T-DXd 5.4 or 6.4 mg/kg, respectively. Median follow-up (Q1–Q3) was 15.8 (8.2–20.7) months and 16.5 (9.4–20.8) months, respectively. Confirmed objective response rate (95% confidence interval) was 50.0% (51/102; 39.9%–60.1%) and 56.0% (28/50; 41.3%–70.0%), respectively. Safety profile was acceptable and generally manageable. Accordingly, median treatment duration (Q1–Q3) was 7.7 (3.7–14.4) months and 8.3 (2.8–13.1) months; drug-related grade 3 or higher treatment-emergent adverse events occurred in 39.6% (40/101) and 60.0% (30/50), with nausea most common (67.3% [68/101], 82.0% [41/50]). Adjudicated drug-related interstitial lung disease occurred in 14.9% (15/101) and 32.0% (16/50), mostly grade 1 or 2 with one grade 5 in each arm. Health-related quality of life was preserved for the duration of T-DXd treatment while sample size was sufficient for analysis, with no adverse effects on health-related quality of life observed at either dose.&lt;br&gt;
Conclusions: T-DXd demonstrated strong and durable responses at both doses, with no clinically significant changes in toxicity. The approved 5.4-mg/kg dose demonstrated a more favorable benefit-risk profile, including lower adjudicated drug-related interstitial lung disease incidence.&lt;br&gt;
ClinicalTrials.gov identifier: NCT04644237</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">HER2-directed therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">HER2-mutant</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">HER2-targeted</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Non–small cell lung cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Trastuzumab deruxtecan</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0309-0167</Issn>
      <Volume>88</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Claudin-18 expression in gastric type adenocarcinoma and HPV-associated adenocarcinoma of the uterine cervix</ArticleTitle>
    <FirstPage LZero="delete">1003</FirstPage>
    <LastPage>1015</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Nobuko</FirstName>
        <LastName>Yasutake</LastName>
        <Affiliation>Department of Gynecology and Obstetrics, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Yokawa</LastName>
        <Affiliation>Department of Pathology and Oncology, Graduate School of Medicine, Dentistry &amp;amp; Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology and Oncology, Graduate School of Medicine, Dentistry &amp;amp; Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Riri</FirstName>
        <LastName>Mishima</LastName>
        <Affiliation>Department of Pathology and Oncology, Graduate School of Medicine, Dentistry &amp;amp; Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Misato</FirstName>
        <LastName>Komamizu</LastName>
        <Affiliation>Department of Gynecology and Obstetrics, Graduate School of Medical Sciences Kyushu University  Fukuoka Japan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryosuke</FirstName>
        <LastName>Kuga</LastName>
        <Affiliation>Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rina</FirstName>
        <LastName>Jiromaru</LastName>
        <Affiliation>Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichiro</FirstName>
        <LastName>Kawatoko</LastName>
        <Affiliation>Department of Medicine and Clinical Science, Kyushu University Beppu Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenzo</FirstName>
        <LastName>Sonoda</LastName>
        <Affiliation>Department of Gynecology, Kyushu University Beppu Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideaki</FirstName>
        <LastName>Yahata</LastName>
        <Affiliation>Department of Gynecology and Obstetrics, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyoko</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Gynecology and Obstetrics, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinao</FirstName>
        <LastName>Oda</LastName>
        <Affiliation>Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetaka</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Pathology and Oncology, Graduate School of Medicine, Dentistry &amp;amp; Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Aims: Claudin-18 (CLDN18) is both a marker for the gastric phenotype and a therapeutic target. However, little is known about its immunoexpression in endocervical adenocarcinomas (ECAs), particularly as detected using the clone 43-14A antibody, or about the gene expression of its isoforms in ECAs.&lt;br&gt;
Methods and results: We examined CLDN18, HIK1083, p16 and Rb expression by immunohistochemistry and high-risk human papillomavirus (HR-HPV) mRNA by in situ hybridization (ISH) in 121 ECAs, including 35 HPV-independent adenocarcinomas (gastric type [GAS], n = 24; non-GAS, n = 11) and 86 HPV-associated ECAs. We also analysed mRNA expression of the CLDN18.1 (lung type) and CLDN18.2 (gastric type) isoforms by quantitative polymerase chain reaction (qPCR) in selected cases. CLDN18 positivity was detected in 8/24 (33%) GASs, 0/11 (0%) non-GASs and 2/86 (2%) HPV-associated ECAs, with positivity defined as staining in ≥75% of tumour cells, as in gastric cancer. When a 5% cut-off was used, CLDN18 positivity was detected in 22/24 (92%) GASs, 0/11 (0%) non-GASs and 6/86 (7%) HPV-associated ECAs; CLDN18 expression was thus significantly associated with GAS histology (P &lt; 0.0001). Among the 6 cases of HPV-associated ECAs with CLDN18 expression (ranging from 5% to 80%), the histological patterns included a mix of usual and mucinous features in 4 cases, pure usual type in 1 and villoglandular variant in 1. Otherwise features such as p16 overexpression and the Rb partial loss pattern were consistent with those of HPV-associated ECAs. Six of 22 (27%) CLDN18-positive GASs were also positive for p16, but their other features—such as CLDN18 expression and the Rb preserved pattern—were the same as in p16 negative GASs. Expression of CLDN18.2 mRNA but not CLDN18.1 mRNA was confirmed in both GASs and HPV-associated ECAs.&lt;br&gt;
Conclusions: CLDN18 (43-14A) emerged as a potential diagnostic and therapeutic marker for GAS. A minor subset of HPV-associated ECAs also can be immunoreactive for CLDN18 and express CLDN18.2 mRNA, suggesting divergent gastric phenotypic differentiation. The caution is that GAS and HPV-associated ECAs can share overlapping histological features and similar expression of CLDN18 and p16.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">claudin-18</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">endocervical adenocarcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gastric type</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">human papillomavirus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">p16</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The Challenge of Diagnosing Scirrhous Gastric Cancer by Endoscopic Biopsy: A Case Report</ArticleTitle>
    <FirstPage LZero="delete">e87334</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Department of Internal Medicine, Clinic IkedaDepartment of Internal Medicine, Clinic Ikeda</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Yoshino</LastName>
        <Affiliation>Department of Pathology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobumasa</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Department of Internal Medicine, Clinic Ikeda</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Scirrhous gastric cancer, also known as linitis plastica, is a rare and aggressive subtype of gastric carcinoma that poses significant diagnostic challenges due to its submucosal infiltration and often normal-appearing mucosa. We report a case involving a 30-year-old Japanese woman who presented with a six-month history of epigastric pain and postprandial vomiting. Initial endoscopic examination revealed erythema and mucosal swelling, with limited antral distensibility and resistance during duodenal intubation. Despite 12 mucosal biopsies, histopathological examination revealed no evidence of malignancy. Given the strong clinical and endoscopic suspicion of scirrhous gastric cancer, additional deep sections and immunohistochemical staining were performed. These revealed scattered signet-ring cell carcinoma and poorly differentiated adenocarcinoma, with positive immunostaining for p53 and Ki67. The patient underwent total gastrectomy, and the diagnosis of scirrhous gastric cancer was confirmed on the resected specimen. This case highlights the importance of a high index of clinical suspicion, close collaboration between endoscopists and pathologists, and the utility of ancillary diagnostic tools, such as immunohistochemistry, in identifying subepithelial gastric malignancies that may be missed on conventional biopsy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">endoscopic biopsy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">esophagogastroduodenoscopy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">immunohistochemistry</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">linitis plastica</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">scirrhous gastric cancer</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2577-171X</Issn>
      <Volume>9</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Mitrofanoff Appendicovesicostomy With Boari Flap for Complete Female Urethral Transection: A Case Report</ArticleTitle>
    <FirstPage LZero="delete">e70154</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Kawada</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Sadahira</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Tominaga</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shingo</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Bekku</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichiro</FirstName>
        <LastName>Yamasaki</LastName>
        <Affiliation>Department of Urology, Kanagawa Children's Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoo</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: Female urethral complete transection caused by pelvic trauma is extremely rare, and no standard management has been established when urethral reconstruction is not feasible.&lt;br&gt;
Case Presentation: A woman in her twenties sustained an open pelvic fracture with perineal injury due to a traffic accident. Complete urethral transection was identified, and a suprapubic cystostomy was placed. After staged vaginal reconstruction and bladder function evaluation, a Mitrofanoff appendicovesicostomy was performed. Because the appendix was not enough to reach the umbilicus, a Boari flap was created to compensate for the length. Urodynamic evaluation showed improvement from a preoperative high-pressure bladder to increased compliance postoperatively, though pharmacological management was still required. Postoperatively, the patient achieved stable clean intermittent catheterization without complications.&lt;br&gt;
Conclusion: The Mitrofanoff procedure can be an effective option in female urethral injuries where reconstruction is impossible. The addition of a Boari flap may expand its applicability by overcoming conduit length limitations.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Boari flap</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">female urethral transection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Mitrofanoff</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japan Society of Mechanical Engineers</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2187-9745</Issn>
      <Volume>12</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Examining OpenFOAM-based LES analysis in terms of inviscid energy conservation and viscous turbulence decay</ArticleTitle>
    <FirstPage LZero="delete">25-00095</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>SUZUKI</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kento</FirstName>
        <LastName>TANAKA</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshinori</FirstName>
        <LastName>KOUCHI</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The present study examines an OpenFOAM-based LES analysis from the viewpoints of inviscid energy conservation and viscous turbulence decay. The Smagorinsky model is employed as the sub-grid scale (SGS) model, and a two-dimensional periodic analytical solution and a three-dimensional periodic Taylor-Green vortex (TGV) are employed to represent inviscid flows. The analytical relationship for the kinetic energy K, dK/dt = 0, with t as the dimensionless time, is utilized to validate the OpenFOAM results. For the viscous flow case, the TGV flow in a three-dimensional periodic cubic domain is adopted, and its turbulence kinetic energy distribution is compared with that obtained by a spectral method to examine the analysis. The OpenFOAM-based analysis exhibits energy conservation error in flows that should ideally conserve energy. For the two-dimensional flow, this error decreases with increasing grid resolution N. However, in the three-dimensional flow, the error does not improve even with higher N. In the three-dimensional TGV flow, the turbulence kinetic energy predicted by OpenFOAM exhibits a strong agreement with that from the spectral method when a standard constant value of the Smagorinsky model is employed and the mesh is sufficiently refined. Conversely, for a condition of relatively coarse mesh, the decay characteristics of turbulent kinetic energy deviate from those of the spectral method, and a higher constant value of the Smagorinsky model than the default value becomes necessary to reproduce comparable results. These results suggests that even in LES simulations where highly accurate conservation laws are not satisfied, adjusting the model constants so that the predicted values match experimental or numerical reference data can improve the apparent reliability of the turbulent kinetic energy in the decaying turbulence.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Turbulent flows</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Numerical simulation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Large-eddy simulation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Energy conservation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Decaying turbulence</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0969-0239</Issn>
      <Volume>32</Volume>
      <Issue>16</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Development of sulfation for cellulose pulp to change its fiber morphology and appearance to transparent in water</ArticleTitle>
    <FirstPage LZero="delete">9663</FirstPage>
    <LastPage>9677</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ayato</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Cellulose pulp (CP) is composed mainly of cellulose which is one of the most useful and sustainable natural polymers. Cellulose-based materials, such as completely dispersed nanofibers and water-soluble cellulose, are transparent in water. Additionally, chemical modification of CP has been employed as a pretreatment for the preparation of nanofibers and to impart absorption properties derived from anionic functional groups. However, little is known about chemically modified CPs comprising micron-scale fibers that are transparent in water.In this study, we synthesized transparent sulfated cellulose pulp (TSCP) that exhibits good dispersion stability, high transparency in water, and highly swollen fiber structures. The sulfation method involved heating sulfamic acid and urea supported on CP. TSCP synthesized using a sulfamic acid amount relative to CP (Q) of 18.5, a molar ratio of urea to sulfamic acid (R) of 0.80, and a reaction temperature of 140 °C exhibited the highest total light transmittance (94.7%) in water, a degree of polymerization (535), and amount of sulfate groups (1.73 mmol/g). Polarization microscopy confirmed that most TSCP fibers swelled in water along the fiber width direction. The structure of hydrous-state TSCP was further confirmed using low-vacuum scanning electron microscopy. The maximum fiber width of the swollen TSCP reached 122 μm, which was approximately six times than that of CP. The crystallinity was equivalent to that of the original CP with a Cellulose I-type crystalline structure. This transparent, hydrous-state TSCP, comprising predominantly swollen CP fibers, demonstrates potential for applications as a transparent material.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Cellulose pulp</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Sulfation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Transparent</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Swollen fiber structure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Microscopy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Refractive index</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Society for Horticultural Science</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0018-5345</Issn>
      <Volume>61</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Interactive Effects of Maximum Daytime and Minimum Nighttime Temperatures on Spinach Growth and Physiological Characteristics</ArticleTitle>
    <FirstPage LZero="delete">444</FirstPage>
    <LastPage>451</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Nethone</FirstName>
        <LastName>Samba</LastName>
        <Affiliation>Faculty of Food and Agricultural Sciences, Fukushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisao</FirstName>
        <LastName>Akasaka</LastName>
        <Affiliation>The United Graduate School of Agricultural Sciences, Iwate University, Iwate, 020-8550, Japan; and Iwate Agricultural Research Center, Kenpoku Agricultural Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken-ichiro</FirstName>
        <LastName>Yasuba</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tanjuro</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Minori</FirstName>
        <LastName>Hikawa-Endo</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoko</FirstName>
        <LastName>Miyama</LastName>
        <Affiliation>Faculty of Food and Agricultural Sciences, Fukushima University, Fukushima, 960-1296, Japan; and The United Graduate School of Agricultural Sciences, Iwate University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>High temperatures restrict spinach growth, and the plant’s growth and physiological responses to heat remain poorly understood. It remains unclear whether high daytime or elevated nighttime temperatures have a more negative impact on spinach growth. In addition, the interaction effect of maximum daytime and minimum nighttime temperatures on spinach growth remains unknown. This study was conducted to address these issues. Spinach was grown in controlled environments under four temperature treatments: 30 and 20 °C (T30/20), 30 and 25 °C (T30/25), 35 and 20 °C (T35/20), and 35 and 25 °C (T35/25). These treatments represent the maximum daytime temperature and minimum nighttime temperature, respectively, and were maintained for 45 days. Plant growth characteristics were monitored, and the physiological responses to temperature regimes were assessed. The results show that compared with T30/20, dry matter production decreased by 15.4% with increased nighttime temperature (T30/25), decreased by 42.3% with increased daytime temperature (T35/20), and decreased by 57.7% when both daytime and nighttime temperatures were increased (T35/25). However, there was no statistically significant interaction effect (P &gt; 0.05) between daytime maximum and nighttime minimum temperatures on plant biomass production variables. In comparison with T30/20, the T35/25 treatment increased significantly plant stomatal conductance, stomatal apertures, transpiration rate, and leaf temperature during heat waves. The T35/25 treatment also decreased the quantum efficiency in light compared with the other treatments. Plant biomass production did not improve with the T35/20 and T35/25 treatments, likely as a result of a decoupling of photosynthesis and stomatal conductance during heat waves. Overall, these results reveal that maximum daytime and minimum nighttime temperatures exert additive effects on spinach growth.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">photosynthesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">quantum efficiency</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">stomatal aperture</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">stomatal conductance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">transpiration</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1123-6337</Issn>
      <Volume>29</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Safety and feasibility of D3 lymph node dissection in oldest-old patients undergoing colorectal cancer surgery: a multi-institutional, retrospective analysis</ArticleTitle>
    <FirstPage LZero="delete">146</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">R.</FirstName>
        <LastName>Inada</LastName>
        <Affiliation>Department of Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">F.</FirstName>
        <LastName>Teraishi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Mitsuhashi</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">S.</FirstName>
        <LastName>Takanaga</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Toshima</LastName>
        <Affiliation>Department of Surgery, Kagawa Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Ohtani</LastName>
        <Affiliation>Department of Surgery, Saiseikai Okayama Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">R.</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Surgery, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">N.</FirstName>
        <LastName>Hori</LastName>
        <Affiliation>Department of Surgery, Tottori Municipal Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">K.</FirstName>
        <LastName>Shigemitsu</LastName>
        <Affiliation>Department of Surgery, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">S.</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Surgery, Okayama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Department of Surgery, Kobe Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Y.</FirstName>
        <LastName>Okano</LastName>
        <Affiliation>Department of Surgery, Onomichi City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Nobuhisa</LastName>
        <Affiliation>Department of Surgery, Himeji Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">F.</FirstName>
        <LastName>Taniguchi</LastName>
        <Affiliation>Department of Surgery, National Hospital Organization Iwakuni Clinical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">W.</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Department of Surgery, Fukuyama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">R.</FirstName>
        <LastName>Shoji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Department of Surgery, Matsuda Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Umeoka</LastName>
        <Affiliation>Department of Surgery, Matsuyama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>Setouchi Colorectal Neoplasm Registration Study Group Collaborators</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Colorectal cancer (CRC) is a significant health burden, with lymph node dissection (LND) playing a critical role in staging and guiding treatment. However, the optimal extent of LND for the oldest-old population (aged ≥ 90 years) remains undefined because of insufficient targeted clinical data. This study aimed to compare the short-term outcomes of D3 versus non-D3 LND in Stage II–III CRC in oldest-old patients.&lt;br&gt;
Methods This retrospective cohort study utilized data from the Setouchi Colorectal Neoplasm Registration database, including 282 oldest-old patients with CRC treated between 2011 and 2022. Patients were stratified into D3 and non-D3 LND groups, with inverse-probability-weighted regression adjustment implemented to address potential confounding factors. Postoperative complications and hospital stays were analyzed using regression models and descriptive statistics.&lt;br&gt;
Results D3 LND resulted in significantly higher lymph node harvests in both Stage II and Stage III patients (p &lt; 0.01). There were no significant differences in overall or major postoperative complications between D3 and non-D3 groups. Hospital stays were comparable for Stage II patients but shorter for Stage III patients in the D3 group (p &lt; 0.01). Complication rates ranged from 28% to 47.7%, with surgical site infections and pneumonia being the most common.&lt;br&gt;
Conclusions D3 LND can be safely performed in oldest-old patients with CRC without increasing postoperative complications or extending hospital stays. These findings support the feasibility of extensive LND in this age gr</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Lymph node dissection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Colorectal cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Oldest-old patients</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Postoperative complication</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>18</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Rare Association of Congenital Glaucoma and Retinitis Pigmentosa: A 22-Year Follow-Up Case</ArticleTitle>
    <FirstPage LZero="delete">e105012</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Ophthalmology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Primary congenital glaucoma is a rare congenital disease with a genetic background that shows high intraocular pressure due to ocular outflow anomalies. Retinitis pigmentosa is a predominant form of inherited retinal disorders. In this study, we present the case of a patient with primary congenital glaucoma in association with retinitis pigmentosa. A four-month-old female baby was brought to the emergency department due to corneal opacity in the left eye. The intraocular pressure measured by a hand-held applanation tonometer was 40 mmHg in the right eye and 36 mmHg in the left eye. She was otherwise healthy and diagnosed with primary congenital glaucoma. She immediately underwent trabeculotomy ab externo in both eyes under general anesthesia, and the intraocular pressure was lowered to 15 mmHg in the right eye and 12 mmHg in the left eye three weeks later. At the age of nine months, she was found to have retinal degeneration along the upper and lower vascular arcades of the fundus in both eyes and was diagnosed with retinitis pigmentosa. At the age of one year and 10 months, the visual acuity was measured at 0.2 in the right eye and 0.2 in the left eye for the first time by a preferential looking procedure. The intraocular pressure was 9 mmHg in both eyes under sedation, and she did not use any topical medication. At the age of three years and three months, the uncorrected visual acuity and best-corrected visual acuity with myopic astigmatism correction were 0.1 and 0.15, respectively, in the right eye and 0.6 and 0.7, respectively, in the left eye. Occlusion therapy with an eye patch over the left eye for one hour daily was started. At the age of four years and 10 months, the best-corrected visual acuity was 0.7 in both eyes. At the age of six years, occlusion therapy was discontinued, and full-correction glasses were prescribed, based on cycloplegic refraction. The visual acuity in the right eye decreased to 0.3 at the age of 11 years and further to 0.1 at the age of 12 years, while the visual acuity in the left eye remained 0.8. Afterwards, she maintained a visual acuity of 0.1 in the right eye and 0.8 in the left eye until the age of 22 years. An incidental presence of primary congenital glaucoma in this patient led to the detection of retinitis pigmentosa in earlier years and allowed long-term follow-up for 22 years. Even though genetic testing was not performed for this patient, the abnormal function of primary cilia, designated as ciliopathy, might explain the co-occurrence of primary congenital glaucoma and retinitis pigmentosa.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">ciliopathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cycloplegic refraction</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">full-correction glasses</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">goldmann perimetry</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">occlusion therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">optical coherence tomography</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">photoreceptor ellipsoid zone</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">primary congenital glaucoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">retinitis pigmentosa</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">trabeculotomy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1746-6148</Issn>
      <Volume>22</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Genetic and phenotypic identities of Staphylococcus coagulans isolated from pustules of dogs with superficial bacterial folliculitis</ArticleTitle>
    <FirstPage LZero="delete">98</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Osumi</LastName>
        <Affiliation>Animal Medical Center, Faculty of Agriculture, Tokyo University of Agriculture and Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuuki</FirstName>
        <LastName>Shinomiya</LastName>
        <Affiliation>Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Thamonwan</FirstName>
        <LastName>Wanganuttara</LastName>
        <Affiliation>Department of Bacteriology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ichiro</FirstName>
        <LastName>Imanishi</LastName>
        <Affiliation>Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yotaro</FirstName>
        <LastName>Shimazaki</LastName>
        <Affiliation>Animal Medical Center, Faculty of Agriculture, Tokyo University of Agriculture and Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keita</FirstName>
        <LastName>Iyori</LastName>
        <Affiliation>1sec Co. Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoichi</FirstName>
        <LastName>Toyoda</LastName>
        <Affiliation>1sec Co. Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaori</FirstName>
        <LastName>Ide</LastName>
        <Affiliation>Animal Medical Center, Faculty of Agriculture, Tokyo University of Agriculture and Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jumpei</FirstName>
        <LastName>Uchiyama</LastName>
        <Affiliation>Department of Bacteriology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Nishifuji</LastName>
        <Affiliation>Animal Medical Center, Faculty of Agriculture, Tokyo University of Agriculture and Technology</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Staphylococcus coagulans, formerly called Staphylococcus schleiferi subsp. coagulans is the second most common isolate from skin lesions of dogs with superficial bacterial folliculitis (SBF). However, the clinical significance of S. coagulans in pustules of canine SBF remains uncertain. This study aimed to investigate the prevalence and genotypic and phenotypic diversity of S. coagulans isolated from pustules in two dogs with SBF.&lt;br&gt;
Results Two dogs with SBF were included in this study. S. schleiferi/coagulans was isolated as the sole organism from three pustules in case #1, whereas it coexisted with S. pseudintermedius in two of seven pustules in case #2. S. pseudintermedius was the sole organism in the remaining five pustules in case #2. Whole genome sequences revealed that all isolates tested were annotated as S. coagulans. The isolates from the same pustules exhibited identical genotypic and phenotypic profiles, indicating clonal multiplication. S. coagulans isolated from different pustules exhibited similar yet distinct genotypic and phenotypic profiles.&lt;br&gt;
Conclusions S. coagulans with identical genetic and phenotypic profiles can be identified as the sole pathogen or coexist with S. pseudintermedius in the pustules of the same dogs with SBF.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Staphylococcus coagulans</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Staphylococcus pseudintermedius</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Dog</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Superficial bacterial folliculitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Antimicrobial susceptibility</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Disk diffusion test</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1999-4923</Issn>
      <Volume>18</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Streamlined Radiosynthesis of [18F]Fluproxadine (AF78): An Unprotected Guanidine Precursor Enables Efficient One-Step, Automation-Ready Labeling for Clinical Use</ArticleTitle>
    <FirstPage LZero="delete">123</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Xinyu</FirstName>
        <LastName>Chen</LastName>
        <Affiliation>Nuclear Medicine, Faculty of Medicine, University of Augsburg</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaito</FirstName>
        <LastName>Ohta</LastName>
        <Affiliation>Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Agency for Health, Safety and Environment, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Yagi</LastName>
        <Affiliation>Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takanori</FirstName>
        <LastName>Sasaki</LastName>
        <Affiliation>Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoko</FirstName>
        <LastName>Nose</LastName>
        <Affiliation>Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaru</FirstName>
        <LastName>Akehi</LastName>
        <Affiliation>Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiko</FirstName>
        <LastName>Yamane</LastName>
        <Affiliation>Department of Molecular Imaging Research, Kobe City Medical Center General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rudolf A.</FirstName>
        <LastName>Werner</LastName>
        <Affiliation>Department of Nuclear Medicine, LMU Hospital, and German Cancer Consortium (DKTK), Partner Site Munich, Ludwig-Maximilians-University of Munich</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Higuchi</LastName>
        <Affiliation>Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Objectives: [18F]Fluproxadine (formerly [18F]AF78) is a PET radiotracer targeting the norepinephrine transporter (NET) with potential applications in cardiac, neurological, and oncological imaging. Its guanidine moiety, while essential for NET binding, presents major radiosynthetic challenges due to high basicity and the harsh deprotection conditions required for protected precursors. Previous methods relied on multistep procedures, strong acids, and complex purification, limiting clinical translation. This study aimed to develop a practical one-step radiosynthesis suitable for routine and automated production. Methods: A direct SN2-type nucleophilic [18F]fluorination was performed using an unprotected guanidine precursor to eliminate deprotection steps. Reaction parameters, including the base system, solvent composition, precursor concentration, and temperature, were optimized under conventional and microwave heating. Radiochemical conversion (RCC) and operational robustness were evaluated, and purification strategies were assessed for automation compatibility. Results: Direct [18F]fluorination using the unprotected precursor reduced the total synthesis time to 60–70 min. Optimal conditions employed a tert-butanol/acetonitrile (4:1) solvent system with K2CO3/Kryptofix222, affording RCC up to 33% under conventional heating. Microwave irradiation further improved efficiency, achieving RCC of up to 64% within 1.5 min at 140 °C. The method showed broad tolerance to variations in the base molar ratio and precursor concentration and enabled isocratic HPLC purification. Conclusions: This one-step radiosynthesis overcomes longstanding challenges in [18F]fluproxadine production by eliminating harsh deprotection and enabling high-yield, automation-ready synthesis, thereby improving clinical feasibility.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">norepinephrine transporter</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">positron emission tomography</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">[18F]AF78</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">[18F]fluproxadine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">radiolabeling</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1422-0067</Issn>
      <Volume>27</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Fgf10 Gene Dosage from a Single Allele Is Insufficient for Forming Multilayered Epithelial Cells in the Murine Lacrimal Gland</ArticleTitle>
    <FirstPage LZero="delete">2113</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shiori</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Department of Cytology and Histology, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keita</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Cytology and Histology, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Tajika</LastName>
        <Affiliation>Department of Radiological Technology, Gumma Prefectural College of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Fujita</LastName>
        <Affiliation>Department of Cytology and Histology, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Bando</LastName>
        <Affiliation>Department of Cytology and Histology, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsutomu</FirstName>
        <LastName>Nohno</LastName>
        <Affiliation>Department of Cytology and Histology, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Miyaishi</LastName>
        <Affiliation>Department of Legal Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideyo</FirstName>
        <LastName>Ohuchi</LastName>
        <Affiliation>Department of Cytology and Histology, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Mutations in the fibroblast growth factor 10 (FGF10) gene in humans cause aplasia of the lacrimal and salivary glands (ALSG). In patients with ALSG, heterozygous loss-of-function mutations are found, and FGF10 haploinsufficiency results in the absence of these secretory organs. Lacrimal glands (LGs) are formed through epithelial thickening, budding, and branching morphogenesis. To compare the variable phenotypes of the Fgf10+/− Harderian glands (HGs) previously reported, we examined the development of LGs in wild-type (WT), Fgf10+/−, and Fgf10-null mice. Pax6 immunostaining was performed to visualize the LG primordia from embryonic day 15.5 (E15.5) onwards. In situ hybridization of the genes encoding the epithelial receptor of FGF10, FGFR2b, and its other ligands was performed to determine their potential involvement in LG development. LG primordia were not observed in Fgf10+/− mice bilaterally at E16.5 or later stages. At E15.5, budding from the developing conjunctival epithelium (CE) was observed in a small fraction of the Fgf10+/− LG primordia. In contrast, the Fgf10-null CE failed to promote budding. Among Fgf1, Fgf3, Fgf7, Fgf10, and Fgf22, Fgf10 was expressed in the mesenchyme surrounding developing LG epithelial cells, whereas Fgf1 was expressed in the LG epithelium of WT mice. Fgf7 was initially expressed in the mesenchyme surrounding the nascent LG epithelium, but its expression subsequently became diffused. Thus, we conclude that among the FGFR2b ligands, initial LG formation is dependent on the mesenchymal factors FGF10 and FGF7, and FGF1 is likely to function as an epithelial factor in the LG primordia. A single allele of Fgf10 was found to be insufficient to support the budding process during LG morphogenesis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">fibroblast growth factor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Fgf10</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Fgf1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Fgf3</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Fgf7</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Fgf22</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Fgfr2b</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mouse</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lacrimal gland</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">development</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Institute of Electrical and Electronics Engineers (IEEE)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2169-3536</Issn>
      <Volume>14</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>FEM-Based Design and Characterization of a Millimeter-Scale Piezoelectric Resonance Force Sensor</ArticleTitle>
    <FirstPage LZero="delete">17960</FirstPage>
    <LastPage>17970</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Aoto</FirstName>
        <LastName>Yamazaki</LastName>
        <Affiliation>Department of Mechanical Engineering, Toyohashi University of Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuma</FirstName>
        <LastName>Akiduki</LastName>
        <Affiliation>Department of Mechanical Engineering, Toyohashi University of Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsuo</FirstName>
        <LastName>Honna</LastName>
        <Affiliation>Riccoh Company Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michiteru</FirstName>
        <LastName>Kitazaki</LastName>
        <Affiliation>Department of Computer Science and Engineering, Toyohashi University of Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Mashimo</LastName>
        <Affiliation>Graduate School of Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>This paper presents a millimeter-scale piezoelectric effect-based force sensor that uses the change in its resonant frequency as the detection principle for high sensitivity and a wide measurement range. Such characteristics are suited for robot hand applications that not only detect small forces but also handle large payloads. We develop a methodology to estimate the relationship between applied force and resonant frequency shift by combining classical contact theory and finite element method (FEM) analysis. Although this relationship is non-linear, the designability of sensitivity and measurement range is demonstrated by the simulation. The simulation results based on the method are verified, showing good agreement with the experimental results. The static characteristics, including sensitivity, standard deviation, and resolution, are evaluated using prototype sensors with characteristic lengths ranging from 1 mm to 4 mm. The 4-mm model has a measurement range of 77 mN to 300 N, and the smallest model, which is one of the smallest force sensors suitable for practical implementation, has a measurement range of 9 mN to 20 N.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Force sensors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">piezoelectric effect</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">resonators</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">transducers</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ultrasonics</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1757-2215</Issn>
      <Volume>19</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Pan-cancer profiling links C1orf50 to DNA repair and immune modulation in ovarian cancer</ArticleTitle>
    <FirstPage LZero="delete">13</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Anna</FirstName>
        <LastName>Rogachevskaya</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Otani</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Ohtsu</LastName>
        <Affiliation>Harvard Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Vanessa D.</FirstName>
        <LastName>Chin</LastName>
        <Affiliation>UMass Chan Medical School, UMass Memorial Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tirso</FirstName>
        <LastName>Peña</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiji</FirstName>
        <LastName>Arai</LastName>
        <Affiliation>Department of Urology, Gunma University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Fujimura</LastName>
        <Affiliation>Department of Molecular Physiology, Faculty of Medicine, Graduate School of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background C1orf50 encodes a small, evolutionarily conserved protein, the function of which remains unclear. Its significance across various human cancers, particularly its specific role in ovarian cancer within an immunogenomic context, is not yet fully understood. Utilizing The Cancer Genome Atlas and single-cell RNA sequencing (scRNA-seq) public datasets, we conducted a comprehensive profiling of C1orf50 across multiple cancer types, with a particular focus on ovarian cancer, to investigate its associations with copy-number status, genomic instability, tumor programs, and the immune microenvironment.&lt;br&gt;
Results Across cancer types, copy-number gain or amplification of C1orf50 was most frequent in ovarian cancer and closely tracked with higher messenger RNA levels. Higher C1orf50 expression was associated with a greater tumor mutational burden and homologous recombination deficiency, as indicated by gene-set patterns that suggested heightened cell-cycle and cellular stress responses accompanied by reduced oxidative phosphorylation, enrichment of regulatory T cells, and depletion of resting memory CD4 T cells. In ovarian cancer, focal events at chromosome 1p34.2 were accompanied by stepwise increases in C1orf50 expression by clinical stage and were linked to higher tumor mutational burden, homologous recombination deficiency, and greater loss of heterozygosity, together with more frequent gene alterations in BRCA1 or BRCA2. Immune composition clustered into profiles consistent with an immunosuppressive context in tumors with higher C1orf50 expression. The scRNA-seq data further revealed that cancer cells enhanced immune-suppressive interactions with various immune cell populations and diminished antigen-presentation signals. Analyses of genomic instability in ovarian cancer suggested mutational processes compatible with base-substitution patterns associated with cytidine deaminase activity and with insertion-deletion patterns characteristic of homologous recombination failure, while transcript-level patterns pointed to a broad downshift of canonical DNA repair activity with apparent compensatory adjustments in related pathways rather than a uniform change in any single pathway.&lt;br&gt;
Conclusions The overexpression of C1orf50 characterizes an aggressive immunogenomic phenotype in ovarian cancer, distinguished by genomic instability, impaired DNA repair mechanisms, and extensive immunosuppression. These findings indicate that C1orf50 warrants consideration as a potential biomarker and a prospective target for therapeutic investigation. Furthermore, they advocate for the progression to prospective validation and functional studies to ascertain its clinical significance.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">C1orf50</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pan-cancer analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">DNA repair</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Gene expression</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tumor microenvironment</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Immune evasion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Single-cell RNA-seq</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Royal Society of Chemistry (RSC)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2041-6520</Issn>
      <Volume>17</Volume>
      <Issue>9</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Gaseous CO2 electrolysis: latest advances in electrode and electrolyzer technologies toward abating CO2 emissions</ArticleTitle>
    <FirstPage LZero="delete">4363</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kazuhide</FirstName>
        <LastName>Kamiya</LastName>
        <Affiliation>Research Center for Solar Energy Chemistry, Graduate School of Engineering Science, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sora</FirstName>
        <LastName>Nakasone</LastName>
        <Affiliation>Research Center for Solar Energy Chemistry, Graduate School of Engineering Science, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Kurihara</LastName>
        <Affiliation>Research Center for Solar Energy Chemistry, Graduate School of Engineering Science, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Asato</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Research Center for Solar Energy Chemistry, Graduate School of Engineering Science, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hazuki</FirstName>
        <LastName>Irie</LastName>
        <Affiliation>Research Center for Solar Energy Chemistry, Graduate School of Engineering Science, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoko</FirstName>
        <LastName>Nakahata</LastName>
        <Affiliation>Research Center for Solar Energy Chemistry, Graduate School of Engineering Science, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuta</FirstName>
        <LastName>Nishina</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Taniguchi</LastName>
        <Affiliation>Research Institute for Chemical Process Technology, National Institute of Advanced Industrial Science and Technology (AIST), Central 5</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Thuy T. H.</FirstName>
        <LastName>Nguyen</LastName>
        <Affiliation>Research Institute for Chemical Process Technology, National Institute of Advanced Industrial Science and Technology (AIST), Central 5</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sho</FirstName>
        <LastName>Kataoka</LastName>
        <Affiliation>Research Institute for Chemical Process Technology, National Institute of Advanced Industrial Science and Technology (AIST), Central 5</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The conversion of CO2 into multicarbon (C2+) products via electrochemical reduction is considered a key technology for the sustainable production of fuels and chemicals. The performance of high-rate gaseous CO2 electrolysis is governed by interrelated factors such as the electrocatalysts, electrodes, electrolytes, and cell architectures. Despite the intensive focus on catalyst research, systematic studies addressing the other components remain scarce, leaving critical gaps in our understanding toward achieving higher performance in CO2 electrolysis systems. The nanoscale design of catalyst surface electronic structures and the macroscale design of electrodes and electrolyzer architectures both influence the overall activity of the electrochemical system. In designing macroscale components, it is necessary to establish benchmarks based on a comprehensive evaluation of CO2 emissions for the entire electrolysis process, because these parameters are directly linked to output metrics such as current density and cell voltage under practical operating conditions. This review summarizes recent advances in electrodes and electrolyzers, and through life-cycle assessment (LCA), evaluates key performance indicators (KPIs) for achieving negative emissions and assesses the current technology readiness of CO2 electrolysis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2475-0328</Issn>
      <Volume>9</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Surgery for Older Cancer Patients: Cross‐Organ Review and Good Practice Statement by the Japanese Geriatric Oncology Guideline Committee</ArticleTitle>
    <FirstPage LZero="delete">1128</FirstPage>
    <LastPage>1136</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Chie</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Ofuchi</LastName>
        <Affiliation>Department of Surgery, Kyushu University Beppu Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiichiro</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, University of Fukui</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Sugimoto</LastName>
        <Affiliation>Department of General Geriatric Medicine, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Murofushi</LastName>
        <Affiliation>Division of Radiation Oncology, Department of Radiology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Okuyama</LastName>
        <Affiliation>Department of Psychiatry/Palliative Care Center, Nagoya City University West Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeaki</FirstName>
        <LastName>Watanuki</LastName>
        <Affiliation>National Center for Global Health and Medicine, National College of Nursing</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chiyo</FirstName>
        <LastName>Imamura</LastName>
        <Affiliation>Advanced Cancer Translational Research Institute, Showa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Sakai</LastName>
        <Affiliation>Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naomi</FirstName>
        <LastName>Sakurai</LastName>
        <Affiliation>Cancer Solutions Co. Ltd</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyotaka</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Division of Medical Oncology, Department of Medicine, School of Medicine, Teikyo University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuo</FirstName>
        <LastName>Tamura</LastName>
        <Affiliation>NPO Clinical Hematology/Oncology Treatment Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Saeki</LastName>
        <Affiliation>Breast Oncology Service, Saitama Medical University International Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Ishiguro</LastName>
        <Affiliation>Breast Oncology Service, Saitama Medical University International Medical Center</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Although the number of older people is increasing, there is a lack of evidence and insufficient consensus regarding postoperative complications and survival in older cancer patients. In this study, we conducted a literature search and systematic review focusing on the outcomes after surgery for older cancer patients.&lt;br&gt;
Methods: Literature focusing on surgical treatment for older cancer patients was extracted from Japanese clinical practice guidelines for gastric cancer, lung cancer, colorectal cancer, liver cancer, and gynecological cancers (uterine body, uterine cervix, ovary, and external genitalia and vagina). Outcomes were reviewed, and committee members determined the strength of evidence on a four-point scale (A to D), with A being the highest and D being the lowest.&lt;br&gt;
Results: Older cancer patients tend to have a higher incidence of postoperative complications and postoperative syndromes, and their expected survival is generally shorter compared to non-older patients. When extensive surgeries such as para-aortic lymph node dissection and/or resection with other organs are performed for older cancer patients, the postoperative mortality rates tend to increase compared to non-older patients.&lt;br&gt;
Conclusion: Surgical treatments for older cancer patients tend to result in higher morbidity even when the patients are in good health status. Nevertheless, there is still a possibility that a certain fraction of the patients achieve treatment outcomes comparable to those of non-older patients. Therefore, surgical indication and procedure for older cancer patients should be carefully determined based on surgical invasiveness and patient tolerability.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">older patients</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">surgery</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Geophysical Union (AGU)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0094-8276</Issn>
      <Volume>53</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Electrical Conductivity of Amorphous and Molten CaCO3 at High Pressures and Its Implications for Mantle Conductivity Anomalies</ArticleTitle>
    <FirstPage LZero="delete">e2025GL119568</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Bin</FirstName>
        <LastName>Zhao</LastName>
        <Affiliation>Institute for Planetary Materials, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yoshino</LastName>
        <Affiliation>Institute for Planetary Materials, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Qi</FirstName>
        <LastName>Chen</LastName>
        <Affiliation>Center for Advanced Radiation Sources, The University of Chicago</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tony</FirstName>
        <LastName>Yu</LastName>
        <Affiliation>Center for Advanced Radiation Sources, The University of Chicago</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Dongzhou</FirstName>
        <LastName>Zhang</LastName>
        <Affiliation>Center for Advanced Radiation Sources, The University of Chicago</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Bin</FirstName>
        <LastName>Chen</LastName>
        <Affiliation>School of Ocean and Earth Science and Technology, University of Hawaii at Manoa</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yanbin</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Center for Advanced Radiation Sources, The University of Chicago</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Impedance spectrometry experiments have been conducted on CaCO3 up to 15 GPa and 2,100 K to identify its state under high pressure. The melting temperature of CaCO3 was also determined by the falling of a Re sphere observed via X-ray radiography. The phase transition from aragonite to the amorphous phase does not cause a leap in the Electrical conductivity (EC), while a drastic increase in the EC, by 1.5–2.0 log units, only occurs with the onset of melting. The EC of amorphous CaCO3 is comparable to other hydrous mantle minerals at similar pressure and temperature conditions. The required fraction of amorphous CaCO3 implies that it can be excluded from the potential origins responsible for the observed high EC anomalies in the upper mantle. If the conductivity anomalies are induced by the presence of carbonate, a low-degree melting of carbonate-bearing peridotite is anticipated.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1068-9265</Issn>
      <Volume>32</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Mesenteric Route Superior Mesenteric Artery First Approach in Robot-Assisted Pancreatoduodenectomy</ArticleTitle>
    <FirstPage LZero="delete">8903</FirstPage>
    <LastPage>8905</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kosei</FirstName>
        <LastName>Takagi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atene</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomokazu</FirstName>
        <LastName>Fuji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Yasui</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeyoshi</FirstName>
        <LastName>Nishiyama</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsubasa</FirstName>
        <LastName>Yanagihara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background. The superior mesenteric artery (SMA) approach is crucial for the successful implementation of robot-assisted pancreatoduodenectomy (RPD). Herein, we present a novel technique, the mesenteric route SMA-first approach, for RPD.&lt;br&gt;
Patients and Methods. A 20-year-old woman with a 50 mm intraductal papillary mucinous neoplasm underwent RPD. As the tumor was large and located close to the mesenteric vessels, we developed the mesenteric route SMA-first approach.&lt;br&gt;
Results. Following the mesenteric Kocher maneuver, the mesenteric route SMA-first approach was applied. With appropriate retraction of the pancreatic head, dissection around the mesenteric vessels was performed and their branches were divided. The uncinate process dissection (PL, ph II) was performed via the mesenteric route. This approach facilitated dorsal dissection, particularly around the large tumor. After dissection of the hepatoduodenal ligament, the remaining pancreatic nerve plexus (PL ph I) was dissected. Finally, the pancreas was divided on the superior mesenteric vein, and the specimen was resected. Operative time was 390 min with minimal blood loss.&lt;br&gt;
Conclusions. The mesenteric route SMA-first approach enables uncinate process dissection via the mesenteric route. This technique may be a safe and feasible option for selected patients, such as nonobese individuals with a large pancreatic head tumor near major vessels.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Robotic pancreaticoduodenectomy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Superior mesenteric artery approach</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Mesenteric route</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1435-2451</Issn>
      <Volume>410</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Robotic distal pancreatectomy using two-surgeon technique (TAKUMI-4): a technical note and initial outcomes</ArticleTitle>
    <FirstPage LZero="delete">171</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kosei</FirstName>
        <LastName>Takagi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomokazu</FirstName>
        <LastName>Fuji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Yasui</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose With the increasing use of minimally invasive distal pancreatectomy, the use of robotic distal pancreatectomy (RDP) is also increasing worldwide. Standardized surgical protocols are essential for safe implementation of RDP. In this study, we present our surgical protocol and initial outcomes of RDP using “two-surgeon technique”.&lt;br&gt;
Methods Our standard RDP protocol included a two-surgeon technique for cooperation, rationality, and education. Short-term outcomes of RDP were also investigated. This retrospective study included 77 consecutive patients who underwent RDP at our institution between April 2021 and January 2025.&lt;br&gt;
Results The median operative time, estimated blood loss, and postoperative hospital stay were 214 min (interquartile range [IQR], 176–253), 10 mL (IQR, 0–50), and 9 days (IQR, 8–10), respectively. A textbook outcome was achieved in 84.4% of patients. Moreover, superior outcomes of RDP (n = 77) compared with those of laparoscopic distal pancreatectomy (n = 62) were confirmed in this study.&lt;br&gt;
Conclusion Using the two-surgeon technique, we successfully standardized and introduced the RDP program. The two-surgeon technique can contribute to the safe introduction of RDP and expansion of the program.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Distal pancreatectomy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Robotic surgery: minimally invasive surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Training</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Outcomes</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0930-2794</Issn>
      <Volume>39</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Impact of visceral fat area on surgical difficulty during robotic distal pancreatectomy (TAKUMI-2)</ArticleTitle>
    <FirstPage LZero="delete">3137</FirstPage>
    <LastPage>3145</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kosei</FirstName>
        <LastName>Takagi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motohiko</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomokazu</FirstName>
        <LastName>Fuji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Yasui</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeyoshi</FirstName>
        <LastName>Nishiyama</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuo</FirstName>
        <LastName>Nagai</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriyuki</FirstName>
        <LastName>Kanehira</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Difficulty scoring systems (DSS) have been developed to quantify the surgical complexity of laparoscopic distal pancreatectomy (LDP). However, few studies have validated these systems in the context of robotic distal pancreatectomy (RDP). Moreover, the impact of body composition on RDP outcomes remains unexplored. This study aimed to investigate the risk factors of surgical difficulty in RDP, including body composition.&lt;br&gt;
Methods: This retrospective study included 72 consecutive patients who underwent RDP at our institution between April 2021 and October 2024. Using a modified DSS for LDP, patients were divided into three difficulty index groups. The association between the difficulty index and outcomes was investigated. Multivariate analyses were performed to identify risk factors associated with surgical difficulty (prolonged operative time) in RDP.&lt;br&gt;
Results: Patients were classified into three difficulty index groups: low (n = 28), intermediate (n = 25), and high (n = 19). Operative time was significantly associated with the surgical index (P = 0.01). Moreover, visceral fat area (VFA) was significantly correlated with operative time (r2 = 0.10, P = 0.008). The multivariate analyses found that VFA (≥ 100 cm2) (odds ratio [OR] 5.03, 95% confidence interval [CI] 1.32–22.4, P = 0.02), malignancy (OR 4.92, 95% CI 1.50–18.9, P = 0.01), and pancreatic resection on the portal vein (OR 4.14, 95% CI 1.24–15.9, P = 0.02) were significant risk factors associated with surgical difficulty.&lt;br&gt;
Conclusion: VFA could be a novel and useful factor for assessing the surgical difficulty associated with RDP.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Robotic distal pancreatectomy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Difficulty score</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Visceral fat area</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japan Medical Association</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2433-3298</Issn>
      <Volume>8</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Case of Hepatocellular Carcinoma Associated with Hepatic Sarcoidosis</ArticleTitle>
    <FirstPage LZero="delete">606</FirstPage>
    <LastPage>608</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yasuo</FirstName>
        <LastName>Nagai</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosei</FirstName>
        <LastName>Takagi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Yasui</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Kariyama</LastName>
        <Affiliation>Department of Gastroenterology, Okayama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomokazu</FirstName>
        <LastName>Fuji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">hepatocellular carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hepatic sarcoidosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">peritoneal sarcoidosis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Gastric Metastasis of Renal Cell Carcinoma Initially Diagnosed by Esophagogastroduodenoscopy</ArticleTitle>
    <FirstPage LZero="delete">e79651</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Kamio</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoichiro</FirstName>
        <LastName>Hirata</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Here, we report a rare case of renal cell carcinoma (RCC) initially detected as a gastric metastasis. A 58-year-old man with epigastric discomfort underwent esophagogastroduodenoscopy, which revealed a reddish semi-pedunculated lesion with a whitish coating. Biopsy and imaging confirmed clear cell RCC metastasis. Contrast-enhanced computed tomography (CT) revealed a primary renal tumor with pancreatic and lymph node metastases. Despite chemotherapy treatment, the patient died after 10 months. Gastric metastases from RCC, although rare, should be considered in highly vascular gastric lesions with white coatings. Clinicians must be vigilant for metastatic diseases with atypical gastric findings.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">clear renal cell carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">esophagogastroduodenoscopy (egd)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gastric metastasis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">metastatic tumor, renal cell carcinoma (rcc)</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2077-0383</Issn>
      <Volume>15</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effect of Surgical Procedures for Rheumatoid Forefoot Deformities on Radiographic Foot Length and Width Variations</ArticleTitle>
    <FirstPage LZero="delete">1877</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Horita</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yohei</FirstName>
        <LastName>Kiso</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kurashiki Sweet Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihisa</FirstName>
        <LastName>Nasu</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuichi</FirstName>
        <LastName>Nakahara</LastName>
        <Affiliation>Department of Musculoskeletal Health Promotion, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Saiga</LastName>
        <Affiliation>Department of Sports Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Nishida</LastName>
        <Affiliation>Locomotive Pain Center, Faculty of Medical Development Field, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: The number of patients with rheumatoid arthritis (RA) undergoing forefoot arthroplasty has increased to better control the disease. Despite patients frequently expressing concerns regarding postoperative foot appearance and footwear-related expectations, no study has investigated postoperative changes in foot length and width in patients with RA. The aim of this study was to evaluate the effect of surgical procedures for rheumatoid forefoot deformities on variations in radiologically determined foot length and width. Methods: In total, 72 feet of 50 women and 3 men (average age: 66.7 years) underwent joint-preserving arthroplasty (n = 33) and arthrodesis of the first metatarsophalangeal joint with shortening osteotomy of the lesser metatarsals or resection arthroplasty of the lesser metatarsal heads (n = 39); procedures were carried out in our institute from August 2013 to February 2020. The mean disease duration was 23.5 years, and the average follow-up period was 17.5 months. Pre- and postoperative hallux valgus angle (HVA), intermetatarsal angle (IMA) of the first and second metatarsals (M1M2A), and IMA of the first and fifth metatarsals (M1M5A) were measured on weightbearing radiographs as well as foot length and width. We also evaluated the correlation between changes in radiographic parameters and variations in radiologically determined foot length and width. Results: Radiologically determined foot width changed significantly from 10.1 cm to 9.7 cm (p &lt; 0.01), while no significant difference was found between pre- and postoperative radiologically determined foot length. HVA, M1M2A, and M1M5A were significantly improved after the surgery (p &lt; 0.01, p &lt; 0.01, and p &lt; 0.01, respectively). A significant negative correlation was found between the variation in radiologically determined foot length and changes in HVA (r = −0.29, p = 0.02) and M1M5A (r = −0.23, p &lt; 0.05), while a significant positive correlation was found between the variation in the foot width and changes in HVA (r = 0.34, p &lt; 0.01), M1M2A (r = 0.55, p &lt; 0.01), and M1M5A (r = 0.45, p &lt; 0.01). There were no significant differences between operative procedures regarding variation in radiologically determined foot length and width. Conclusions: Surgical procedure for rheumatoid forefoot deformity improved radiographic parameters and reduced radiographic foot width while maintaining foot length.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">forefoot surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">foot length</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">foot width</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">rheumatoid arthritis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2050-0904</Issn>
      <Volume>14</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Oculogyric Crisis During Chronic Aripiprazole Therapy: A Diagnostic Challenge in the Emergency Department</ArticleTitle>
    <FirstPage LZero="delete">e72067</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Tokioka</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama Universitye, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences Okayama University  Japan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Nojima</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ippei</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Tsukahara</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsunori</FirstName>
        <LastName>Nakao</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Oculogyric crisis can occur even during chronic, stable aripiprazole therapy without recent dose escalation. In patients with acute upward eye deviation and an otherwise normal neurologic examination, medication review is key to recognizing drug-induced dystonia and avoiding unnecessary neurologic workup.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">acute dystonia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">aripiprazole</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">drug-induced movement disorder</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">oculogyric crisis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1865-1380</Issn>
      <Volume>19</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Association of Wet-Bulb Globe Temperature with heat-related illness hospitalizations in Japan: a time-stratified, case-crossover study</ArticleTitle>
    <FirstPage LZero="delete">11</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Yamamura</LastName>
        <Affiliation>Department of Epidemiology, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Hongo</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Yumoto</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumiya</FirstName>
        <LastName>Sasai</LastName>
        <Affiliation>Department of Epidemiology, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Tokioka</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Obara</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Nojima</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Kanda</LastName>
        <Affiliation>Emergency and Critical Care Medicine, Nippon Medical School Musashikosugi Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Yokobori</LastName>
        <Affiliation>Department of Emergency and Critical Care Medicine, Nippon Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromichi</FirstName>
        <LastName>Naito</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yorifuji</LastName>
        <Affiliation>Department of Epidemiology, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsunori</FirstName>
        <LastName>Nakao</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Heat-related illnesses are a serious public health concern and are exacerbated by global warming. Wet-Bulb Globe Temperature (WBGT) is widely used as a heat stress indicator, but its clinical impact remains unclear. This study aimed to investigate the association between hourly variations in WBGT and the incidence of hospitalizations for heat-related illness in Japan using a nationwide database. By incorporating individual-level clinical data and performing stratified analyses, we sought to provide a more granular understanding of how heat exposure affects the risk of heat-related illness requiring hospitalization.&lt;br&gt;
Methods We conducted a time-stratified, case-crossover study using data collected from July to September in 2020 and 2021 in the Heatstroke STUDY registry. The inclusion criteria were patients registered in the Heatstroke STUDY registry, specifically hospitalized patients with heat-related illness who were transported to participating hospitals during the study period. Hourly WBGT values were assigned based on the nearest monitoring station to each hospital. Conditional logistic regression and distributed lag models were used to estimate associations between WBGT and the risk of hospitalization.&lt;br&gt;
Results A total of 1,653 heat-related illness hospitalizations were analyzed. The mean patient age was 67.9 years; 67.6% were male. Each 1 °C increase in WBGT at onset (hospital arrival) was associated with a significantly increased risk of hospitalization (OR 1.10, 95% CI: 1.05–1.15). The cumulative effect over the prior six hours was also significant (OR 1.56, 95% CI: 1.50–1.62). Compared with WBGT &lt; 25 °C, adjusted ORs were 3.39 (25–27 °C), 8.81 (28–30 °C), and 22.10 (≥ 31 °C). Stratified analyses suggested stronger associations among several subgroups; however, only patients with mental disorders showed statistically significant effect modification, whereas elevated WBGT posed a risk across all groups.&lt;br&gt;
Conclusions Higher WBGT levels were associated with an increased risk of heat-related hospitalization. Although the effect appeared greater in some subgroups, only patients with mental disorders demonstrated statistically significant effect modification, suggesting elevated WBGT confers risk broadly.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Wet-Bulb Globe Temperature</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Heat stroke</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Heat related illness</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Global warming</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Association of Carboxyhemoglobin With Severity and Outcomes in Hypothermic Patients: A Retrospective Cohort Study</ArticleTitle>
    <FirstPage LZero="delete">e97962</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuya</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Yumoto</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Hongo</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Obara</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Nojima</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromichi</FirstName>
        <LastName>Naito</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsunori</FirstName>
        <LastName>Nakao</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction&lt;br&gt;
Carboxyhemoglobin (COHb), an endogenous marker of carbon monoxide production mediated by heme oxygenase-1, may reflect physiological stress responses in critically ill patients. However, its clinical relevance in accidental hypothermia remains unclear.&lt;br&gt;
&lt;br&gt;
Methods&lt;br&gt;
We conducted a single-center retrospective cohort study of adult patients admitted to the emergency ICU with accidental hypothermia between January 1, 2019, and March 31, 2025. Patients were categorized into low- and high-COHb groups based on median COHb levels upon emergency department arrival. Associations between COHb levels, disease severity (Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores), and 28-day mortality were analyzed using regression models adjusted for clinical confounders.&lt;br&gt;
&lt;br&gt;
Results&lt;br&gt;
Among the 88 patients, who had a median admission temperature of 28.7°C, 45 were classified into the low-COHb group and 43 into the high-COHb group, based on a median COHb level of 0.3%. Lower COHb levels on admission were significantly associated with higher APACHE II scores (β = −4.20; 95% CI, −7.56 to −0.85), but not with SOFA scores. Admission and minimum COHb levels were not associated with 28-day mortality. However, higher maximum COHb levels within the first 24 hours were independently associated with lower 28-day mortality (adjusted OR, 0.17; 95% CI, 0.023 to 0.93).&lt;br&gt;
&lt;br&gt;
Conclusions&lt;br&gt;
Lower COHb levels were associated with greater disease severity, and higher maximum COHb levels were associated with lower 28-day mortality. COHb may reflect systemic stress in accidental hypothermia, but its prognostic value appears limited.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">carbon monoxide</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">carboxyhemoglobin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">heme oxygenase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hypothermia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">sepsis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2079-7737</Issn>
      <Volume>15</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Alpha-Ketoglutarate Drives an Osteogenic and Extracellular Matrix Gene Program in Periodontal Ligament Fibroblasts via Selective Reduction of H3K27me3</ArticleTitle>
    <FirstPage LZero="delete">372</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryu</FirstName>
        <LastName>Hasegawa</LastName>
        <Affiliation>Department of Periodontology and Endodontology, Tohoku University Graduate School of Dentistry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeki</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Operative Dentistry, Okayama University Graduate School, Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rahmad Rifqi</FirstName>
        <LastName>Fahreza</LastName>
        <Affiliation>Department of Periodontology and Endodontology, Tohoku University Graduate School of Dentistry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin-Ho</FirstName>
        <LastName>Tsai</LastName>
        <Affiliation>Department of Operative Dentistry, Okayama University Graduate School, Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshino</FirstName>
        <LastName>Daidouji</LastName>
        <Affiliation>Department of Periodontology and Endodontology, Tohoku University Graduate School of Dentistry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masato</FirstName>
        <LastName>Omori</LastName>
        <Affiliation>Department of Periodontology and Endodontology, Tohoku University Graduate School of Dentistry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuhiro</FirstName>
        <LastName>Kajikawa</LastName>
        <Affiliation>Department of Periodontology and Endodontology, Tohoku University Graduate School of Dentistry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Periodontology and Endodontology, Tohoku University Graduate School of Dentistry</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Periodontal disease damages the tissues that support teeth and can ultimately lead to tooth loss, yet effective treatments to regenerate these tissues are still limited. Recent studies have shown that substances produced during normal cellular metabolism can influence how genes are regulated, but their role in periodontal regeneration has not been fully clarified. In this study, we investigated whether alpha-ketoglutarate, a naturally occurring metabolite involved in energy production, could promote periodontal tissue regeneration. We found that alpha-ketoglutarate enhanced bone-related and extracellular matrix-related gene expression in human periodontal ligament cells by reducing a repressive gene-regulatory signal that normally suppresses these genes. Importantly, alpha-ketoglutarate did not broadly alter chromatin accessibility, indicating that its effects were mediated through selective gene regulation. Furthermore, oral administration of alpha-ketoglutarate promoted alveolar bone regeneration and collagen-rich tissue formation in a mouse model of periodontal disease. Because alpha-ketoglutarate is a naturally occurring molecule in the body, these findings suggest that metabolite-based regulation of gene activity may represent a promising and safe approach for periodontal tissue regeneration.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">alpha-ketoglutarate</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">periodontal ligament</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">extracellular matrix</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">epigenetic regulation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">H3K27me3</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2072-6694</Issn>
      <Volume>18</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Antigen Remodeling in Colorectal Cancer: How Radiotherapy and Chemotherapy Enhance Immunotherapy Responsiveness</ArticleTitle>
    <FirstPage LZero="delete">715</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Matsumi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunitoshi</FirstName>
        <LastName>Shigeyasu</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Moriwake</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Kayano</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Colorectal cancer (CRC) is traditionally considered a “cold tumor” characterized by low immunogenicity and limited responsiveness to immune checkpoint inhibitors (ICIs). However, recent findings reveal that cytotoxic modalities can reprogram this immunologically inert landscape. This review integrates these evolving concepts to guide the optimization of future treatments. Radiotherapy induces extensive DNA double-strand breaks, which may generate de novo mutations through error-prone repair while simultaneously exposing cryptic antigens via increased transcriptional instability, alternative splicing, and enhanced proteasomal processing. Chemoradiation also amplifies epigenetic and epitranscriptomic sources of neoepitope diversity, including RNA editing and stress-induced splicing alterations, expanding the immunopeptidome beyond canonical mutation-driven neoantigens. These changes collectively enhance antigen presentation and facilitate T-cell priming. Chemotherapy further reduces immunosuppressive cell populations and promotes dendritic cell activation, creating a permissive milieu for subsequent immune engagement. Clinically, the VOLTAGE studies demonstrated that long-course chemoradiotherapy can sensitize even mismatch repair–proficient rectal cancers to PD-1 blockade, yielding clinically meaningful pathological responses. In contrast, mismatch repair–deficient rectal tumors may respond completely to ICIs alone. Short-course radiotherapy combined with chemotherapy and ICIs has also shown encouraging activity in the setting of total neoadjuvant therapy. Collectively, these findings support a paradigm in which radiotherapy, chemotherapy, and epigenetic/epitranscriptomic alterations—including RNA editing—act as potent modulators of tumor antigenicity. By expanding the neoantigen repertoire and reshaping the tumor microenvironment, these strategies can transform CRC from a cold tumor into one that is increasingly responsive to immunotherapy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">colorectal cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">immunotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">radiotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">chemotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">neoantigens</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1341-9625</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Turning pancreatic cancer from cold to hot: the promise of a p53-expressing oncolytic adenovirus (OBP-702)</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Kuroda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Tazawa</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuhiko</FirstName>
        <LastName>Kanaya</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiko</FirstName>
        <LastName>Kakiuchi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Kagawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuo</FirstName>
        <LastName>Urata</LastName>
        <Affiliation>Oncolys BioPharma Inc</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Pancreatic cancer remains one of the most lethal malignancies, with limited therapeutic options and poor responsiveness to immune checkpoint inhibitors (ICIs). This resistance is largely attributed to its profoundly immunosuppressive and desmoplastic tumor microenvironment (TME), characterized by low tumor mutational burden, dense stroma, and abundant immunosuppressive cell populations. Therefore, strategies capable of enhancing tumor immunogenicity and overcoming immune evasion are urgently needed. Oncolytic virotherapy is a promising approach, offering not only tumor-selective cytotoxicity, but also potent immunomodulatory effects. Of these agents, Telomelysin (OBP-301, Suratadenoturev), a telomerase-specific oncolytic adenovirus, demonstrated clinical safety but limited efficacy in refractory tumors. To address this challenge, we developed OBP-702, a next-generation, p53-armed, oncolytic adenovirus designed to augment antitumor activity. Preclinical studies have shown that OBP-702 exerts robust cytotoxicity through multiple mechanisms, including p53-mediated apoptosis and autophagy, E1A–E2F1-mediated p21 suppression, and inhibition of oncogenic KRAS pathways. Importantly, OBP-702 induces strong immunogenic cell death, activates dendritic cells, and promotes tumor-specific T-cell responses, effectively converting immunologically “cold” pancreatic tumors into “hot” tumors. OBP-702 also remodels the immunosuppressive TME by reducing granulocyte–macrophage colony-stimulating factor (GM-CSF) secretion, suppressing myeloid-derived suppressor cells (MDSCs), and targeting stromal components, such as cancer-associated fibroblasts (CAFs). These effects contribute to enhanced responses to ICIs and standard chemotherapies. Given its multifaceted antitumor functions and ability to overcome key barriers in pancreatic cancer, OBP-702 represents a highly promising therapeutic candidate. A first-in-human clinical trial evaluating endoscopic ultrasonography-guided intratumoral injection of OBP-702 is currently in preparation, expected to advance clinical translation of this novel virotherapeutic strategy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Oncolytic adenovirus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">p53</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">OBP-702</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Immunogenic cell death</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tumor microenvironment</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pancreatic cancer</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2073-445X</Issn>
      <Volume>15</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Study on the Development of an Image Classification System for Urban Sprawl Areas in Japan</ArticleTitle>
    <FirstPage LZero="delete">275</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryota</FirstName>
        <LastName>Hemmi</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehito</FirstName>
        <LastName>Ujihara</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryosuke</FirstName>
        <LastName>Ando</LastName>
        <Affiliation>National Institute for Land and Infrastructure Management, Ministry of Land, Infrastructure Transport and Tourism</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiji</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>In Japan, unlike in many other countries, urbanization has progressed while original rural road structures have been retained, leading to distinctive urban sprawl areas with intermingling residential lots and farmland. Currently, much of Japan’s urban areas consist of urban sprawl areas, posing considerable challenges for infrastructure development. However, for such urban sprawl areas in Japan, it is difficult to say that methods have been established to identify their spatial distribution based on quantitative evaluation. Therefore, for this study, we used machine learning to investigate a system that extracts sprawling urban areas from aerial photographs divided into meshes. In the system’s design, we prioritized precision to ensure the reliable detection of urban sprawl areas. Consequently, the accuracy of identifying sprawl areas achieved precision of 0.81, recall of 0.63, and an F-score of 0.71. Examination of the classification results of sprawl areas revealed that most misclassifications occurred near class boundaries. By contrast, areas with particularly high levels of urban sprawl showed few misclassifications.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">image classification</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">machine learning</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">sprawl</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Cambridge University Press (CUP)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1460-3969</Issn>
      <Volume>25</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effects of sagging correction calibration error on radiation therapy equipment using image analysis</ArticleTitle>
    <FirstPage LZero="delete">e5</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Radiology, Chugoku Central Hospital of the Mutual Aid Association of Public School Teachers</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Nakayama</LastName>
        <Affiliation>Department of Radiology, Chugoku Central Hospital of the Mutual Aid Association of Public School Teachers</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junki</FirstName>
        <LastName>Oshita</LastName>
        <Affiliation>Department of Radiology, Chugoku Central Hospital of the Mutual Aid Association of Public School Teachers</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayaka</FirstName>
        <LastName>Tsunoda</LastName>
        <Affiliation>Department of Radiology, Graduate School of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Saeki</LastName>
        <Affiliation>Department of Radiological Technology, Kawasaki Medical School Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Tanabe</LastName>
        <Affiliation> Faculty of Medicine, Graduate School of Health Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose: This study investigates the effect of sagging correction errors on image quality and geometric coordinate accuracy.&lt;br&gt;
Methods: This study utilised the Elekta radiotherapy system, ball bearing (BB), Catphan phantom and MultiMet-WL phantom. Ten distinct flex maps (FMs) were acquired by positioning the BB at the accuracy isocentre and introducing shifts of 0.2, 0.4 and 0.6 mm in the left, table and up directions, respectively. Cone-beam computed tomography images of the Catphan phantom were acquired using 10 FMs. The images were analysed for modulation transfer function (MTF) values and geometric coordinates. Additionally, the Winston–Lutz (W-L) test was conducted under reference couch positions and with a 0.3 mm couch shift.&lt;br&gt;
Results: For the Catphan phantom analysis, the standard deviations of MTF10% across FMs were 0.19. The centre-of-gravity coordinates of the insert exhibited shifts of approximately 0.2, 0.4 and 0.6 mm when comparing reference images to those acquired with the shifted FMs. The results of the W-L test with a 0.3 mm couch shift showed radiation isocentre deviations exceeding 1 mm compared to the reference couch positions.&lt;br&gt;
Conclusions: Minor sagging correction calibration errors did not remarkably impact image quality; however, they altered the geometric coordinates of the image isocentre. These calibration errors decreased the accuracy of off-isocentre positioning.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">flex map</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">sagging</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Winston–Lutz test</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Streptococcal Toxic Shock Syndrome Following Intestinal Obstruction in a Patient With Crohn’s Disease</ArticleTitle>
    <FirstPage LZero="delete">e100138</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ayano</FirstName>
        <LastName>Nishio</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiro</FirstName>
        <LastName>Inokuchi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mikako</FirstName>
        <LastName>Ishiguro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Aoyama</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Takahara</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sakiko</FirstName>
        <LastName>Hiraoka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Oguni</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuto</FirstName>
        <LastName>Matsuoka</LastName>
        <Affiliation>Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyuki</FirstName>
        <LastName>Kanazawa</LastName>
        <Affiliation>Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Streptococcal toxic shock syndrome (STSS) is a rare, life-threatening complication of invasive group A streptococcal (iGAS) infections. We report the case of a 24-year-old woman with Crohn's disease receiving immunosuppressive therapy who developed STSS following intestinal obstruction. On day 2, she developed fever, altered mental status, hypoxemia, erythema, and hypotension. Chest CT revealed bilateral pulmonary infiltrates, and blood cultures grew emm1-positive M1UK Streptococcus pyogenes, confirming STSS. Early multidisciplinary intervention resulted in rapid recovery without sequelae. This case emphasizes the importance of considering iGAS-induced STSS in septic shock, especially in immunocompromised patients, and highlights the need for prompt recognition and treatment.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">crohn’s disease (cd)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">group a streptococcus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">immunosuppression</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">intestinal obstruction</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">streptococcal toxic shock syndrome (stss)</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Ovid Technologies (Wolters Kluwer Health)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1743-9159</Issn>
      <Volume>112</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Total thymectomy is oncologically superior to partial thymectomy in patients with thymic carcinoma: insights from a multicenter real-world data analysis</ArticleTitle>
    <FirstPage LZero="delete">2301</FirstPage>
    <LastPage>2310</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mikio</FirstName>
        <LastName>Okazaki</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiharu</FirstName>
        <LastName>Mitsuhashi</LastName>
        <Affiliation>Center of Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetaka</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Pathology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Habu</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Shien</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Suzawa</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromasa</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mototsugu</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Kurosaki</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiji</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eisuke</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsurou</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiya</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makio</FirstName>
        <LastName>Hayama</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Tao</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaomi</FirstName>
        <LastName>Yamane</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetoshi</FirstName>
        <LastName>Inokawa</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuji</FirstName>
        <LastName>Hirami</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Washio</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiko</FirstName>
        <LastName>Misao</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motohiro</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshifumi</FirstName>
        <LastName>Sano</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masao</FirstName>
        <LastName>Nakata</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Kawamata</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Although total thymectomy has been the standard surgical approach for thymic epithelial tumors, an increasing number of recent reports suggest that partial thymectomy for early-stage thymomas may yield outcomes comparable to those of total thymectomy. However, whether partial thymectomy is a viable alternative for thymic carcinoma remains unclear.&lt;br&gt;
Materials and methods: A total of 106 patients with thymic carcinoma underwent curative intended resection at 19 institutions between January 2010 and December 2021. Excluding 14 patients with incomplete resection, 92 patients with thymic carcinoma who underwent total (n = 73) or partial thymectomy (n = 19) were compared. Overall survival (OS) and recurrence-free survival (RFS) were analyzed using Kaplan–Meier curves and Cox proportional hazard models. Overlap weighting was applied to adjust for potential confounding factors.&lt;br&gt;
Results: Among patients with clinical stage I disease, 79.3% were upstaged to stage II or higher postoperatively. Unadjusted analyses revealed no statistically significant differences in OS and RFS between the total and partial thymectomy groups, although a trend toward poorer outcomes in the partial thymectomy group was observed. After overlap weighting, partial thymectomy was associated with significantly poorer OS (P = 0.0027) and higher recurrence risk (P &lt; 0.0001). Early postoperative recurrence occurred more frequently in the partial thymectomy group.&lt;br&gt;
Conclusion: Partial thymectomy was associated with significantly worse survival and recurrence outcomes in thymic carcinoma. Given the limitations of preoperative diagnosis, total thymectomy should remain the preferred surgical approach for undiagnosed thymic epithelial tumors to achieve optimal oncologic control and minimize the risk of recurrence.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">partial thymectomy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">real-world data analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">retrospective comparative cohort study</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">thymic carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">thymic epithelial tumors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">total thymectomy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0007-1188</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Induction of IL-9-producing CD8+ T cells by ascochlorin derivatives</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Natsumi</FirstName>
        <LastName>Imano</LastName>
        <Affiliation>Department of Immunology, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mikako</FirstName>
        <LastName>Nishida</LastName>
        <Affiliation>Department of Metabolic Immune Regulation, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miho</FirstName>
        <LastName>Tokumasu</LastName>
        <Affiliation>Department of Immunology, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Weiyang</FirstName>
        <LastName>Zhao</LastName>
        <Affiliation>Department of Immunology, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nahoko</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Metabolic Immune Regulation, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Heiichiro</FirstName>
        <LastName>Udono</LastName>
        <Affiliation>Department of Metabolic Immune Regulation, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background and Purpose: Ascochlorin (ASC) is an antiviral antibiotic from the fermented broth of Ascochyta viciae which exerts an inhibitory effect to cancers. Its impact on immune cells has not been examined. In this study, we obtained ASC derivatives with less cytotoxicity and determined whether they affected T cells, indicating possible immune-mediated antitumour effects.&lt;br&gt;
Experimental Approach: Newly synthesised ASC derivatives were screened for inhibitory effects on T-cell antigen receptor (TCR)-stimulated proliferative responses using murine CD4+ and CD8+ T cells. Two compounds were identified that exhibited &gt;10-fold less toxicity compared with ASC. N184, the less toxic of the two, was analysed for its in vivo antitumour effects, and in vitro effects on CD8+ T-cell proliferation, survival, cytokine production and exhaustion, using microscopy, qPCR and flow cytometry.&lt;br&gt;
Key Results: N184 induced limited IL-9 production in CD8+ T cells following TCR stimulation, thereby improving cell survival. It also enhanced cytokine production in the late phase of proliferation and suppressed the induction of exhaustion. N184 suppressed tumour growth in mice in a CD8+ T cell-dependent manner. The effect was partially prevented by an IL-9-neutralising antibody.&lt;br&gt;
Conclusion and Implications: N184 induces differentiation of IL-9-producing CD8+ T cells in vitro and elicits antitumour immunity in an IL-9-dependent manner.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">ascochlorin derivative</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CD8 positive T lymphocytes</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cell survival</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">IFN-γ</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">interleukin-9</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tc9</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tumour immunity</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Frontiers Media SA</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2235-2988</Issn>
      <Volume>15</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Binding of IgA1 and surface-expressed collagen-binding protein of Streptococcus mutans contributes to IgA nephropathy pathogenesis</ArticleTitle>
    <FirstPage LZero="delete">1673581</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Daiki</FirstName>
        <LastName>Matsuoka</LastName>
        <Affiliation>Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kana</FirstName>
        <LastName>Suehara</LastName>
        <Affiliation>Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuhei</FirstName>
        <LastName>Naka</LastName>
        <Affiliation>Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taro</FirstName>
        <LastName>Misaki</LastName>
        <Affiliation>Division of Nephrology, Seirei Hamamatsu General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuyuki</FirstName>
        <LastName>Nagasawa</LastName>
        <Affiliation>Department of General Internal Medicine, Hyogo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seigo</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Department of Internal Medicine, Japan Self-Defense Force Iruma Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuto</FirstName>
        <LastName>Suehiro</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryota</FirstName>
        <LastName>Nomura</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michiyo</FirstName>
        <LastName>Matsumoto-Nakano</LastName>
        <Affiliation>Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: The present study was conducted to examine the interaction between collagen-binding protein (Cnm) of Streptococcus mutans and immunoglobulin (IgA) to clarify the possible involvement in IgA nephropathy (IgAN) development.&lt;br&gt;
Methods: The binding of Cnm to human immunoglobulins was examined using an enzyme-linked immunosorbent assay. A nephritis-induced rat model was employed to confirm the localization of Cnm.&lt;br&gt;
Results: IgA1 showed significantly greater binding ability to Cnm than to other bacterial surface proteins, and Cnm showed significantly greater binding ability to IgA1 than to other immunoglobulins. In rats administered Cnm, IgA deposition was observed in the glomerular mesangial region. Furthermore, biotin-labeled Cnm was observed in the same region as IgA deposition in the Cnm group.&lt;br&gt;
Conclusions: Taken together, it is considered that following invasion into the bloodstream, Cnm binds to and forms a complex with IgA1, leading to deposition of IgA1 in renal glomeruli.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">bacterial surface proteins</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">collagen-binding protein</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">human immunoglobulins</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">IgA nephropathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Streptococcus mutans</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effective Treatment of Advanced Hepatocellular Carcinoma with Extensive Peritoneal Dissemination Using Lenvatinib</ArticleTitle>
    <FirstPage LZero="delete">69</FirstPage>
    <LastPage>74</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shinya</FirstName>
        <LastName>Wakatsuki</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinya</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Ueno</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takaomi</FirstName>
        <LastName>Namba</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yorito</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manabu</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Diagnostic Pathology, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Diagnostic Pathology, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Okabayashi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/70075</ArticleId>
    </ArticleIdList>
    <Abstract>Patients with hepatocellular carcinoma (HCC) and extensive peritoneal dissemination generally have a poor prognosis and are often resistant to systemic therapy. We report the case of a 47-year-old woman with HCC and massive peritoneal dissemination who presented with malignant ascites requiring repeated cell-free and concentrated ascites reinfusion therapy and peritoneovenous shunt placement, as well as malignant pleural effusion requiring pleurodesis. Combined immunotherapy with durvalumab/tremelimumab was initiated;however, disease progression was observed after three treatment courses, prompting a switch to lenvatinib therapy. Two months after initiation of lenvatinib, CT imaging demonstrated complete disappearance of arterial enhancement in the primary hepatic lesion, along with reduction in the size of peritoneal dissemination nodules. Thirteen months after switching to lenvatinib (16 months after the initial diagnosis), the alpha-fetoprotein level continued to decrease, and the disease remained stable under treatment. Despite the extremely high tumor burden, lenvatinib achieved disease stabilization and symptomatic improvement.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">diagnostic laparoscopy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hepatocellular carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">peritoneal dissemination</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lenvatinib</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Metastatic Intraocular Tumor Likely from Hepatocellular Carcinoma Mimicking Panuveitis</ArticleTitle>
    <FirstPage LZero="delete">63</FirstPage>
    <LastPage>67</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Eri</FirstName>
        <LastName>Takasu</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Shiode</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroya</FirstName>
        <LastName>Kindo</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuhei</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mio</FirstName>
        <LastName>Hosokawa</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Matoba</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Kanzaki</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuro</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Adachi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Morizane</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/70074</ArticleId>
    </ArticleIdList>
    <Abstract>A 77-year-old man undergoing treatment for hepatocellular carcinoma (HCC) presented with blurred vision in his right eye, persisting for 2 months. Slit-lamp microscopy and fundus examination revealed inflammatory cells in the anterior chamber, severe vitreous opacities, and retinal vasculitis in the right eye. The patient underwent vitreous surgery with biopsy, and vitreous cytology confirmed a metastatic intraocular tumor originating from the HCC. Radiotherapy was administered to the right eye, with no recurrence of intraocular inflammation observed at 10 months post-irradiation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">metastatic intraocular tumor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hepatocellular carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">panuveitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">uveitis masquerade syndrome</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Changes in Prescribing Patterns of Antiviral Drugs before and after Public Coverage Termination among Hospitalized COVID-19 Patients in Regional Hospitals in Japan: A Retrospective, Multicenter Study</ArticleTitle>
    <FirstPage LZero="delete">55</FirstPage>
    <LastPage>62</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hidemasa</FirstName>
        <LastName>Akazawa</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinnosuke</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shohei</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumio</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/70073</ArticleId>
    </ArticleIdList>
    <Abstract>In Japan, antiviral agents for COVID-19 were freely available until September 2023 as part of national policy. This study evaluated changes in these agents’ prescribing patterns and the patient outcomes following the policy shift. We conducted a multicenter retrospective study at four hospitals in Japan’s Okayama and Kagawa prefectures from January 2022 to March 2024. The study period was divided into the public-expenditure phase (January 2022 to September 2023) and the post-expenditure phase (October 2023 to March 2024). We extracted the hospitalized patients’ clinical data from the electronic database. The study’s primary outcome was the antiviral prescription rate; the secondary outcome was in-hospital mortality. Among the 302 hospitalized patients (median age 85 years), 52.0% were classified as having a mild condition. Of the patients with mild conditions, 37.7% were diagnosed in outpatient settings prior to hospitalization. During the public-expenditure phase, 47.4% of the patients received antivirals as outpatients, mainly molnupiravir (80.9%). In the post-expenditure period, 80.0% of the patients were prescribed antivirals, mostly molnupiravir (91.7%). The antiviral prescription rate was significantly higher after the policy change. The overall in-hospital mortality was 15.8%, with no significant difference between the two periods (17.0% vs. 10.5%). Despite the termination of government funding, antiviral prescriptions remained frequent at community hospitals located in highly aging regions of western Japan such as Okayama and Kagawa prefectures. Mortality remains high among the elderly, highlighting the need for continued antiviral therapy and booster vaccinations.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">coronavirus disease 2019</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">public expenditure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">prescribing pattern</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">prognosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Japan</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Time Course of the Development and Loss of Delta-9-tetrahydrocannabinol Tolerance: Effects on Hypothermia and Spontaneous Locomotor Activity in Mice</ArticleTitle>
    <FirstPage LZero="delete">47</FirstPage>
    <LastPage>54</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yukiomi</FirstName>
        <LastName>Eguchi</LastName>
        <Affiliation>Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soichiro</FirstName>
        <LastName>Ushio</LastName>
        <Affiliation>Department of Emergency and Disaster Medical Pharmacy, Faculty of Pharmaceutical Sciences, Fukuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichi</FirstName>
        <LastName>Irie</LastName>
        <Affiliation>Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuta</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miyu</FirstName>
        <LastName>Eguchi</LastName>
        <Affiliation>Department of Emergency and Disaster Medical Pharmacy, Faculty of Pharmaceutical Sciences, Fukuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Oncology and Infectious Disease Pharmacy, Faculty of Pharmaceutical Sciences, Fukuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenichi</FirstName>
        <LastName>Mishima</LastName>
        <Affiliation>Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/70072</ArticleId>
    </ArticleIdList>
    <Abstract>Deregulation of cannabis use is gradually expanding in Europe and the United States. However, the biological processes driving tolerance to delta-9-tetrahydrocannabinol (Δ9-THC), the main psychoactive component of cannabis, remain unclear. Thus, this study aimed to investigate the mechanisms and time course of tolerance development and loss to Δ9-THC in mice. Male ICR mice (7 weeks old) were administered Δ9-THC once daily for 3 days and then divided into three groups according to the washout period (3-, 10-, and 17-day washout groups). After each washout, changes in body temperature and locomotor activity were measured following re-exposure to Δ9-THC. Furthermore, the mRNA expression levels of CB1 and CB2 receptors in the brain were evaluated using real-time PCR. On day 1, significant hypothermia and reduced spontaneous locomotor activity were observed in the Δ9-THC-treated mice compared with the vehicle-treated mice. Tolerance to the hypothermic and locomotor-suppressing effects of Δ9-THC developed on days 2 and 3, respectively, and dissipated after 3 and 11 days of washout, respectively. These differences in the rates of tolerance development and recovery may reflect distinct underlying mechanisms. No significant changes in receptor mRNA expression were observed. These findings highlight the complexity of Δ9-THC tolerance and its potential implications for long-term cannabis use.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">delta-9-tetrahydrocannabinol</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cannabis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tolerance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">locomotor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hypothermic</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Kinesiophobia Is Associated with Disability, Poor Quality of Life, Psychological Morbidity, and Surgery Dissatisfaction in Patients with Lumbar Microdiscetomy: A Cross-Sectional Controlled Study</ArticleTitle>
    <FirstPage LZero="delete">39</FirstPage>
    <LastPage>46</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Nihal</FirstName>
        <LastName>Tezel</LastName>
        <Affiliation>Department of Physical and Rehabilitation Medicine, Health Sciences University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aslı Gençay</FirstName>
        <LastName>Can</LastName>
        <Affiliation>Department of Physical and Rehabilitation Medicine, Faculty of Medicine, Ankara Yıldırım Beyazıt University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/70071</ArticleId>
    </ArticleIdList>
    <Abstract>The study aimed to determine the prevalence of kinesiophobia in patients who had undergone lumbar microdiscectomy and to examine its associations with pain intensity, disability, quality of life, depression, anxiety, and satisfaction with surgery. Forty-eight patients with microdiscectomy and 48 healthy controls were enrolled. The Tampa Scale for Kinesiophobia (TSK), Roland-Morris Disability Index (RMDI), Hospital Anxiety and Depression Scale (HADS-A and HADS-D, respectively), and Short Form-36 Health Survey (SF-36) were administered to both groups. The scores of TSK, RMDI, HADS-A, and HADS-D were significantly higher and SF-36 scores were significantly lower in the microdiscectomy than the control group (p&lt;0.001 for all). In the microdiscectomy group, median (min-max) RMDI, HADS-A, and HADS-D scores were 19 (4-34), 10 (0-18), and 9 (0-18), respectively, in kinesiophobic patients, and were significantly higher than 6 (2-20), 3 (0-11), 2.5 (0-11) in non-kinesiophobic patients (all p&lt;0.001). The median (min-max) SF-36 PCS, SF-36 MCS, and VAS scores for surgery satisfaction were 36.5 (8.7-75), 52.1 (11-95), 5, 5 (0-10), respectively, in kinesiophobic patients and were significantly lower than 71 (28-95), 85.5 (9-93), 8.5 (3-10) in non-kinesiophobic patients (all p&lt;0.05). TSK scores were significantly correlated with RMDI, HADS-A, HADS-D, SF-36, and surgery satisfaction scores (all p&lt;0.05). Kinesiophobic patients with lumbar microdiscectomy therefore showed greater disability and psychological morbidity, poorer quality of life, and lower satisfaction with surgery.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">kinesiophobia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">microdiscectomy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">disability</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">quality of life</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">depression</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The Preoperative Anterior Pelvic Plane Angle Predicts Cup Anteversion Changes at 1 Year after Total Hip Arthroplasty</ArticleTitle>
    <FirstPage LZero="delete">31</FirstPage>
    <LastPage>37</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kyota</FirstName>
        <LastName>Ishibashi</LastName>
        <Affiliation>Department of Orthopedic Surgery, Hachinohe City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirotaka</FirstName>
        <LastName>Oishi</LastName>
        <Affiliation>Department of Orthopedic Surgery, Hachinohe City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Department of Orthopedic Surgery, Hachinohe City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosuke</FirstName>
        <LastName>Kawamura</LastName>
        <Affiliation>Department of Orthopedic Surgery, Hachinohe City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Isamu</FirstName>
        <LastName>Sasaki</LastName>
        <Affiliation>Department of Orthopedic Surgery, Hachinohe City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiji</FirstName>
        <LastName>Sasaki</LastName>
        <Affiliation>Department of Orthopedic Surgery, Hirosaki University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hikaru</FirstName>
        <LastName>Kamada</LastName>
        <Affiliation>Department of Orthopedic Surgery, Hachinohe City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masakazu</FirstName>
        <LastName>Kogawa</LastName>
        <Affiliation>Department of Orthopedic Surgery, Hachinohe City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sunao</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Orthopedic Surgery, Hachinohe City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Numasawa</LastName>
        <Affiliation>Department of Orthopedic Surgery, Hachinohe City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuyuki</FirstName>
        <LastName>Ishibashi</LastName>
        <Affiliation>Department of Orthopedic Surgery, Hirosaki University Graduate School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/70070</ArticleId>
    </ArticleIdList>
    <Abstract>We investigated global alignment changes following total hip arthroplasty (THA) and predictive alignment parameters for increased cup anteversion (CA) by retrospectively analyzing the primary THA data of 75 patients treated at our hospital (49 women, 26 men; age 65.1±5.7 years, BMI 28.3±3.4 kg/m2). Global alignment parameters, i.e., the anterior pelvic plane angle (APPa) and proximal femoral shaft angle (PFSa) and other alignment parameters were measured. CA was evaluated based on the patients’ standing coronal radiographs. ΔCA was defined as the difference in CA from 2 weeks before to 1 year after each THA. We classified the cases as stable (S) (CA &lt; 10°; n=63) and pelvic retroversion (R) (CA ≥ 10°; n=12) groups. Associations between ΔCA and alignment parameters were evaluated by linear regression and a receiver operating characteristic (ROC) analysis. A significant decrease in the PFSa occurred between the 2-week and 1-year post-THA timepoints (7.8±4.3° vs. 4.2±3.6°, p&lt;0.001), with no notable change in other alignment parameters. At 1-year post-THA, the CA of 12 (16%) patients had increased to 4.5±4.4°. Only the preoperative APPa was positively associated with ΔCA (β=0.165, p=0.020). The ROC analysis revealed that the optimal cut-off value for increased CA in the APPa is 2.1° (area under the curve, 0.700; p=0.020; odds ratio, 4.80). The APPa change predicted increased CA, which emphasizes the importance of the use of preoperative standing radiography for identifying the optimal cup positioning for post-THA changes in CA.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">total hip arthroplasty</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">global alignment</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">anterior pelvic plane</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cup anteversion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pelvic tilt</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Development of a Stroke Discharge Support Evaluation Scale for Ward Nurses in Acute Care Hospitals</ArticleTitle>
    <FirstPage LZero="delete">17</FirstPage>
    <LastPage>30</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Yano</LastName>
        <Affiliation>Department of Nursing, Faculty of Human Health Sciences, Niimi University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoko</FirstName>
        <LastName>Takahata</LastName>
        <Affiliation>Graduate School of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Yamaguchi</LastName>
        <Affiliation>Faculty of Nursing, Shikoku University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinya</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Graduate School of Health Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/70069</ArticleId>
    </ArticleIdList>
    <Abstract>This study aimed to develop a scale enabling nurses to objectively evaluate their own stroke discharge support, as a basis for enhancing its overall effectiveness. A draft scale was created based on a literature review, and consisted of a 51-item, 5-point Likert-type questionnaire administered to ward nurses engaged in stroke discharge support at acute care hospitals. Factor analysis was performed to refine the scale. Construct validity was assessed using the known-groups method, and reliability was evaluated through internal consistency analysis. The resulting Stroke Discharge Support Evaluation Scale comprises 29 items across 5 factors, each rated on a 5-point Likert scale. Analysis of the data collected from 237 valid responses demonstrated good internal consistency and supported the scale’s construct validity. The Stroke Discharge Support Evaluation Scale is a reliable and valid tool enabling ward nurses in acute care hospitals to evaluate their own stroke discharge support.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">stroke</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">discharge support</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">scale development</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Novel Nomogram that Predicts Chronic Hemodialysis Patients’ Survival Based on Their Sedentary Behavior</ArticleTitle>
    <FirstPage LZero="delete">9</FirstPage>
    <LastPage>16</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Sugahara</LastName>
        <Affiliation>Department of Hygiene, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Innoshima General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuyuki</FirstName>
        <LastName>Miyatake</LastName>
        <Affiliation>Department of Hygiene, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Nishi</LastName>
        <Affiliation>Innoshima General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Ujike</LastName>
        <Affiliation>Innoshima General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiichi</FirstName>
        <LastName>Koumoto</LastName>
        <Affiliation>Innoshima General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichi</FirstName>
        <LastName>Namio</LastName>
        <Affiliation>Department of Hygiene, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuhei</FirstName>
        <LastName>Hishii</LastName>
        <Affiliation>Department of Hygiene, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Faculty of Social Studies, Shikokugakuin University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromi</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Hygiene, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yorimasa</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Innoshima General Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/70068</ArticleId>
    </ArticleIdList>
    <Abstract>Appropriate treatments for chronic hemodialysis patients are a public health challenge in Japan. Sedentary behavior appears to be closely associated with these patients’ survival. We thus sought to develop a nomogram that predicts survival based on the duration of chronic hemodialysis patients’ sedentary behavior. One hundred twenty-four patients under chronic hemodialysis (73 men, 51 women, age 71.7±11.1 years) were enrolled in this cohort study. The patients wore a triaxial accelerometer that measured both their sedentary behavior, i.e., total sedentary behavior (minutes) and their maximum sedentary bouts (min) on non-hemodialysis days. We obtained the Kaplan-Meier curve and used the log-rank test and a Cox proportional hazards model to evaluate the relationship between the patients’ sedentary behavior and their survival. We also used a Cox proportional hazards model to develop a nomogram for the patients’ 5-year survival rate. Forty-six patients died during the follow-up period. When we stratified the patients by the medians of total sedentary behavior and maximum sedentary bouts, we observed significant between-group differences. After adjustment for confounding factors in a Cox proportional hazards model, total sedentary behavior and maximum sedentary bouts were identified as critical survival factors, and we generated a nomogram using an index of sedentary behavior. Our analysis results demonstrated that sedentary behavior on non-dialysis days was closely associated with the survival of the chronic hemodialysis patients, suggesting that a decrease in sedentary behavior would prolong their survival. The nomogram developed herein based on sedentary behavior may be useful for predicting the outcomes of chronic hemodialysis patients.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">nomogram</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">chronic hemodialysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">sedentary behavior</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cox proportional hazards model</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Kaplan- Meier curve</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Usefulness of D-dimer Assay to Confirm the Course of Overt Venous Thromboembolism (VTE) in Cancer Patients</ArticleTitle>
    <FirstPage LZero="delete">1</FirstPage>
    <LastPage>7</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hidenaru</FirstName>
        <LastName>Yamaoka</LastName>
        <Affiliation>Department of Cardiovascular Medicine, IMS Tokyo Katsushika General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiro</FirstName>
        <LastName>Sarashina</LastName>
        <Affiliation>Seisukai Kuroda Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Akagi</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuru</FirstName>
        <LastName>Munemasa</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazufumi</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Department of General Internal Medicine 3, Kawasaki Medical School General Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinsuke</FirstName>
        <LastName>Yuasa</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/70067</ArticleId>
    </ArticleIdList>
    <Abstract>Venous thromboembolism (VTE) is a serious complication in patients with cancer. In this population, the presence of thrombi is often assessed at cancer diagnosis by measuring D-dimer levels, which have high sensitivity but low specificity for identifying VTE at this clinical time point. However, the usefulness of D-dimer measurement during anticoagulation therapy has not been fully established, despite its widespread use. In this retrospective observational study, we investigated whether D-dimer measurement during anticoagulation therapy in cancer patients could predict overt VTE at follow-up. The study included patients who underwent D-dimer testing and contrast-enhanced computed tomography between 30 and 100 days after initiation of anticoagulation therapy. Eighty-two patients were included: 60 with cancer and 22 without. The diagnostic performance of D-dimer for overt VTE was as follows: sensitivity, 85.7%; specificity, 87.2%; positive predictive value, 78.3%; and negative predictive value, 89.2%. These findings suggest that D-dimer measurement at follow-up has high sensitivity and specificity for overt VTE in cancer patients and may aid in assessing thrombotic status. Clinically, if anticoagulation therapy is continued until D-dimer levels become negative, the absence of overt VTE could be inferred without additional invasive testing.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">D-dimer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">venous</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">thromboembolism</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cancer</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0001-690X</Issn>
      <Volume>153</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Impact of Schizophrenia Spectrum Disorders on the Receipt of Invasive and Systemic Therapy for Colorectal Cancer: A Nationwide Multicenter Retrospective Cohort Study in Japan</ArticleTitle>
    <FirstPage LZero="delete">191</FirstPage>
    <LastPage>199</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Neuropsychiatry, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuto</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taisuke</FirstName>
        <LastName>Ishii</LastName>
        <Affiliation>Division of Health Services Research, National Cancer Center Institute for Cancer Control, National Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomone</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Division of Health Services Research, National Cancer Center Institute for Cancer Control, National Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maiko</FirstName>
        <LastName>Fujimori</LastName>
        <Affiliation>Division of Survivorship Research, National Cancer Center Institute for Cancer Control, National Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Nakaya</LastName>
        <Affiliation>Tohoku Medical Megabank Organization, Tohoku University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Kawamura</LastName>
        <Affiliation>Department of Medical Informatics, Shimane University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Otsuki</LastName>
        <Affiliation>Department of Psychiatry, Faculty of Medicine, Shimane University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunitoshi</FirstName>
        <LastName>Shigeyasu</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taichi</FirstName>
        <LastName>Shimazu</LastName>
        <Affiliation>Division of Behavioral Sciences, National Cancer Center Institute for Cancer Control, National Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shiro</FirstName>
        <LastName>Hinotsu</LastName>
        <Affiliation>Department of Biostatistics and Data Management, Sapporo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Uchitomi</LastName>
        <Affiliation>Department of Cancer Survivorship and Digital Medicine, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masatoshi</FirstName>
        <LastName>Inagaki</LastName>
        <Affiliation>Department of Psychiatry, Faculty of Medicine, Shimane University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: This study examined treatment disparities for colorectal cancer among patients diagnosed with schizophrenia spectrum disorders (SSD), focusing on invasive treatments and stage-appropriate systemic therapy within a universal healthcare system.&lt;br&gt;
Method: In this nationwide retrospective cohort study (2018–2021), we identified 248,966 colorectal cancer patients, including 2337 diagnosed with SSD, using linked cancer registry and insurance claims data in Japan. The presence of SSD was classified according to ICD-10 codes F20–29. We used multivariable logistic regression to compare the odds of receiving stage-appropriate adjuvant chemotherapy and systemic therapy, as well as the odds of receiving surgical or endoscopic treatments, between the two groups. The analysis adjusted for age, sex, clinical stage, and scores on the Charlson Comorbidity Index and Barthel Index.&lt;br&gt;
Results: The clinical stage distribution at diagnosis for colorectal cancer differed significantly between patients with SSD and those without psychiatric disorders (p &lt; 0.001). After adjusting for clinical stage and other covariates, patients with SSD demonstrated significantly lower odds of receiving surgical or endoscopic treatment (adjusted odds ratio [aOR], 0.83; 95% CI, 0.73–0.94). The disparities were more pronounced for systemic therapy; patients with SSD had substantially lower odds of receiving adjuvant chemotherapy for stage III disease (aOR, 0.33; 95% CI, 0.26–0.41) and systemic therapy for stage IV disease (aOR, 0.23; 95% CI, 0.17–0.31).&lt;br&gt;
Conclusion: Patients with SSD encounter substantial disparities in accessing standard colorectal cancer care, particularly systemic therapies. These findings highlight the urgent need for interventions to ensure equitable cancer treatment for this vulnerable population.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">colorectal cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">healthcare disparities</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">psycho-oncology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">schizophrenia spectrum disorders</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2077-0383</Issn>
      <Volume>15</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Perioperative Ozoralizumab Management for Patients with Rheumatoid Arthritis Who Underwent Orthopaedic Surgery: A Retrospective Case Series</ArticleTitle>
    <FirstPage LZero="delete">1422</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Nishida</LastName>
        <Affiliation>Locomotive Pain Center, Faculty of Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihisa</FirstName>
        <LastName>Nasu</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryozo</FirstName>
        <LastName>Harada</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kurashiki Sweet Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuichi</FirstName>
        <LastName>Nakahara</LastName>
        <Affiliation>Locomotive Pain Center, Faculty of Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Horita</LastName>
        <Affiliation>Locomotive Pain Center, Faculty of Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masamitsu</FirstName>
        <LastName>Natsumeda</LastName>
        <Affiliation>Rheumatic Disease Center, Mabi Memorial Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuichi</FirstName>
        <LastName>Naniwa</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Objectives: Launched in Japan in 2022, ozoralizumab (OZR) is a novel, anti-tumour necrosis factor (TNF)-α inhibitor for treating rheumatoid arthritis (RA) that is refractory to conventional therapies. However, there is a lack of evidence regarding its perioperative management. Methods: This retrospective case series included nine patients with RA who underwent a total of 12 either RA-related (n = 9) or unrelated (n = 3) orthopaedic procedures. We reviewed patient demographics, surgical procedures, perioperative OZR discontinuation periods, and postoperative complications. Results: The mean preoperative OZR discontinuation period was 15.8 days (range, 2–25 days). Sutures were removed at a mean of 12.8 days postoperatively (range, 11–14 days) after adequate wound healing had been confirmed. The mean total discontinuation period was 34.9 days (range, 27–43 days). No cases of surgical site infection (SSI) or delayed wound healing (DWH) were observed during a minimum follow-up period of three months. One patient experienced a disease flare before OZR was restarted. Conclusions: Preoperative OZR discontinuation for up to four weeks appeared to be safe in this cohort. These findings may assist orthopaedic surgeons in determining an appropriate perioperative discontinuation strategy for OZR that minimises SSI and DWH risk while reducing the likelihood of RA flare.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">delayed wound healing</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">discontinuation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ozoralizumab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">orthopaedic surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">perioperative management</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">rheumatoid arthritis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">surgical site infection</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2221-3759</Issn>
      <Volume>14</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The Influence of Fluidic Flow Stress on the Development of the Secondary Palate</ArticleTitle>
    <FirstPage LZero="delete">9</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masayo</FirstName>
        <LastName>Nagata</LastName>
        <Affiliation>Department of Orthodontics, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Hayano</LastName>
        <Affiliation>Department of Orthodontics, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ziyi</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Department of Molecular Biology and Biochemistry, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Kosami</LastName>
        <Affiliation>Department of Orthodontics, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Kamioka</LastName>
        <Affiliation>Department of Orthodontics, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Craniofacial development is orchestrated by a finely regulated interplay of numerous genes and signaling pathways. Palatogenesis proceeds through a complex, stepwise process, in which endogenous mechanical stresses within tissues have been implicated. However, the impact of exogenous fluidic flow mechanical stress derived from maternal movement on palatal development remains unclear. In this study, we investigated the effect of exogenous fluidic flow mechanical stress on palatal morphogenesis, focusing on the horizontal outgrowth of palatal shelves after elevation. Palatal tissues dissected from mouse embryos were subjected to organ culture with or without mechanical loading (loaded and unloaded groups, respectively). Stress magnitude was quantified by calculating wave energy, and morphometric and molecular analyses were performed. Compared with the unloaded group, palatal shelves in the loaded group showed significant increases in thickness and volume, accompanied by enhanced cell proliferation, nuclear translocation of YAP and β-catenin, and upregulation of the osteogenic markers Osterix and Osteocalcin. No significant difference in apoptosis was observed. These findings indicate that exogenous mechanical stress promotes cell proliferation and osteogenic differentiation through the Hippo and WNT/β-catenin pathways in palate explants. Our results suggest that moderate maternal movement-induced mechanical stress contributes to normal palatogenesis, providing new insights into the mechanisms underlying cleft palate.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">mechanical stress</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">palatal development</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">β-catenin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">YAP</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0031-9317</Issn>
      <Volume>178</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Reactive Carbonyl Species Mediate Isothiocyanate Signaling Pathway in Arabidopsis thaliana Guard Cells</ArticleTitle>
    <FirstPage LZero="delete">e70775</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sumaiya</FirstName>
        <LastName>Farzana</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Md. Moshiul</FirstName>
        <LastName>Islam</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshimasa</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shintaro</FirstName>
        <LastName>Munemasa</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun'ichi</FirstName>
        <LastName>Mano</LastName>
        <Affiliation>Science Research Center, Yamaguchi University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiyuki</FirstName>
        <LastName>Murata</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Our previous results demonstrated that depletion of glutathione (GSH) rather than elevation of levels of reactive oxygen species (ROS) is highly correlated with the decrease in stomatal aperture induced by isothiocyanates (ITCs), although ROS is considered a key second messenger in stomatal closure, suggesting that another signal component regulates stomatal apertures along with GSH depletion. This study, using Arabidopsis, clarified that reactive carbonyl species (RCS), especially acrolein and 4-hydroxy-(E)-2-nonenal, are determinants of stomatal aperture responses to ITCs. All tested ITCs, allyl isothiocyanate (AITC), sulforaphane (SFN), benzyl isothiocyanate (BITC), and phenethyl isothiocyanate (PEITC), significantly induced stomatal closure, which was inhibited by the RCS scavengers, carnosine and pyridoxamine. The RCS scavengers suppressed ITC-induced depletion of GSH but not elevation of ROS levels. All tested ITCs (AITC, SFN, BITC, and PEITC) increased levels of RCS and non-RCS aldehydes in the epidermal tissues. However, acrolein, 4-hydroxy-(E)-2-nonenal, crotonaldehyde, and (E)-2-pentenal induced stomatal closure at 10 and 100 μM, whereas propionaldehyde, butyraldehyde, and n-pentanal did not at concentrations up to 100 μM. Acrolein and 4-hydroxy-(E)-2-nonenal more effectively induced stomatal closure and GSH depletion than crotonaldehyde and (E)-2-pentenal did. The contents of RCS were more strongly correlated with GSH levels and stomatal closure than with ROS levels. These results suggest that RCS, especially acrolein and 4-hydroxy-(E)-2-nonenal, acts as key regulators of stomatal closure in guard cells in response to ITCs.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">arabidopsis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">GSH depletion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">isothiocyanate</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">reactive carbonyl species</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">reactive oxygen species</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1422-0067</Issn>
      <Volume>26</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Specific Heat-Killed Lactic Acid Bacteria Enhance Mucosal Aminopeptidase N Activity in the Small Intestine of Aged Mice</ArticleTitle>
    <FirstPage LZero="delete">5742</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Tsuruta</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mami</FirstName>
        <LastName>Wakisaka</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takumi</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Bio-Lab Co., Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aoi</FirstName>
        <LastName>Nishijima</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihito</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mao</FirstName>
        <LastName>Teraoka</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tianyang</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kuiyi</FirstName>
        <LastName>Chen</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Nishino</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Aminopeptidase N (APN), an enzyme expressed in the small intestinal mucosa, is involved in dietary protein digestion. Previous studies have shown that oral administration of fermented milk containing lactic acid bacteria (LAB) enhances mucosal APN activity in young mice. This study aimed to investigate whether LAB strains stimulate mucosal APN activity in aged mice and to evaluate its relevance to age-related changes in body composition. The underlying molecular mechanisms were also explored in vitro. Experiment 1: Aged C57BL/6J mice were fed diets supplemented with heat-killed LAB strains—Enterococcus faecalis OU-23 (EF), Leuconostoc mesenteroides OU-03 (LM), or Lactiplantibacillus plantarum SNK12 (LP). Compared to the aged Control group, the ileal APN activity was significantly higher in the LP group. LP administration also elevated serum Gla-osteocalcin levels and decreased serum CTX-1 levels. Experiment 2: IEC-6 cells were co-cultured with LP that had been treated with RNase, DNase, or lysozyme. APN activity was significantly lower in cells co-cultured with DNase- or lysozyme-treated LP compared to those co-cultured with untreated LP. A specific LAB strain may enhance mucosal APN activity in the aged intestine, potentially contributing to improved bone metabolism. This effect may be mediated by bacterial DNA and peptidoglycan.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">aging</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">aminopeptidase N</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bone metabolism</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lactic acid bacteria</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">small intestine</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Proceedings of the National Academy of Sciences</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0027-8424</Issn>
      <Volume>123</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A nuclear CobW/WW-domain factor represses the CO2-concentrating mechanism in the green alga Chlamydomonas reinhardtii</ArticleTitle>
    <FirstPage LZero="delete">e2518136123</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Shimamura</LastName>
        <Affiliation>Graduate School of Biostudies, Division of Integrated Life Science, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Yasuda</LastName>
        <Affiliation>Graduate School of Biostudies, Division of Integrated Life Science, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Yamahara</LastName>
        <Affiliation>Graduate School of Biostudies, Division of Integrated Life Science, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirobumi</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Graduate School of Biostudies, Division of Integrated Life Science, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin-Ichiro</FirstName>
        <LastName>Ozawa</LastName>
        <Affiliation>Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryutaro</FirstName>
        <LastName>Tokutsu</LastName>
        <Affiliation>Graduate School of Science, Division of Biological Sciences, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayumi</FirstName>
        <LastName>Yamagami</LastName>
        <Affiliation>Graduate School of Biostudies, Division of Integrated Life Science, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomonao</FirstName>
        <LastName>Matsushita</LastName>
        <Affiliation>Graduate School of Science, Division of Biological Sciences, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichiro</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Graduate School of Biostudies, Division of Integrated Life Science, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideya</FirstName>
        <LastName>Fukuzawa</LastName>
        <Affiliation>Graduate School of Biostudies, Division of Integrated Life Science, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yamano</LastName>
        <Affiliation>Graduate School of Biostudies, Division of Integrated Life Science, Kyoto University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Microalgae induce a CO2-concentrating mechanism (CCM) to maintain photosynthesis when CO2 is limited. Because this system consumes a substantial portion of photosynthetically generated ATP, its suppression when CO2 levels rise is critical for energy balance, yet the underlying mechanism remains unclear. Here, we identify a nuclear repressor of the CCM in the green alga Chlamydomonas reinhardtii. A pull-down screen for interacting partners of the master activator CCM1/CIA5 revealed an uncharacterized protein that tightly associates with CCM1. This protein, CCM1-binding protein 1 (CBP1), combines a CobW/CobW_C GTP-binding metallochaperone module with a WW-domain characteristic of protein–protein interactions. CBP1 colocalizes and interacts with CCM1 in the nucleus regardless of CO2 conditions. Disruption of CBP1 does not affect growth or CCM induction under CO2 limitation but derepresses 27 of 41 CCM1-dependent low-CO2 inducible genes under high-CO2 conditions. These include the periplasmic and intracellular carbonic anhydrases (CAH1 and LCIB) and inorganic carbon transporters/channels (LCIA, LCI1, BST1, and BST3). Consistently, cbp1 mutants accumulate CAH1 and LCIB proteins and exhibit 40% higher inorganic carbon affinity under high-CO2 conditions; this phenotype is rescued by CBP1 complementation or by acetazolamide treatment. Crucially, cbp1 mutants exhibit significant growth delays under high-CO2 conditions, especially when light is limiting, providing direct evidence that CBP1-mediated repression is essential for energy conservation. Thus, CBP1 prevents unnecessary CCM activity when CO2 is abundant, acting upstream of both transporter/channel and carbonic anhydrase modules. Our findings suggest a regulatory mechanism potentially linking zinc-dependent protein chemistry to CCM gene repression, providing insights into energy-efficient CO2 sensing in aquatic photosynthetic organisms.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">carbonic anhydrase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Chlamydomonas reinhardtii</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CO2-concentrating mechanism</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">photosynthesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pyrenoid</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1521-6543</Issn>
      <Volume>65</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2013</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Synthesis of biopterin and related pterin glycosides</ArticleTitle>
    <FirstPage LZero="delete">300</FirstPage>
    <LastPage>309</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Hanaya</LastName>
        <Affiliation>Department of Chemistry, Faculty of Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>School of Pharmacy, Shujitsu University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Certain pterins having a hydroxyalkyl side chain at C-6 have been found as glycosidic forms in certain prokaryotes, such as 2′-O-(α-D-glucopyranosyl)biopterin from various kinds of cyanobacteria, and limipterin from a green sulfur photosynthetic bacterium. Synthetic studies on glycosides of biopterin and related pterins have been made in view of the structural proof as well as for closer examination of their biological activities and functions. The syntheses of these natural pterin glycosides have effectively been achieved, mostly through appropriately protected N2-(N,N-dimethylaminomethylene)-3-[2-(4-nitrophenyl)ethyl]pterin derivatives as glycosyl acceptors, and are reviewed here. © 2013 IUBMB Life 65(4):300–309, 2013.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">pteridine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pterin glycoside</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">biopterin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ciliapterin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">neopterin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">limipterin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tepidopterin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">asperopterin-A</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">protecting group</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">glycosylation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>SAGE Publications</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1756-2848</Issn>
      <Volume>19</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Clinical efficacy and safety of endoscopic ultrasound-guided ablation therapies for pancreatic neuroendocrine tumors: a systematic review and meta-analysis</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuto</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiharu</FirstName>
        <LastName>Mitsuhashi</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Pancreatic neuroendocrine tumors (pNETs) are rare; however, they are increasingly being detected. Although surgical resection remains the standard treatment, its invasiveness has prompted interest in less invasive alternatives, particularly for small non-functional pNETs (NF-pNETs) and insulinomas.&lt;br&gt;
Objectives: To evaluate the clinical efficacy and safety of endoscopic ultrasound-guided ethanol injection (EUS-EI) and radiofrequency ablation (EUS-RFA) for pNETs.&lt;br&gt;
Design: A systematic review and meta-analysis.&lt;br&gt;
Data sources and methods: A literature search of PubMed, MEDLINE, and Google Scholar was conducted (April 2005–April 2025). Studies were eligible if they reported clinical outcomes of EUS-EI or EUS-RFA in adult patients with insulinomas or NF-pNETs. The primary endpoints were clinical success (short-term symptom resolution or radiological response) and adverse event (AE) rates. Data were pooled using a random-effects model.&lt;br&gt;
Results: Twenty-six studies were included in the meta-analysis. For insulinomas, the pooled clinical success rate was 77% (95% confidence interval (CI), 59–88) for EUS-EI and 95% (95% CI, 89–97) for EUS-RFA. The pooled incidence of total AEs was 32% (95% CI, 17–51) for EUS-EI and 25% (95% CI, 15–39) for EUS-RFA. For NF-pNETs, the pooled clinical success rates were 76% (95% CI, 54–90) for EUS-EI and 85% (95% CI, 74–92) for EUS-RFA, and the pooled incidence of total AEs was 27% (95% CI, 20–35) and 26% (95% CI, 17–38), respectively. The most common moderate or severe AEs were pancreatitis in 12 patients (7.6%) after EUS-EI, and pancreatic fluid collection in 4 patients (1.9%) and pancreatic duct stricture in 3 patients (1.4%) after EUS-RFA. One fatal case occurred in a 97-year-old patient following EUS-RFA.&lt;br&gt;
Conclusion: Both EUS-EI and EUS-RFA are effective, relatively safe, and minimally invasive treatment options for pNETs. However, severe AE can occur, and careful patient selection and treatment indication are essential.&lt;br&gt;
Trial registration: Not registered.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">ablation techniques</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">endoscopic ultrasonography</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ethanol</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pancreatic neuroendocrine tumors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">radiofrequency ablation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0022-152X</Issn>
      <Volume>62</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>An Improved Synthesis of a Key Intermediate for Glycosylation of Biopterin and Its Application for the First Synthesis of Microcystbiopterin B</ArticleTitle>
    <FirstPage LZero="delete">2021</FirstPage>
    <LastPage>2029</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Hanaya</LastName>
        <Affiliation>Department of Chemistry, Faculty of Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuta</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Chemistry, Faculty of Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuya</FirstName>
        <LastName>Iwasaki</LastName>
        <Affiliation>Department of Chemistry, Faculty of Science, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>A key intermediate for the selective 2′-O-glycosylation of biopterin, N2-(N,N-dimethylaminomethylene)-1′-O-(4-methoxybenzyl)-3-[2-(4-nitrophenyl)ethyl]biopterin (12), was efficiently synthesized via a novel route starting from d-glucose, leading to an improved overall yield. This new pathway involves the preparation of a 5-deoxy-l-arabinose phenylhydrazone derivative (9) as a crucial intermediate in the construction of the pteridine ring. Utilizing compound 12, the first synthesis of microcystbiopterin B (4) was accomplished by glycosylation of 12 with 4,6-di-O-acetyl-2-O-(4-methoxybenzyl)-3-O-methyl-α-d-glucopyranosyl bromide (19) in the presence of silver triflate and tetramethylurea, followed by stepwise deprotection.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">microcystbiopterin B </Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pteridine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pterin glycoside</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">structural identification</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0022-3492</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A retrospective cohort study comparing periodontal regeneration using fibroblast growth factor‐2 versus autologous bone graft</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshiki</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Pathophysiology–Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Pathophysiology–Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Ito‐Shinoda</LastName>
        <Affiliation>Department of Pathophysiology–Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mai</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Pathophysiology–Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Ishii</LastName>
        <Affiliation>Department of Pathophysiology–Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuki</FirstName>
        <LastName>Nonomura</LastName>
        <Affiliation>Department of Pathophysiology–Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetaka</FirstName>
        <LastName>Ideguchi</LastName>
        <Affiliation>Department of Pathophysiology–Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Okubo</LastName>
        <Affiliation>Department of Periodontics and Endodontics, Division of Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazu</FirstName>
        <LastName>Takeuchi‐Hatanaka</LastName>
        <Affiliation>Department of Periodontics and Endodontics, Division of Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Omori</LastName>
        <Affiliation>Department of Pathophysiology–Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>The Center for Graduate Medical Education (Dental Division), Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shogo</FirstName>
        <LastName>Takashiba</LastName>
        <Affiliation>Department of Pathophysiology–Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Fibroblast growth factor-2 (FGF-2) is a novel agent utilized in periodontal regeneration therapy. However, its clinical efficacy compared with autologous bone graft (ABG), a long-established treatment, remains unclear. This study aimed to compare the clinical outcomes of FGF-2 and ABG and to assess the impact of patient background factors on outcomes when using FGF-2.&lt;br&gt;
Methods: We collected the subjects from January 2013 to September 2023. Clinical outcomes included the vertical bone defect improvement rate (VBDIR) and the probing pocket depth improvement (PPDI). Clinical outcomes between the two groups were compared using analysis of covariance (ANCOVA), adjusting for age, sex, smoking history, and hypertension. Additionally, a multilevel linear analysis was performed to assess factors influencing outcomes in FGF-2.&lt;br&gt;
Results: A total of 180 sites from 141 patients (FGF-2: 150 sites; ABG: 30 sites) were evaluated. Both VBDIR and PPDI significantly improved postoperatively in both groups. There were no significant differences in clinical outcomes between FGF-2 and ABG. In FGF-2, smoking history was positively associated, while the preoperative bone defect angle (BDA) was negatively associated with clinical outcomes.&lt;br&gt;
Conclusions: FGF-2 might exhibit clinical outcomes comparable to those of ABG, suggesting it is a clinically viable alternative for vertical bone defects. When using FGF-2, patient-specific factors such as smoking history and preoperative BDA should be considered carefully.&lt;br&gt;
The name in the trial registry: A survey of clinical practice and evaluation of treatment outcomes of periodontal regenerative therapy using REGROTH at Okayama University Hospital</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">autologous bone graft</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fibroblast growth factor-2</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">periodontal pocket</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">periodontal regeneration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">periodontitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">vertical bone defect</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2059-3635</Issn>
      <Volume>11</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Osimertinib inhibits the MYLK4-mediated phosphorylation of CDKAL1 to suppress stemness and chemoresistance in rhabdomyosarcoma</ArticleTitle>
    <FirstPage LZero="delete">26</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takuto</FirstName>
        <LastName>Itano</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rongsheng</FirstName>
        <LastName>Huang</LastName>
        <Affiliation>Department of Cellular Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiji</FirstName>
        <LastName>Nakata</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Fujimura</LastName>
        <Affiliation>Department of Cellular Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>18</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Central Serous Chorioretinopathy in Parallel With Onset and Relapses of Minimal Change Nephrotic Syndrome: A 28-Year Case Follow-Up</ArticleTitle>
    <FirstPage LZero="delete">e102426</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Department of Ophthalmology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Central serous chorioretinopathy is an idiopathic disease that manifests as one or several localized, small, dome-shaped serous retinal detachments on fundus examination. The pathophysiology involves fluid leakage from the choroidal capillaries, known as the choriocapillaris, into the subretinal space through sites of damage in the retinal pigment epithelium. This case report discusses the underlying causes of central serous chorioretinopathy-like findings in minimal change nephrotic syndrome.&lt;br&gt;
&lt;br&gt;
The patient was a 33-year-old woman who developed nephrotic syndrome that was confirmed to be minimal change disease by renal biopsy. She experienced two major relapses of nephrotic syndrome at the ages of 36 and 41 years. She also had a minor relapse at the age of 37 years, five months after the first major relapse at the age of 36 years, as well as four additional minor relapses at the ages of 44, 46, 50, and 51 years. The onset of central serous chorioretinopathy-like manifestations, which were localized to the left eye, occurred three months after the initial onset of nephrotic syndrome at the age of 33 years. Two subsequent episodes of relapse of central serous chorioretinopathy-like manifestations were observed in both eyes at intervals of five months and one month, respectively, after major relapses of nephrotic syndrome at the ages of 36 and 41 years. Thereafter, she did not develop further central serous chorioretinopathy-like manifestations.&lt;br&gt;
&lt;br&gt;
She discontinued oral prednisolone at the age of 54 years and experienced no further relapses of nephrotic syndrome through her latest visit at the age of 61 years. She maintained normal renal function and good visual acuity in both eyes. The long-term, consistent temporal association between episodes of central serous chorioretinopathy and the onset and relapses of minimal change nephrotic syndrome is strongly supported by longitudinal clinical observations spanning 28 years. This parallel course suggests a possible shared pathophysiological mechanism or common triggering factors underlying both diseases.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">central serous chorioretinopathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">corticosteroid</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cyclosporine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fluorescein angiography</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">minimal change disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">minimal change nephrotic syndrome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">photoreceptor ellipsoid zone</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">renal biopsy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">steroid-induced retinal pigment epitheliopathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">steroid pulse therapy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>China Anti-cancer Association</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2095-3941</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>SPRED2 suppresses the stemness of hepatocellular carcinoma through the p53/miR-506-3p/KLF4 pathway</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tong</FirstName>
        <LastName>Gao</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sachio</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Department of Pathophysiology and Drug Discovery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aye</FirstName>
        <LastName>Moh-Moh-Aung</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tianyi</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayoshi</FirstName>
        <LastName>Fujisawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teizo</FirstName>
        <LastName>Yoshimura</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective: We previously reported that endogenous Sprouty-related, EVH1 domain-containing protein 2 (SPRED2), an inhibitor of the Ras/Raf/ERK-MAPK pathway, controls hepatocellular carcinoma (HCC) cell stemness by downregulating the expression of pluripotency factors, such as Nanog, c-Myc, and KLF4, in an ERK-dependent fashion. However, the exact mechanisms by which SPRED2 regulates HCC cell stemness have not been established.&lt;br&gt;
Methods: Three human HCC cell lines [HepG2 (parental and SPRED2-deficient), HLE, and Hep3B] were used. Cells were transfected to downregulate or overexpress proteins. Western blot and RT-qPCR were used to evaluate the level of protein and mRNA expression. Co-immunoprecipitation and ChIP-qPCR were used to examine protein-protein interactions and the activation of gene transcription. Clinical HCC tissues were also used to validate in vitro data.&lt;br&gt;
Results: KLF4 was identified as the major pluripotency factor responsible for SPRED2-mediated downregulation of HCC cell stemness and KLF4 expression was regulated by miR-506-3p. SPRED2 formed a protein complex with the tumor suppressor (p53) and upregulated miR-506 gene transcription by binding to the promoter region, resulting in subsequent downregulation of KLF4 mRNA expression. There was a negative correlation between KLF4 expression and miR-506-3p and a positive correlation between miR-506-3p expression and SPRED2 in human HCC samples, highlighting the relevance of the study findings.&lt;br&gt;
Conclusions: The current study revealed a novel SPRED2/p53/miR-506-3p/KLF4 axis through which SPRED2 contributes to the suppression of HCC cell stemness and provides a potential new target to prevent HCC progression.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">SPRED2</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">p53</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">KLF4</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">miR-506-3p</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">stemness</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>BMJ</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2044-6055</Issn>
      <Volume>15</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effectiveness of education programme to increase competency of health cadres in Indonesia: a cluster non-randomised controlled trial</ArticleTitle>
    <FirstPage LZero="delete">e095428</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Dewie</FirstName>
        <LastName>Sulistyorini</LastName>
        <Affiliation>Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">K A T M Ehsanul</FirstName>
        <LastName>Huq</LastName>
        <Affiliation>Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Abdulfatai Olamilekan</FirstName>
        <LastName>Babaita</LastName>
        <Affiliation>Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sadia A</FirstName>
        <LastName>Aivey</LastName>
        <Affiliation>Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Gao</FirstName>
        <LastName>Huiying</LastName>
        <Affiliation>Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kana</FirstName>
        <LastName>Kazawa</LastName>
        <Affiliation>Faculty of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuko</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mayumi</FirstName>
        <LastName>Kako</LastName>
        <Affiliation>Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michiko</FirstName>
        <LastName>Moriyama</LastName>
        <Affiliation>Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives Health cadres, who assist midwives in supporting pregnant women in community settings, need to enhance their competencies in identifying risk factors and referring high-risk pregnant women to midwives for further care. Since the capabilities of these health cadres are influenced by maternal complications, an educational programme was implemented to strengthen their skills. Therefore, this study aimed to evaluate the competency of health cadres by providing a researcher-developed educational programme.&lt;br&gt;
Design An open-label, cluster non-randomised controlled trial.&lt;br&gt;
Setting and participants Health cadres with at least 1 year of work experience were recruited at six public health centres (PHCs) in Banjarnegara Regency, Indonesia.&lt;br&gt;
Interventions Six PHCs were selected and allocated into intervention group (IG=3 PHCs) and control group (CG=3 PHCs) groups. A total of 133 female health cadres were enrolled across the selected PHCs. At each PHC, a systematic random sampling method was used to select the participants. The researchers and health professionals provided a 3-week period of theoretical and scenario-based simulations to the IG, while the CG received no education.&lt;br&gt;
Outcome measures Researcher-developed questionnaires and checklists were used to assess the knowledge, skills (health assessment, communication, attitude) and confidence. The primary endpoint was competency, a total score of knowledge and skills. The outcome domains were compared between the two groups, and a linear mixed-effect model was used to account for cluster-level variation.&lt;br&gt;
Results A total of 130 (97.7%) completed the study (IG:64, CG:66). The competency score showed significant improvement at endline (CG=49.5 and IG=52.5; p=0.002). The median scores for health assessment skills (CG=12 vs IG=14; p&lt;0.001) and communication skills (CG=7 vs IG=8; p&lt;0.001) were increased in the IG compared with the CG. Mixed-effect model indicated that groups (β (95% CI) 2.49 (0.57 to 4.41), p=0.012), baseline knowledge (β(95% CI) 0.73 (0.54 to 0.92), p&lt;0.001) and midline health assessment skills (β (95% CI) 0.54 (0.25 to 0.82), p&lt;0.001) were significant positive predictors, while age was negatively associated with competency (β (95% CI) −0.20 (−0.30 to −0.10), p&lt;0.001)).&lt;br&gt;
Conclusion Education effectively increased the competency of health cadres. A well-structured education programme is necessary for health cadres to improve and maintain their competencies in monitoring high-risk pregnant women.&lt;br&gt;
Trial registration number NCT06134518.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2211-1247</Issn>
      <Volume>45</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Immunopeptidomics combined with full-length transcriptomics uncovers diverse neoantigens</ArticleTitle>
    <FirstPage LZero="delete">116781</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takamasa</FirstName>
        <LastName>Ishino</LastName>
        <Affiliation>Department of Tumor Microenvironment, Okayama University, Graduate School of Medicine Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomofumi</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Tumor Microenvironment, Okayama University, Graduate School of Medicine Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Serina</FirstName>
        <LastName>Tokita</LastName>
        <Affiliation>Division of Cancer Immunology, Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Youki</FirstName>
        <LastName>Ueda</LastName>
        <Affiliation>Department of Tumor Microenvironment, Okayama University, Graduate School of Medicine Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsushige</FirstName>
        <LastName>Kawase</LastName>
        <Affiliation>Division of Cell Therapy, Chiba Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Takano</LastName>
        <Affiliation>Department of Tumor Microenvironment, Okayama University, Graduate School of Medicine Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yin Min</FirstName>
        <LastName>Thu</LastName>
        <Affiliation>Department of Tumor Microenvironment, Okayama University, Graduate School of Medicine Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuta</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Computational Biology and Medical Sciences, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chie</FirstName>
        <LastName>Owa</LastName>
        <Affiliation>Department of Computational Biology and Medical Sciences, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Inozume</LastName>
        <Affiliation>Department of Dermatology, Chiba University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wenhao</FirstName>
        <LastName>Zhou</LastName>
        <Affiliation>Department of Tumor Microenvironment, Okayama University, Graduate School of Medicine Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joji</FirstName>
        <LastName>Nagasaki</LastName>
        <Affiliation>Department of Tumor Microenvironment, Okayama University, Graduate School of Medicine Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Vitaly</FirstName>
        <LastName>Kochin</LastName>
        <Affiliation>Department of Immunology, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihide</FirstName>
        <LastName>Ueno</LastName>
        <Affiliation>Division of Cellular Signaling, National Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinya</FirstName>
        <LastName>Kojima</LastName>
        <Affiliation>Division of Cellular Signaling, National Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Honobe-Tabuchi</LastName>
        <Affiliation>Department of Dermatology, University of Yamanashi</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuyoshi</FirstName>
        <LastName>Kawamura</LastName>
        <Affiliation>Department of Dermatology, University of Yamanashi</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Ohnuma</LastName>
        <Affiliation>Department of Dermatology, Kumamoto Kenhoku Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takamitsu</FirstName>
        <LastName>Matsuzawa</LastName>
        <Affiliation>Department of Dermatology, Chiba University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Kawahara</LastName>
        <Affiliation>Department of Dermatology, Chiba University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuo</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>KOTAI Biotechnologies, Inc</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jason</FirstName>
        <LastName>Lin</LastName>
        <Affiliation>Division of Cell Therapy, Chiba Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Koseki</LastName>
        <Affiliation>Division of Systems Biology, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyoshi</FirstName>
        <LastName>Nishikawa</LastName>
        <Affiliation>Department of Immunology, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoo</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Department of Urology, Okayama University, Graduate School of Medicine Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoya</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Gastroenterology, Graduate School of Medicine, Chiba University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teppei</FirstName>
        <LastName>Shimamura</LastName>
        <Affiliation>Division of Systems Biology, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Morishita</LastName>
        <Affiliation>Department of Computational Biology and Medical Sciences, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yutaka</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Mano</LastName>
        <Affiliation>Division of Cellular Signaling, National Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Torigoe</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Kanaseki</LastName>
        <Affiliation>Division of Cancer Immunology, Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahito</FirstName>
        <LastName>Kawazu</LastName>
        <Affiliation>Division of Cell Therapy, Chiba Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Togashi</LastName>
        <Affiliation>Department of Tumor Microenvironment, Okayama University, Graduate School of Medicine Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Neoantigens are crucial for antitumor immunity and immune checkpoint inhibitor (ICI) efficacy by triggering strong immune responses. However, conventional methods for identifying neoantigens, such as whole-exon sequencing and short-read RNA sequencing (RNA-seq), appear to be insufficient, and the tumor mutational burden cannot sufficiently predict ICI efficacy. In this study, we employed a proteogenomic approach using long-read RNA-seq with Pacific Biosciences Single-Molecule Real-Time Sequencing technology to analyze full-length transcripts in combination with the human leukocyte antigen ligandome. As a result, many neoantigen candidates were identified, which were unregistered in a comprehensive database, including those from non-coding regions. Additionally, we validated the responses of specific T cell receptors (TCRs) to these candidates and identified several pairs of TCRs and neoantigens. These findings highlight the presence of more diverse neoantigens than expected that cannot be identified by conventional methods.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">cancer immunology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">neoantigen</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">long-read RNA sequencing</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">HLA ligandome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">single-cell RNA sequencing</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">single-cell TCR sequencing</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">exhausted T cell</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Geophysical Union (AGU)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2169-9313</Issn>
      <Volume>131</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Electrical Conductivity of Carbonatite Melts to 20 GPa: Constraints on Partial Melting Atop the 410‐km Discontinuity and in the Lower Mantle Transition Zone</ArticleTitle>
    <FirstPage LZero="delete">e2025JB033390</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Bin</FirstName>
        <LastName>Zhao</LastName>
        <Affiliation>Institute for Planetary Materials, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jintao</FirstName>
        <LastName>Zhu</LastName>
        <Affiliation>Institute for Planetary Materials, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Qi</FirstName>
        <LastName>Chen</LastName>
        <Affiliation>Center for Advanced Radiation Sources, University of Chicago</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yoshino</LastName>
        <Affiliation>Institute for Planetary Materials, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Deep-origin carbonatite melts are considered to be the products of partial-melting of the oceanic crust in the subduction zones. In this study, we conducted electrical conductivity (EC) measurements on two samples, the composition of which resemble the partial-melting products atop the 410-km discontinuity and in the lower part of the transition zone. The EC of carbonatite melts was investigated using impedance spectroscopy combined with a multi-anvil press up to 20 GPa. Pressure has a great effect on the EC of the carbonatite melts. While the EC dropped overall by 0.6 log unit from 3 to 20 GPa for varying compositions, the pressure effect becomes weaker above 10 GPa. The Hashin-Shtrikman mixing model indicates that melt fraction of 0–0.3 vol% is necessary to account for the EC atop the 410-km discontinuity beneath NE China, north Philippine Sea, north Pacific, and Australian craton. However, this value soars to 1–4.5 vol% for the lower part of the transition zone in the same regions, and further increases to 3.7–7.3 vol% for cold subduction regions if the slab surface temperature is 300 K lower. The difference in the needed melt fraction at different depths implies that the magnitude of partial melting is much larger in the lower part of the mantle transition zone, and it is thus likely to be the main barrier to the recycled carbonates towards the deep interior.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">carbon</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">carbonatite melts</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">electrical conductivity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">impedance spectroscopy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">multi-anvil press</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Baishideng Publishing Group Inc.</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1948-5190</Issn>
      <Volume>17</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Endoscopic features of oral and pharyngolaryngeal papillomas and their role in distinguishing squamous cell carcinoma</ArticleTitle>
    <FirstPage LZero="delete">110594</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Hamada</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiyasu</FirstName>
        <LastName>Kono</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiji</FirstName>
        <LastName>Kawano</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiro</FirstName>
        <LastName>Kawahara</LastName>
        <Affiliation>Department of Practical Gastrointestinal Endoscopy, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>BACKGROUND&lt;br&gt;
Oral and pharyngolaryngeal papillomas are occasionally detected during esophagogastroduodenoscopy. However, their endoscopic features have not been sufficiently investigated.&lt;br&gt;
AIM&lt;br&gt;
To distinguish oral and pharyngolaryngeal papillomas from elevated squamous carcinomas, this study examined their endoscopic features.&lt;br&gt;
METHODS&lt;br&gt;
Forty-seven patients with oral or pharyngeal papilloma participated in this study. The endoscopic characteristics of papillomas were identified by focusing on narrowband and blue laser imaging representations.&lt;br&gt;
RESULTS&lt;br&gt;
Papillomas were classified into three patterns based on their endoscopic features: Salmon roe-like polyps, polyps without capillary transparency, and pinecone-like polyps, with salmon roe-like polyps most prevalent (48.9%). We subsequently analyzed features differentiating papillomas and squamous cell carcinomas in the same region and found that squamous cell carcinomas exhibited at least one of the following three features: Uneven or absent lobulated structure, irregular morphology of capillaries, and coexistence of flat lesions. In contrast, papillomas displayed a uniform lobulated structure, homogeneous or non-visible capillaries, and an absence of flat components. When any of these characteristics were present, two endoscopic specialists evaluated the lesions for the diagnosis of squamous cell carcinoma, with sensitivities of 100% and 97.6% and specificities of 68.9% and 93.3%.&lt;br&gt;
CONCLUSION&lt;br&gt;
Understanding distinct endoscopic patterns of oropharyngeal papillomas and squamous cell carcinomas provides valuable guidance to endoscopists performing esophagogastroduodenoscopy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Esophagogastroduodenoscopy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Human papillomavirus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Laryngeal polyp</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Papilloma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pharyngeal polyp</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>16</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Salivary short chain fatty acids serve as biomarkers of periodontal inflammatory burden</ArticleTitle>
    <FirstPage LZero="delete">1786</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kazu</FirstName>
        <LastName>Takeuchi-Hatanaka</LastName>
        <Affiliation>Division of Periodontics and Endodontics, Department of Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Shirahase</LastName>
        <Affiliation>Sysmex Corporation</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Sysmex Corporation</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mari</FirstName>
        <LastName>Kono</LastName>
        <Affiliation>Sysmex Corporation</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Toya</LastName>
        <Affiliation>Sysmex Corporation</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Konishi</LastName>
        <Affiliation>Present address: Diagnostics Division, IVD Enzyme Department, Nagase Diagnostics</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Omori</LastName>
        <Affiliation>Department of Pathophysiology-Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shogo</FirstName>
        <LastName>Takashiba</LastName>
        <Affiliation>Department of Pathophysiology-Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Periodontitis is a chronic inflammatory condition associated with systemic diseases. Early detection and intervention are crucial; however, conventional diagnostic methods require specialized dental procedures. Therefore, we aimed to develop a noninvasive saliva-based screening method that can be easily performed outside dental clinics. This cross-sectional pilot study evaluated three periodontal indices—probing depth, Periodontal Inflamed Surface Area (PISA), and periodontal epithelial surface area—in relation to short-chain fatty acids (SCFAs) and bacterial profiles in the saliva. Saliva samples collected during the day exhibited stronger correlations with periodontal indices than waking time samples, demonstrating a significant association with periodontal pathogens, protease activity, and elevated levels of butyric acid. The diagnostic thresholds for PISA were 300 mm2 and 600 mm2. Multivariate logistic regression and likelihood ratio analyses identified the combination of enzymatic SCFA markers and dipstick-based occult blood or leukocyte detection as a promising biomarker pair. Combining enzymatic SCFA markers with occult blood demonstrated a positive likelihood ratio of 3.4 and a negative likelihood ratio of 0.19 for PISA ≥ 600 mm2, with a post-test probability of 77%, sensitivity of 86%, and specificity of 75%. These findings suggest that combining salivary enzymatic and dipstick-based biomarkers provides a simple, cost-effective, and moderately informative screening strategy for periodontitis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Periodontitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Screening</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Saliva</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Short-chain fatty acid</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Periodontal inflamed surface area</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Crosssectional studies</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Frontiers Media SA</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1663-9812</Issn>
      <Volume>16</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Regulatory considerations for developing phage therapy medicinal products for the treatment of antimicrobial resistant bacterial infections</ArticleTitle>
    <FirstPage LZero="delete">1713471</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ai</FirstName>
        <LastName>Fukaya-Shiba</LastName>
        <Affiliation>Office of Regulatory Science Coordination, Pharmaceuticals and Medical Devices Agency</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Ogata</LastName>
        <Affiliation>Office of Regulatory Science Coordination, Pharmaceuticals and Medical Devices Agency</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryosuke</FirstName>
        <LastName>Kuribayashi</LastName>
        <Affiliation>Office of Cellular and Tissue-based Products, Pharmaceuticals and Medical Devices Agency</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Sakurai</LastName>
        <Affiliation>Office of Cellular and Tissue-based Products, Pharmaceuticals and Medical Devices Agency</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kanako</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Office of Regulatory Science Coordination, Pharmaceuticals and Medical Devices Agency</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Takadama</LastName>
        <Affiliation>Office of New Drug IV, Pharmaceuticals and Medical Devices Agency</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jihei</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Office of New Drug IV, Pharmaceuticals and Medical Devices Agency</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jumpei</FirstName>
        <LastName>Uchiyama</LastName>
        <Affiliation>Department of Bacteriology, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Ohge</LastName>
        <Affiliation>Department of Infectious Diseases, Hiroshima University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takamasa</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Pathogen Genomics Center, National Institute of Infectious Diseases, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideyuki</FirstName>
        <LastName>Tamaki</LastName>
        <Affiliation>Biomanufacturing Process Research Center, National Institute of Advanced Industrial Science and Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Infectious Diseases, International University of Health and Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kotaro</FirstName>
        <LastName>Kiga</LastName>
        <Affiliation>Department of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetomo</FirstName>
        <LastName>Iwano</LastName>
        <Affiliation>Laboratory of Veterinary Biochemistry, Rakuno Gakuen University School of Veterinary Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Recently, there have been growing expectations that treatment of infections with bacteriophages (phages), viruses which specifically infect bacteria, can be used as a treatment option for antimicrobial resistant bacterial infections. In Europe and the United States, in addition to phage therapy as a form of personalized medicine, development of pre-defined phage therapy medicinal products (PTMPs) is progressing, and clinical trials are underway. From October 2024 to July 2025, the Pharmaceuticals and Medical Devices Agency exchanged opinions on trends and points to consider in drug development of PTMPs used for antimicrobial resistant bacterial infections with external experts. Development of PTMPs for regulatory approval requires quality control strategies, establishment of manufacturing methods, non-clinical evaluations, and clinical trial plans based on the characteristics of the phage. In this document, based on the regulatory and development trends in Europe and the United States, the current considerations on quality, non-clinical evaluation, and clinical trial planning including the Cartagena Act in the development of PTMPs in Japan are summarized. The basic concepts presented here are intended to be applied to antimicrobial resistant bacterial infections targeted by PTMPs but can be mostly applicable to bacterial infections in general. We hope that these findings will further accelerate more active development of PTMPs towards timely patient access to innovative products.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">phage therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bacteriophage</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">antimicrobial resistance (AMR)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">quality considerations</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">non-clinical evaluation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">clinical trial plan</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">the Cartagena Act</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>18</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Endoscopic Topical Application (ETA) Therapy for Refractory Overactive Bladder: A First-in-Human Report</ArticleTitle>
    <FirstPage LZero="delete">e101143</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Sadahira</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Sugihara</LastName>
        <Affiliation>Department of Surgery, Nishi Fukuyama Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toyohiko</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoo</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masami</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Refractory overactive bladder (OAB) remains a clinical challenge despite established therapies, such as anticholinergics, β3-agonists, and intradetrusor botulinum toxin (BTX). Emerging evidence suggests that sensory mechanisms within the bladder, including those involving the trigone where superficial afferent networks are present, may contribute to persistent urinary urgency and frequency in some patients. Although intradetrusor BTX injection is effective in selected patients, its impact on these superficial pathways may be limited because the injected drug predominantly distributes within the detrusor. Endoscopic topical application (ETA) therapy delivers BTX directly to the trigone under air cystoscopy, potentially providing targeted modulation of sensory hyperexcitability. We report a 72-year-old woman with long-standing refractory OAB who experienced only partial improvement with repeated intradetrusor BTX injections but achieved clinically meaningful symptom relief after ETA therapy. Nocturia, urgency, urgency urinary incontinence, and voided volume were improved, with no complications other than transient postoperative urethral pain. This case suggests that ETA therapy may represent a promising sensory-focused option for refractory OAB.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">bladder trigone</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">botulinum toxin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">endoscopic topical application</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">new drug delivery systems</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">refractory overactive bladder</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>SAGE Publications</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0963-6897</Issn>
      <Volume>35</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Addition of human platelet lysate to islet culture medium suppresses islet loss and improves transplantation outcomes</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Noguchi</LastName>
        <Affiliation>Department of Regenerative Medicine, Graduate School of Medicine, University of the Ryukyus</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chika</FirstName>
        <LastName>Miyagi-Shiohira</LastName>
        <Affiliation>Department of Regenerative Medicine, Graduate School of Medicine, University of the Ryukyus</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Sadahira</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masami</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Issei</FirstName>
        <LastName>Saitoh</LastName>
        <Affiliation>Department of Pediatric Dentistry, Asahi University School of Dentistry</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0029-6473</Issn>
      <Volume>2026</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Knowledge and Attitudes Toward Pain Management Among Nurses in University-Affiliated Hospitals in Western Japan: A Cross-Sectional Study</ArticleTitle>
    <FirstPage LZero="delete">9991157</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Mengyao</FirstName>
        <LastName>Xi</LastName>
        <Affiliation>Graduate School of Health Sciences, Okayama University,</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Kajiwara</LastName>
        <Affiliation>Faculty of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takako</FirstName>
        <LastName>Hiramatsu</LastName>
        <Affiliation>Department of Nursing, Kawasaki Medical School Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michiko</FirstName>
        <LastName>Morimoto</LastName>
        <Affiliation>Faculty of Health Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Pain is a major global concern. Nurses’ knowledge and attitudes toward pain management are critical determinants of pain care quality and patient outcomes, making them essential for effective clinical practice.&lt;br&gt;
Objective: This study aimed to assess nurses’ pain management knowledge and attitudes using the Japanese version of the Knowledge and Attitudes Survey Regarding Pain (J-KASRP), applied for the first time in Japan, and to examine how background factors affect these aspects.&lt;br&gt;
Methods: A descriptive, cross-sectional survey was conducted with 1589 nurses in three university-affiliated hospitals in Western Japan. Data were collected using a questionnaire capturing sociodemographic information and the J-KASRP. Descriptive statistics, t-tests, one-way ANOVA, and effect size were used to analyze J-KASRP scores and subdomains. Tukey’s honestly significant difference test was applied for post hoc comparisons across clinical experience patterns.&lt;br&gt;
Results: Of 1001 respondents, 856 valid responses (85.5%) were analyzed. The mean age was 30.1 years (SD = 8.3), and the mean total correct response rate for the J-KASRP was 59.8%; only 1.3% scored ≥ 80%. Cancer-related pain had the lowest J-KASRP subdomain score (42.5%, SD = 20.3%). Higher total J-KASRP scores were found for those with a higher level of education, prior clinical pain education, and recent opioid administration experience (all p &lt; 0.001, effect size &gt; 0.2). In an exploratory pattern analysis, regardless of education level, respondents with both education and opioid administering experience had the highest total and pharmacology subdomains’ scores. No significant differences in cancer-related pain subdomain were observed across patterns of clinical experiences.&lt;br&gt;
Conclusions: This first application of the J-KASRP in Japan revealed that nurses’ pain management knowledge and attitudes need to be strengthened, especially for cancer-related pain and opioid pharmacology. The study findings highlight the importance of pain management strengthening education and training to enhance nurses’ evidence-based knowledge and clinical competence.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">knowledge andattitudes</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">nurses</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">painmanagement</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2313-433X</Issn>
      <Volume>12</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>FluoNeRF: Fluorescent Novel-View Synthesis Under Novel Light Source Colors and Spectra</ArticleTitle>
    <FirstPage LZero="delete">16</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Lin</FirstName>
        <LastName>Shi</LastName>
        <Affiliation>Department of Artificial Intelligence, Kyushu Institute of Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kengo</FirstName>
        <LastName>Matsufuji</LastName>
        <Affiliation>Department of Artificial Intelligence, Kyushu Institute of Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michitaka</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Computer Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Kawahara</LastName>
        <Affiliation>Graduate School of Informatics, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Okabe</LastName>
        <Affiliation>Department of Computer Science, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Synthesizing photo-realistic images of a scene from arbitrary viewpoints and under arbitrary lighting environments is one of the important research topics in computer vision and graphics. In this paper, we propose a method for synthesizing photo-realistic images of a scene with fluorescent objects from novel viewpoints and under novel lighting colors and spectra. In general, fluorescent materials absorb light with certain wavelengths and then emit light with longer wavelengths than the absorbed ones, in contrast to reflective materials, which preserve wavelengths of light. Therefore, we cannot reproduce the colors of fluorescent objects under arbitrary lighting colors by combining conventional view synthesis techniques with the white balance adjustment of the RGB channels. Accordingly, we extend the novel-view synthesis based on the neural radiance fields by incorporating the superposition principle of light; our proposed method captures a sparse set of images of a scene from varying viewpoints and under varying lighting colors or spectra with active lighting systems such as a color display or a multi-spectral light stage and then synthesizes photo-realistic images of the scene without explicitly modeling its geometric and photometric models. We conducted a number of experiments using real images captured with an LCD and confirmed that our method works better than the existing methods. Moreover, we showed that the extension of our method using more than three primary colors with a light stage enables us to reproduce the colors of fluorescent objects under common light sources.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">novel-view synthesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">neural radiance fields</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">relighting</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">superposition principle</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fluorescence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Stokes shift</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1758-5902</Issn>
      <Volume>18</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Procedural Transhiatal Approach for the Thoracic Para‐Aortic Lymph Node: A Case Report</ArticleTitle>
    <FirstPage LZero="delete">e70066</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Noma</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushige</FirstName>
        <LastName>Takeda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hijiri</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kento</FirstName>
        <LastName>Kawasaki</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyoshi</FirstName>
        <LastName>Kunitomo</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoaki</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Tanabe</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The thoracic posterior para-aortic lymph node (TPAN) is classified as an extra-regional lymph node in esophageal cancer, with metastasis indicating poor prognosis. However, some cases with suspected TPAN metastasis may benefit from esophagectomy with lymph node dissection, including TPAN. This report presents the case of a 58-year-old man with upper thoracic esophageal squamous cell carcinoma and suspected simultaneous TPAN metastasis who underwent neoadjuvant chemotherapy followed by thoracoscopic subtotal esophagectomy and procedural transhiatal TPAN dissection. This transhiatal approach provided direct access to the lymph node without additional thoracic incisions, ensuring safe resection in coordination with the assistant and following anatomical landmarks systematically. Pathological examination showed a false-positive TPAN finding, though the patient later developed distant recurrence. Compared with conventional approaches, this transhiatal technique allows for procedural and reproducible lymphadenectomy while minimizing respiratory burden. This case highlights the feasibility of a transhiatal approach for TPAN dissection.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">112aoP</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">esophageal cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">thoracic posterior para-aortic lymph node</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>BMJ</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0143-005X</Issn>
      <Volume>80</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Exposure-induced mediator–outcome confounders in causal mediation: implications and visualisation</ArticleTitle>
    <FirstPage LZero="delete">129</FirstPage>
    <LastPage>130</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Etsuji</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Shinozaki</LastName>
        <Affiliation>Interfaculty Initiative in Information Studies, the University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiji</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Okayama University of Science</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2366-1070</Issn>
      <Volume>13</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Asian Subgroup Analysis of Patients in the Phase 2 DeLLphi-301 Study of Tarlatamab for Previously Treated Small Cell Lung Cancer</ArticleTitle>
    <FirstPage LZero="delete">1041</FirstPage>
    <LastPage>1054</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Myung-Ju</FirstName>
        <LastName>Ahn</LastName>
        <Affiliation>Hematology-Oncology Department, Samsung Medical Center (SMC), Sungkyunkwan University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Byoung Chul</FirstName>
        <LastName>Cho</LastName>
        <Affiliation>Medical Oncology Department-501, ABMRC, Yonsei University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kadoaki</FirstName>
        <LastName>Ohashi</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Izumi</LastName>
        <Affiliation>Thoracic Oncology, National Cancer Center Hospital East</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jong-Seok</FirstName>
        <LastName>Lee</LastName>
        <Affiliation>Hematology/Oncology, Seoul National University Bundang Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ji-Youn</FirstName>
        <LastName>Han</LastName>
        <Affiliation>Center for Lung Cancer, National Cancer Center-Graduate School of Cancer Science and Policy</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chi-Lu</FirstName>
        <LastName>Chiang</LastName>
        <Affiliation>Department of Chest Medicine, Taipei Veterans General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuang</FirstName>
        <LastName>Huang</LastName>
        <Affiliation>Amgen Inc.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ali</FirstName>
        <LastName>Hamidi</LastName>
        <Affiliation>Amgen Inc.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sujoy</FirstName>
        <LastName>Mukherjee</LastName>
        <Affiliation>Amgen Inc.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Krista Lin</FirstName>
        <LastName>Xu</LastName>
        <Affiliation>Amgen Asia Pacific Pte. Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiraoki</FirstName>
        <LastName>Akamatsu</LastName>
        <Affiliation>Internal Medicine III, Wakayama Medical University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: Tarlatamab is a bispecific T-cell engager (BiTE®) immunotherapy that binds delta-like ligand 3 on the surface of small cell lung cancer (SCLC) cells and CD3 on T cells, facilitating T cell-mediated cancer cell lysis. In the primary analysis of the phase 2 DeLLphi-301 study (NCT05060016), tarlatamab showed a favourable benefit-to-risk profile with durable objective responses and promising survival outcomes in patients with previously treated SCLC. Here, phase 2 data for the Asia region subgroup are presented.&lt;br&gt;
Methods: Patients with previously treated, advanced SCLC received 10 mg tarlatamab every 2 weeks. The primary endpoint was objective response rate (ORR) by blinded independent central review (RECIST version 1.1). Key secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS) and safety. The present analysis includes patients enrolled at sites in Asia.&lt;br&gt;
Results: A total of 43 patients were enrolled at sites in Asia. ORR was 46.3% (95% confidence interval [CI], 30.7–62.6) and median DOR was 7.2 months (95% CI 3.9 to not estimable). The median follow-up was 16.6 months for PFS and 21.2 months for OS. Median PFS was 5.4 months (95% CI 3.0–8.1) and median OS was 19.0 months (95% CI 11.4 to not estimable). The most common treatment-emergent adverse event (AE) was cytokine release syndrome (48.8%), and all such events were grade 1 or 2. There were no discontinuations due to treatment-related AEs.&lt;br&gt;
Conclusions: Tarlatamab demonstrated durable responses and promising survival outcomes with a manageable safety profile in this post hoc analysis of patients from Asia with previously treated SCLC.&lt;br&gt;
Trial Registration: ClinicalTrials.gov, NCT05060016.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Small cell lung cancer (SCLC)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tarlatamab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">DLL3</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Bispecific T-cell engager</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Asian patients</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0919-8172</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Daytime Bladder Control Status in Toddlerhood Is Associated With Subsequent Bedwetting in Preschool Years: A Nationwide Cohort Study of Over 30 000 Japanese Children</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takatoshi</FirstName>
        <LastName>Moriwake</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naomi</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Tominaga</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Uraguchi</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ichiro</FirstName>
        <LastName>Tsuboi</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kasumi</FirstName>
        <LastName>Yoshinaga</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Yamanoi</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Kawada</LastName>
        <Affiliation>Department of Urology Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University  Okayama Japan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Sadahira</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shingo</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Bekku</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Edamura</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soshi</FirstName>
        <LastName>Takao</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yorifuji</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoo</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives: Nocturnal enuresis is common in early childhood. While daytime bladder control typically precedes nighttime continence, the temporal relationship between early daytime bladder control and subsequent bedwetting remains unclear. We investigated whether daytime bladder control status at age 2.5 years—as indicated by diaper use—is associated with bedwetting at age 4.5 years in a Japanese nationwide cohort.&lt;br&gt;
Methods: We analyzed data from the Japanese Longitudinal Survey of Newborns in the 21st Century (2010 cohort). Daytime bladder control was assessed at age 2.5 years through caregiver-reported diaper use, and bedwetting frequency at age 4.5 years through parental questionnaires. Modified Poisson regression estimated risk ratios (RRs), adjusting for birth-related factors, socioeconomic status, daycare attendance, and developmental milestones.&lt;br&gt;
Results: Among 32 168 children, 26 651 (82.8%) still used diapers at 2.5 years. Bedwetting prevalence at 4.5 years was 42.2%: 34.5% in children who achieved daytime bladder control at 2.5 years versus 43.9% in those still using diapers. After multivariable adjustment, incomplete daytime bladder control at 2.5 years was associated with higher bedwetting risk (adjusted RR 1.25; 95% CI, 1.20–1.31). Multinomial regression revealed dose–response relationships: odds ratios 1.41 (95% CI, 1.30–1.52) for “sometimes” and 1.58 (95% CI, 1.42–1.77) for “often” bedwetting.&lt;br&gt;
Conclusions: Daytime bladder control status at 2.5 years was associated with a 25% increased bedwetting risk at 4.5 years. This association likely reflects individual differences in bladder control maturation rather than causal effects. While daytime bladder control may serve as a developmental marker, its validity as an intervention target remains unestablished.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">bedwetting</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cohort study</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">daytime bladder control</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">nocturnal enuresis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2050-0904</Issn>
      <Volume>13</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Experience and Insight Into Genetic Diagnosis of Infective Aortic Aneurysm</ArticleTitle>
    <FirstPage LZero="delete">e71586</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shinnosuke</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takumi</FirstName>
        <LastName>Fujimori</LastName>
        <Affiliation>Microbiology Division, Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Iio</LastName>
        <Affiliation>Microbiology Division, Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Culture-negative infected aneurysms possibly occur in various clinical situations, including prior antibiotic exposure. Accurate microbial identification is crucial for an optimal antimicrobial strategy. 16S ribosomal RNA gene sequence analysis would provide a useful tool for precise bacterial identification.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">16S rRNA</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">culture-negative</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Enterobacter hormaechei</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">infected aneurysm</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0301-486X</Issn>
      <Volume>190</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Prognostic Value of Serum (1→3)-β-D-Glucan Levels in Patients with Candidemia Stratified by Compliance with Candida Bundle: A Multicenter Retrospective Cohort Study (2016–2023)</ArticleTitle>
    <FirstPage LZero="delete">90</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hidemasa</FirstName>
        <LastName>Akazawa</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinnosuke</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshie</FirstName>
        <LastName>Higuchi</LastName>
        <Affiliation>Department of General Internal Medicine, Okayama Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Center for Medical Education and Internationalization, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Iio</LastName>
        <Affiliation>Microbiology Division, Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukinobu</FirstName>
        <LastName>Akamatsu</LastName>
        <Affiliation>Department of General Medicine, Tottori Municipal Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuto</FirstName>
        <LastName>Haruki</LastName>
        <Affiliation>Department of Pharmacy, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshitaka</FirstName>
        <LastName>Iwamoto</LastName>
        <Affiliation>Department of General Medicine, NHO Okayama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuichi</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shun</FirstName>
        <LastName>Fujisato</LastName>
        <Affiliation>Department of Pharmacy, Okayama Rousai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soichiro</FirstName>
        <LastName>Ako</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Candidemia is a severe systemic infection with a high mortality risk. While β-D-glucan (BDG) serves as a diagnostic biomarker, its prognostic value in candidemia, particularly in association with Candida bundle compliance, remains unclear.&lt;br&gt;
Methods In this retrospective multicenter cohort study, we evaluated 96 patients with candidemia across nine Japanese hospitals between 2016 and 2023. Candida bundle compliance was assessed using five key components: central venous catheter removal within 24 h of diagnosis, appropriate initial antifungal therapy, ophthalmologic examination, follow-up blood cultures until clearance, and antifungal therapy for at least two weeks post-clearance. Analyses stratified patients by serum BDG status (positive/negative) and compliance with the Candida bundle (high: 4–5 points; low: 0–3 points). The primary outcome was 30-day mortality, and the secondary outcome was defined as endophthalmitis incidence.&lt;br&gt;
Results Of 96 eligible patients with candidemia, 70 (72.9%) were BDG-positive and 26 (27.1%) were BDG-negative. The overall 30-day mortality was 17.7%. Among BDG-positive patients, 15 (21.4%) died, while 2 (7.7%) died in BDG-negative cohorts (p = 0.09). Serum BDG positivity demonstrated a statistically significant association with decreased survival rates in the low bundle adherence group (p = 0.02), whereas this correlation was not observed among patients in the high-compliance cohort (p = 0.66). Endophthalmitis occurred in 25.0% of patients, without significant correlation to serum BDG status. C. albicans was associated with a significantly higher incidence of endophthalmitis compared with non-albicans species (45.7% vs. 8.9%).&lt;br&gt;
Conclusions Serum BDG positivity potentially correlates with worse survival in candidemia, particularly in patients with low bundle compliance. This emphasizes the importance of adherence to standardized Candida management protocols for optimizing patient outcomes.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Candidemia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Prognosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">β-D-glucan</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Candida bundle</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Endophthalmitis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2688-1152</Issn>
      <Volume>6</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Severe Intracranial Infection</ArticleTitle>
    <FirstPage LZero="delete">100026</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shinnosuke</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takumi</FirstName>
        <LastName>Fujimori</LastName>
        <Affiliation>Microbiology Division, Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Iio</LastName>
        <Affiliation>Microbiology Division, Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">bloodstream infection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">brain abscess</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mixed infection</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Oxford University Press (OUP)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1083-7159</Issn>
      <Volume>30</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Pharmacovigilance study for the identification of mogamulizumab-induced immune-related adverse events using a real-world database</ArticleTitle>
    <FirstPage LZero="delete">oyaf201</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Miyata</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Izawa-Ishizawa</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Niimura</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Yoshioka</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mizusa</FirstName>
        <LastName>Hyodo</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuto</FirstName>
        <LastName>Itokazu</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsumi</FirstName>
        <LastName>Miyata</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fuka</FirstName>
        <LastName>Aizawa</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Yagi</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kei</FirstName>
        <LastName>Kawada</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Hamano</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshito</FirstName>
        <LastName>Zamami</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuhiro</FirstName>
        <LastName>Goda</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Ishizawa</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Mogamulizumab is a humanized anti-CCR4 monoclonal antibody used for relapsed/refractory adult T-cell leukemia, cutaneous T-cell lymphoma, and/or Sézary syndrome. Reports of immune-related adverse events (irAEs) in these patients are increasing, and the association between irAEs and mogamulizumab remains to be elucidated. This study aimed to evaluate the association between mogamulizumab and immune-related adverse events (irAEs), as well as to characterize the irAEs associated with mogamulizumab using data from a large-scale spontaneous reporting system.&lt;br&gt;
Methods: We performed an exploratory hypothesis-generating analysis of patients from 1967 to September 2023 using VigiBase, a World Health Organization spontaneous adverse event reporting system database. We performed a disproportionality analysis and determined the reporting odds ratios and information components between the drugs of interest and each irAE.&lt;br&gt;
Results: Mogamulizumab was associated with some irAEs, including myocarditis, severe cutaneous adverse reactions, hepatitis, and myositis. Mogamulizumab exhibited significantly higher reporting rates of these 4 irAEs compared to the anticancer agents other than mogamulizumab. Conversely, the reporting rate of other irAEs, including endocrine autoimmune diseases induced by immune checkpoint inhibitors, was not significant in patients who received mogamulizumab.&lt;br&gt;
Conclusions: Mogamulizumab is associated with irAEs, including myocarditis, severe cutaneous adverse reactions, hepatitis, and myositis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">irAEs</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mogamulizumab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">VigiBase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">disproportionality analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">sézary syndrome</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2772-5723</Issn>
      <Volume>5</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Feasibility and Diagnostic Utility of Mucosal T-Cell Flow Cytometry for Intestinal Graft-Versus-Host Disease</ArticleTitle>
    <FirstPage LZero="delete">100820</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takumi</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ennishi</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuharu</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mai</FirstName>
        <LastName>Hiramatsu</LastName>
        <Affiliation>Division of Medical Support, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Araki</FirstName>
        <LastName>Hirabata</LastName>
        <Affiliation>Division of Medical Support, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahide</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Division of Medical Support, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background and Aims: Timely diagnosis of intestinal complications after hematopoietic stem cell transplantation (HSCT), including graft-versus-host disease (GVHD), transplant-associated thrombotic microangiopathy, and cytomegalovirus infection, is essential for appropriate management. This study evaluated whether mucosal T-cell profiling from endoscopic biopsies could support the diagnosis of these post-transplant conditions.&lt;br&gt;
Methods: We prospectively analyzed 58 intestinal biopsy specimens from 21 post-HSCT patients. Paired samples were obtained from the stomach and duodenum during upper endoscopy and from the ileum and large intestine during colonoscopy. Lymphocytes were isolated from each specimen and analyzed using flow cytometry. These data were integrated with those of a previously collected cohort (35 patients, 51 samples) for comparative immunophenotypic analysis across histologically defined groups.&lt;br&gt;
Results: Duodenal biopsies yielded more lymphocytes than did gastric biopsies (mean ± standard deviation: 532 ± 823 vs 233 ± 392 cells; P = .070), with comparable yields between the ileum and colon. Among 41 evaluable cases, the CD56+:CD3+ ratio was significantly lower in patients with GVHD (5.5 ± 2.2%) than in those with nonspecific or no inflammation (28.4 ± 16.3%; P = .006). A cutoff value of &lt;11% provided 85.7% sensitivity and 83.3% specificity for diagnosing GVHD (area under the curve = 0.91).&lt;br&gt;
Conclusion: Mucosal T-cell profiling using endoscopic biopsies is feasible and may aid in the diagnosis of GVHD after HSCT. A decreased CD56+:CD3+ ratio is a promising marker for distinguishing GVHD from other post-transplant intestinal conditions.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">cytomegalovirus infection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">flow cytometry</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">graft-versus-host disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hematopoietic stem cell transplantation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">T lymphocytes</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2077-0383</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Oral Health-Related Quality of Life and Self-Reported Oral Health Status Are Associated with Change in Self-Reported Depression Status: A Cohort Study</ArticleTitle>
    <FirstPage LZero="delete">376</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Noriko</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Department of Preventive Dentistry, Division of Dentistry, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Maruyama</LastName>
        <Affiliation>Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Toyama</LastName>
        <Affiliation>Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuzuki</FirstName>
        <LastName>Katsube</LastName>
        <Affiliation>Dental School, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Tabuchi</LastName>
        <Affiliation>Division of Epidemiology, School of Public Health, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ekuni</LastName>
        <Affiliation>Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Objectives: Oral health-related quality of life (OHRQoL) may influence mental health outcomes, yet longitudinal evidence on its association with depression remains limited. This study aimed to examine whether oral health status and OHRQoL are associated with a change in self-reported depression status among adults in Japan. Methods: We analyzed data from the Japan COVID-19 and Society Internet Survey (JACSIS), conducted in 2022 and 2023. A total of 15,068 participants aged ≥20 years without depression at baseline were included. Depression status was identified by self-reported measures between the two survey waves. Logistic regression models estimated odds ratios (ORs) and 95% confidence intervals (CIs) for change in self-reported depression status in relation to OHRQoL and oral health status, adjusting for sociodemographic and behavioral factors. Results: During follow-up, 218 participants (1.45%) reported a change in self-reported depression status. Poorer OHRQoL was significantly associated with a change in self-reported depression status (OR: 1.018; 95% CI: 1.001–1.036; p = 0.039). Additional risk factors included younger age (OR: 0.974; 95% CI: 0.964–0.985), participation in hobbies and cultural activities (OR: 2.224; 95% CI: 1.498–3.302), habitual use of sleeping pills or anxiolytics (current use OR: 3.512; 95% CI: 2.267–5.442), increased loneliness (OR: 1.217; 95% CI: 1.140–1.299), lower life satisfaction (OR: 0.900; 95% CI: 0.836–0.969), and poor self-rated health (OR: 2.921; 95% CI: 1.810–4.715). Conclusions: Impaired OHRQoL was associated with a change in self-reported depression status, potentially through psychosocial mechanisms. These findings suggest that oral health and OHRQoL may be relevant factors to consider in integrated oral and mental health approaches in clinical practice.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">oral health-related quality of life</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">depression status</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cohort study</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2079-6374</Issn>
      <Volume>16</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Magnetic Detection of Cancer Cells Using Tumor-Homing Peptide-Modified Magnetic Nanoparticles</ArticleTitle>
    <FirstPage LZero="delete">45</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shengli</FirstName>
        <LastName>Zhou</LastName>
        <Affiliation>Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuji</FirstName>
        <LastName>Furutani</LastName>
        <Affiliation>Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kei</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sakuya</FirstName>
        <LastName>Kako</LastName>
        <Affiliation>Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazunori</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Kiwa</LastName>
        <Affiliation>Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Ohtsuki</LastName>
        <Affiliation>Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Magnetic nanoparticles (MNPs) provide a platform for target detection because of their magnetic responsiveness to alternating magnetic fields (AMFs). We developed a detection method using MNPs modified with tumor-homing peptides (THPs), PL1 and PL3, which selectively bind to protein components enriched in malignant tissues. THP-MNPs were synthesized using maleimide-PEG-NHS linkers and characterized using transmission electron microscopy. Human glioblastoma cancer U87MG and normal tissue-derived HEK293 cells were incubated with THP-MNPs, and the magnetic signals were measured using a high-temperature superconducting quantum interference device (SQUID) magnetometer under an AMF (1.06 kHz). Dark-field microscopy confirmed the preferential binding of THP-MNPs to U87MG cells. In the absence of cells, THP-MNPs exhibited AMF-dependent signal enhancement, which correlated with particle size reduction due to THP release. This increase was completely suppressed in the presence of U87MG cells, indicating a strong THP-mediated interaction. PL3-MNPs exhibited superior discrimination between malignant and non-malignant cells. These results demonstrate that SQUID-based magnetic measurements using THP-MNPs enable rapid and label-free cancer cell detection.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">magnetic nanoparticle</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tumor-homing peptide</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">superconducting quantum interference devices</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1340-6868</Issn>
      <Volume>32</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Clinical significance on switching CDK4/6 inhibitors among 13,284 patients with metastatic breast cancer</ArticleTitle>
    <FirstPage LZero="delete">1405</FirstPage>
    <LastPage>1416</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Nishina</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maki</FirstName>
        <LastName>Tanioka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Takada</LastName>
        <Affiliation>Medical AI Project, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Tsukioki</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuko</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadahiko</FirstName>
        <LastName>Shien</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Recent clinical trials have shown that switching to a combination therapy of a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) and endocrine therapy (ET) prolongs progression-free survival (PFS) compared with ET monotherapy. Reports indicate that abemaciclib provides benefits regardless of the PIK3CA mutation status; however, its clinical benefits remain insufficient. This study aimed to evaluate the clinical significance of switching CDK4/6i + ET in a large real-world cohort. Using a medical database, we identified 13,284 patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer who received CDK4/6i + ET between 2008 and 2022. Patients were categorized into five groups based on their first- and second-line therapy patterns. We compared the median time to discontinuation (TTD) among the groups. In patients who switched from one CDK4/6i + ET to another CDK4/6i + ET, the second-line TTD and total TTD of first- and second-line therapies (n = 542) were significantly longer than those in patients who switched from CDK4/6i + ET to ET monotherapy (n = 490) (the second-line TTD: 11.2 vs. 4.9 months, p &lt; 0.01; total TTD: 25.1 vs. 20.5 months, p &lt; 0.01). The order of palbociclib and abemaciclib administration did not significantly affect the second-line or total TTD in patients who switched from one CDK4/6i + ET to another CDK4/6i + ET. Switching from one CDK4/6i + ET to another CDK4/6i + ET resulted in a significantly longer TTD than switching to ET monotherapy. Considering the phase III clinical trial results of capivasertib, switching to CDK4/6i + ET is a viable therapeutic option regardless of the PIK3CA mutation status.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Cyclin-dependent kinase 4/6 inhibitors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Endocrine therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">HR-positive/HER2-negative advanced breast cancer </Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Progression-free survival</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Time to discontinuation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Society for Microbiology</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0066-4804</Issn>
      <Volume>69</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Genomic portrayal of emerging carbapenem-resistant El Tor variant Vibrio cholerae O1</ArticleTitle>
    <FirstPage LZero="delete">e00740-25</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sreeja</FirstName>
        <LastName>Shaw</LastName>
        <Affiliation>ICMR-National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Agila Kumari</FirstName>
        <LastName>Pragasam</LastName>
        <Affiliation>V. Ramalingaswami Bhawan, Indian Council of Medical Research</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Goutam</FirstName>
        <LastName>Chowdhury</LastName>
        <Affiliation>ICMR-National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Prosenjit</FirstName>
        <LastName>Samanta</LastName>
        <Affiliation>ICMR-National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Deboleena</FirstName>
        <LastName>Roy</LastName>
        <Affiliation>ICMR-National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Debjani</FirstName>
        <LastName>Ghosh</LastName>
        <Affiliation>ICMR-National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Thandavarayan</FirstName>
        <LastName>Ramamurthy</LastName>
        <Affiliation>ICMR-National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jigna</FirstName>
        <LastName>Karia</LastName>
        <Affiliation>Medical College Baroda</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Govind</FirstName>
        <LastName>Ninama</LastName>
        <Affiliation>Medical College Baroda</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin-ichi</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukihiro</FirstName>
        <LastName>Akeda</LastName>
        <Affiliation>National Institute of Infectious Diseases</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hemanta</FirstName>
        <LastName>Koley</LastName>
        <Affiliation>ICMR-National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Asish Kumar</FirstName>
        <LastName>Mukhopadhyay</LastName>
        <Affiliation>ICMR-National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The escalating prevalence of carbapenem-resistant (CR) enteric pathogens elicits significant challenges to public health management and effective antimicrobial therapy. While carbapenem resistance is rare in Vibrio cholerae O1 (VC), the recent emergence of CR strains reveals a concerning shift in their antimicrobial resistance (AMR) landscape. This study aims to characterize the resistance mechanisms in newly identified El Tor CRVC isolated from cholera patients in Gujarat, India during 2019. Fifty VC isolates were screened for major virulence-associated genes along with the determination of their antibiotic resistance profiles using Kirby-Bauer disk diffusion and MIC assays. Whole-genome sequencing (WGS) was employed to investigate the underlying mechanisms of CR. All the isolates exhibited hypervirulent Haitian alleles of major virulence genes and AMR profiles of typical multidrug resistance (MDR). Strikingly, 12% (6/50) of them were resistant to carbapenems and other antibiotics. Molecular analysis revealed that these CR isolates were clonally related and harbored a 142 kbp IncA/C type conjugative mega-plasmid with several AMR encoding genes, including blaNDM-1, that can be easily transferred to other bacterial species and confer donor AMR patterns. The plasmid’s competence for horizontal gene transfer presents a significant risk of dissemination to other enteric pathogens and thereby may complicate the treatment. This finding emphasizes the urgent need for enhanced genomic surveillance and robust antimicrobial stewardship programs aimed at curbing the spread of CRVC strains and mitigating their impact on cholera treatment and containment strategies.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">antimicrobial resistance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Vibrio cholerae</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">blaNDM-1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">carbapenem resistance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">horizontal gene transfer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">IncA/C plasmid</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1432-0851</Issn>
      <Volume>75</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Gut microbial metabolite butyrate boosts p53-expressing telomerase-specific oncolytic adenovirus efficacy by enhancing infectivity and activating MHC-I/cGAS-STING</ArticleTitle>
    <FirstPage LZero="delete">10</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Kuroda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Mikane</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunya</FirstName>
        <LastName>Hanzawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Kadowaki</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Hamada</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoma</FirstName>
        <LastName>Sugimoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chiaki</FirstName>
        <LastName>Yagi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuhiko</FirstName>
        <LastName>Kanaya</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiko</FirstName>
        <LastName>Kakiuchi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Kikuchi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunitoshi</FirstName>
        <LastName>Shigeyasu</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Tazawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Kagawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuo</FirstName>
        <LastName>Urata</LastName>
        <Affiliation>Oncolys BioPharma, Inc.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The gut microbiota plays an essential role in regulating host immunity, and its metabolites such as butyrate exert immunomodulatory effects by acting as histone deacetylase inhibitors. Oncolytic virotherapy has emerged as a promising approach for cancer treatment, and we have developed OBP-702, a telomerase-specific oncolytic adenovirus that expresses p53 and elicits strong systemic antitumor responses. In this study, the potential synergy between butyrate and OBP-702 was investigated in colorectal cancer models. Using human and murine colorectal carcinoma cell lines, butyrate was found to directly enhance the infectivity of OBP-702 by upregulating CAR and integrins, thereby promoting apoptosis and autophagy in tumor cells. In addition, butyrate indirectly boosted systemic antitumor immunity by upregulating MHC-I expression through activation of the cGAS-STING pathway and enhancing CD8 + T cell recruitment via CXCL10 secretion. These findings were supported by in vivo experiments using CT26 subcutaneous, bilateral, and orthotopic tumor models, in which the combination of oral butyrate and intratumoral OBP-702 administration produced synergistic antitumor effects. These results highlight the therapeutic potential of integrating gut microbial metabolites with oncolytic virotherapy as a novel immunotherapeutic strategy for colorectal cancer.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Butyrate</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Oncolytic adenovirus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">MHC-I</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CD8 + T cells</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cancer immunotherapy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山医学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0030-1558</Issn>
      <Volume>137</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>令和６年度岡山医学会賞　胸部・循環研究奨励賞（砂田賞）</ArticleTitle>
    <FirstPage LZero="delete">95</FirstPage>
    <LastPage>97</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Kawana</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山医学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0030-1558</Issn>
      <Volume>137</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>令和６年度岡山医学会賞　総合研究奨励賞（結城賞）</ArticleTitle>
    <FirstPage LZero="delete">92</FirstPage>
    <LastPage>94</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Yumoto</LastName>
        <Affiliation>Department of Emergency, Critical Care and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山医学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0030-1558</Issn>
      <Volume>137</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>令和６年度岡山医学会賞　がん研究奨励賞（林原賞・山田賞）</ArticleTitle>
    <FirstPage LZero="delete">89</FirstPage>
    <LastPage>91</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>Takihira</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0009-2541</Issn>
      <Volume>695</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Flash vaporization and migration of iodine in the oceanic plate subduction zone</ArticleTitle>
    <FirstPage LZero="delete">123031</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Noriyuki</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Earth and Planetary Sciences, Faculty of Science, Hokkaido University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Kameda</LastName>
        <Affiliation>Institute for Planetary Materials, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miki</FirstName>
        <LastName>Amo</LastName>
        <Affiliation>Geology and Geophysics Division, Technology Department, Japan Organization for Metals and Energy Security</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Crustal fluids in subduction zones, such as subsurface aquifers, submarine seeps, and gas hydrate waters, are often rich in iodine (I2) and methane (CH4). Large-scale aquifers in the Kanto subduction zone, where the Pacific Plate (PAC) and the Philippine Sea Plate (PHS) are subducting, also exhibit high concentrations of I2 and CH4. However, the origin and behavior of I2 in the subduction zone are unclear, and its coexistence with CH4 remains unresolved. To investigate this, we compiled the I2 phase diagram under high-pressure and high-temperature (P–T) conditions to predict its physicochemical properties in the subduction zone. We then applied the P–T paths of subducted PAC and PHS sediments to the I2 phase diagram. Our findings reveal that I2 can exist as a liquid in the young and hot PHS subduction zone. Transient decompressions during earthquake ruptures can cause liquid iodine to flash-vaporize and be expelled from subducted sediments. Along with I2, thermogenic CH4 and hydrogen (H2) generated in the subducted sediments are also released and transported upward, likely by slab-dehydrated fluids. Additionally, H2 may enhance microbial CH4 production through hydrogenotrophic methanogenesis. In subduction zones of young and hot oceanic plates such as the PHS, crustal fluids are enriched in I2 and coexist with CH4 owing to the simultaneous expulsion of I2, CH4, and H2 from the same subducted sediments and their migration via deep fluids. Large subsurface aquifers can act as traps and reservoirs for migrating I2 and CH4, forming large-scale I2 and CH4 deposits.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Iodine circulation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Flash vaporization</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Microbial methane</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Thermogenic methane</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Thermogenic hydrogen</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Subducted sediments</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1465-3249</Issn>
      <Volume>27</Volume>
      <Issue>8</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Clinical outcomes of Japanese patients treated with out-of-specification tisagenlecleucel in a phase 3b trial</ArticleTitle>
    <FirstPage LZero="delete">938</FirstPage>
    <LastPage>943</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Hematology, Oncology, and Cardiovascular Medicine, Kyushu University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Division of Hematology, Department of Medicine, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiyuki</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Pediatrics, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Emiko</FirstName>
        <LastName>Sakaida</LastName>
        <Affiliation>Department of Hematology, Chiba University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidefumi</FirstName>
        <LastName>Hiramatsu</LastName>
        <Affiliation>Department of Pediatrics, Graduate School of Medicine, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahide</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Hematology, Institute of Science Tokyo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Yoshihara</LastName>
        <Affiliation>Department of Hematology, Hyogo Medical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Ando</LastName>
        <Affiliation>Department of Cell Therapy and Transfusion Medicine, Juntendo University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyoshi</FirstName>
        <LastName>Koh</LastName>
        <Affiliation>Department of Hematology/Oncology, Saitama Children’s Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Hematology and Oncology, Osaka University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumiko</FirstName>
        <LastName>Iwamoto</LastName>
        <Affiliation>Medical Affairs, Novartis Pharma K.K.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ranjan</FirstName>
        <LastName>Tiwari</LastName>
        <Affiliation>Development Advance Quantitative Sciences, Novartis Healthcare Private Limited</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuharu</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: The final manufactured tisagenlecleucel product should meet the commercial product release specifications to ensure the quality in terms of safety, purity, identity, and potency. However, it may occasionally fail to meet these specifications due to the nature of patient-derived cells with variable properties as starting material and the complex manufacturing process. The final product that does not meet at least one of the commercial release specifications is referred to as “out-of-specification” (OOS). However, the benefit-risk profile of OOS tisagenlecleucel has not yet been fully elucidated.&lt;br&gt;
Aims: To evaluate the safety and efficacy of OOS tisagenlecleucel in Japanese patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) and B-cell acute lymphoblastic leukemia (B-ALL).&lt;br&gt;
Methods: This is a single-arm, open-label, multicenter phase 3b study (NCT04094311). Patients consistent with label indication were enrolled and followed-up for 3 months.&lt;br&gt;
Results: Of the 29 patients enrolled between December 2019 and May 2022 across 13 qualified sites in Japan, 28 received tisagenlecleucel, and of these, 23 had r/r DLBCL and 5 had r/r B-ALL. The primary reasons for OOS were low cell viability (15 of 24 batches) and low dose (8 of 23 batches) tisagenlecleucel in the r/r DLBCL group, and high dose (4 of 5 batches) in the r/r B-ALL group. In patients with r/r DLBCL, the grade 3 or 4 cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome occurred in 3 and 1 patients, respectively. Response assessments were performed for 15 of 23 patients with r/r DLBCL: 6 achieved a complete response, and 1 achieved a partial response as the best response within 3 months.&lt;br&gt;
Conclusions: Despite the limited patient sample size, our findings affirm that the infusion of OOS tisagenlecleucel is a viable option, with no observed increase in toxicity and outcomes comparable to those of in-specification products in clinical and real-world studies.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">CAR-T</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">DLBCL</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Out-of-specification</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Safety</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tisagenlecleucel</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0007-8506</Issn>
      <Volume>74</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Improvement of anodic oxide film characteristics of Al-Cu alloy by refinement of IMCs with large-area electron beam irradiation</ArticleTitle>
    <FirstPage LZero="delete">263</FirstPage>
    <LastPage>267</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Shinonaga</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science &amp; Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">A.</FirstName>
        <LastName>Sebe</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science &amp; Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">M.</FirstName>
        <LastName>Taniguchi</LastName>
        <Affiliation>Shimano Research Laboratories, R&amp;D Strategy Dept., SHIMANO INC.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Shimano Research Laboratories, R&amp;D Strategy Dept., SHIMANO INC.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">A.</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science &amp; Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Al-Cu alloy has been widely applied to automobile products due to its light weight and high strength, but pitting corrosion easily occurs due to intermetallic compounds (IMCs) in Al-Cu alloy. Anodizing process has been conventionally performed to improve the corrosion resistance of Al-Cu alloy surface. However, IMCs in Al-Cu alloy lead to defects in anodic oxide film. In this study, refinement of IMCs in Al-Cu alloy surface by large-area EB irradiation was proposed. Experimental results show that reflectance and corrosion resistance of anodic oxide film formed on Al-Cu alloy surface are improved by refinement of IMCs with the EB irradiation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Electron beam</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">aluminum</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">anodic oxide film</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2059-7029</Issn>
      <Volume>10</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Association between adjuvant chemotherapy and outcomes in resected locoregional recurrence of hormone receptor-positive HER2-negative breast cancer: a multi-institutional retrospective study</ArticleTitle>
    <FirstPage LZero="delete">105889</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Y.</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Breast Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">E.</FirstName>
        <LastName>Tokuda</LastName>
        <Affiliation>Department of Medical Oncology, Fukushima Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Y.</FirstName>
        <LastName>Sagara</LastName>
        <Affiliation>Department of Breast Surgery, Social Medical Corporation Hakuaikai Sagara Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">F.</FirstName>
        <LastName>Hara</LastName>
        <Affiliation>Department of Breast Oncology, Aichi Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">S.</FirstName>
        <LastName>Sasada</LastName>
        <Affiliation>Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">M.</FirstName>
        <LastName>Sawaki</LastName>
        <Affiliation>Department of Breast Oncology, Aichi Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">C.</FirstName>
        <LastName>Kanbayashi</LastName>
        <Affiliation>Department of Breast Oncology, Niigata Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Yamanaka</LastName>
        <Affiliation>Department of Breast Surgery and Oncology, Kanagawa Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Onishi</LastName>
        <Affiliation>Department of Breast Oncology, National Cancer Center Hospital East</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Y.</FirstName>
        <LastName>Fujiki</LastName>
        <Affiliation>Department of Breast Surgery, Social Medical Corporation Hakuaikai Sagara Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">A.</FirstName>
        <LastName>Suto</LastName>
        <Affiliation>Department of Breast Oncology, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Y.</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Breast and Endocrine Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">E.</FirstName>
        <LastName>Tokunaga</LastName>
        <Affiliation>Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Aruga</LastName>
        <Affiliation>Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">R.</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Division of Breast Surgery, Chiba Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Fujisawa</LastName>
        <Affiliation>Department of Breast Oncology, Gunma Prefectural Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">S.</FirstName>
        <LastName>Saji</LastName>
        <Affiliation>Department of Medical Oncology, Fukushima Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">H.</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Advanced Clinical Research and Development, Nagoya City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Shien</LastName>
        <Affiliation>Department of Breast and Endocrine Surgery, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: To evaluate the association of adjuvant chemotherapy and prognosis for locoregional recurrence (LRR) in hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative subtype breast cancer.&lt;br&gt;
Patients and methods: We carried out a multi-institutional retrospective cohort study in patients with breast cancer who developed HR-positive HER2-negative LRR. Patients who underwent curative surgery for LRR between 2014 and 2018 were categorized based on whether they received adjuvant chemotherapy for LRR (CTx versus no-CTx). Invasive disease-free survival (iDFS) was evaluated between the groups by Cox proportional hazards analysis. The primary analysis used a double-robust Cox model incorporating inverse probability of treatment weighting, and a sensitivity analysis using propensity score matching was also carried out.&lt;br&gt;
Results: A total of 958 patients were included. The median time from the primary surgery to LRR diagnosis was 9.5 years (interquartile range 3.1-10.1 years). There were 235 patients (25%) in the CTx group and 722 (75%) in the no-CTx group. Among all patients, the 5-year iDFS rate was 75.4% [95% confidence interval (CI) 72.4% to 78.2%]. Multivariate analysis showed better iDFS in the CTx group (hazard ratio 0.70, 95% CI 0.49-0.99, P = 0.045). Sensitivity analysis supported these findings. Subgroup analyses showed that the CTx group had better iDFS in cases with non-ipsilateral breast tumor recurrence (IBTR), recurrences during adjuvant endocrine therapy for primary breast cancer, and without perioperative chemotherapy for primary breast cancer. Secondary analysis showed no significant difference with a worse trend toward overall survival in the CTx group with multivariate Cox proportional hazards analysis.&lt;br&gt;
Conclusion: Adjuvant chemotherapy for HR-positive HER2-negative LRR was associated with better iDFS, particularly in cases of non-IBTR, recurrences during adjuvant endocrine therapy, and no prior perioperative chemotherapy for their primary tumor. However, the retrospective design and inability to distinguish true recurrences from new primary tumors in IBTR warrant cautious interpretation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">breast cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">locoregional recurrence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">adjuvant chemotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">inverse probability of treatment weighting</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0718-9508</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Suppression of Na+ Uptake Via Apoplastic Flow by Chitosan in Rice</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Maoxiang</FirstName>
        <LastName>Zhao</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Md. Asadulla Al</FirstName>
        <LastName>Galib</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshimasa</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiko</FirstName>
        <LastName>Hirai</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshitaka</FirstName>
        <LastName>Nakashima</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shintaro</FirstName>
        <LastName>Munemasa</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Izumi C.</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiyuki</FirstName>
        <LastName>Murata</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose: Chitosan enhances tolerance to salinity in rice. Apoplastic flow plays a crucial role in the accumulation of sodium (Na+) in rice under salinity. This study investigated the effects of exogenous chitosan on apoplastic flow and Na+ uptake in NaCl-treated rice seedlings. Methods: We employed an apoplastic tracer, trisodium salt of 8-hydroxy-1,3,6-pyrenetrisulphonic acid (PTS), in order to evaluate apoplastic flow in rice (Oryza sativa L., cv. Nipponbare) seedlings that were hydroponically grown in the solution containing NaCl (0 and 25 mM), and chitosan (0 mg L− 1, 10 mg L− 1, and 50 mg L− 1). Results: Application of 25 mM NaCl significantly increased PTS uptake and Na+ content in shoots but did not affect K+ content, resulting in a lower K+/Na+ ratio although 25 mM NaCl did not affect the seedling growth. The application of chitosan suppressed Na+-enhanced PTS uptake and Na+ accumulation in shoots without affecting the K+ content, which led to a higher K+/Na+ ratio. Moreover, chitosan did not affect the reducing sugar content or electrical conductivity in the solution containing NaCl. Conclusions: These results suggest that application of chitosan suppressed Na+-enhanced apoplastic flow to reduce Na+ uptake in rice seedlings.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Rice · Salinity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Apoplastic flow</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Trisodium-8-hydroxy-1,3,6-pyrenetrisulphonic acid</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Chitosan</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Frontiers Media SA</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1664-042X</Issn>
      <Volume>16</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Activation of the pentose phosphate pathway by microcurrent stimulation mediates antioxidant effects in inflammation-stimulated macrophages</ArticleTitle>
    <FirstPage LZero="delete">1666999</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Mikiko</FirstName>
        <LastName>Uemura</LastName>
        <Affiliation>Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriaki</FirstName>
        <LastName>Maeshige</LastName>
        <Affiliation>Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atomu</FirstName>
        <LastName>Yamaguchi</LastName>
        <Affiliation>Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xiaoqi</FirstName>
        <LastName>Ma</LastName>
        <Affiliation>Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yunfei</FirstName>
        <LastName>Fu</LastName>
        <Affiliation>Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taketo</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Assisted Reproductive Technology Center, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mami</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Graduate School of Science, Technology and Innovation, Kobe University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuya</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Graduate School of Science, Technology and Innovation, Kobe University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohisa</FirstName>
        <LastName>Hasunuma</LastName>
        <Affiliation>Graduate School of Science, Technology and Innovation, Kobe University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ji</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Department of Toxicology and Sanitary Chemistry, School of Public Health, Capital Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyo</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Department of Nutrition, Faculty of Health and Nutrition, Shubun University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidemi</FirstName>
        <LastName>Fujino</LastName>
        <Affiliation>Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: Excessive inflammatory responses in macrophages lead to increased oxidative stress, and the excessive production of reactive oxygen species (ROS) causes tissue damage, contributing to the development of chronic diseases and tissue deterioration. Therefore, controlling the inflammatory response and ROS production is crucial for human health. Electrical stimulation (ES) has been shown to have antioxidant and anti-inflammatory effects on macrophages. However, the key pathway underlying these effects remains unclear.&lt;br&gt;
Methods: In this study, ES was applied to Lipopolysaccharide (LPS)-stimulated macrophages, and the production of ROS and 8–hydroxy–2′–deoxyguanosine (8-OHdG), inflammatory cytokine expression, and intracellular metabolites were analyzed in a glucose-6-phosphate dehydrogenase (G6PD) knockdown experiment, the rate-limiting enzyme of the Pentose Phosphate Pathway(PPP).&lt;br&gt;
Results: ES significantly increased sedoheptulose 7-phosphate (S7P), an intermediate metabolite in PPP, and reduced ROS and 8-OHdG production and the expression of inflammatory cytokines in LPS-stimulated macrophages. Meanwhile, ES did not exert antioxidant effects in G6PD-knockdown macrophages.&lt;br&gt;
Discussion: These findings indicate that the antioxidant effects of ES are mediated by PPP in LPS-stimulated macrophages.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">microcurrent stimulation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pentose phosphate pathway (PPP)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">NADPH</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">oxidative stress</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">macrophage</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">glucose metabolism</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Institution of Engineering and Technology (IET)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1751-9659</Issn>
      <Volume>19</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Subspace-Guided Feature Reconstruction for Unsupervised Anomaly Localization</ArticleTitle>
    <FirstPage LZero="delete">e70157</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Katsuya</FirstName>
        <LastName>Hotta</LastName>
        <Affiliation>Iwate University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chao</FirstName>
        <LastName>Zhang</LastName>
        <Affiliation>University of Toyama</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Hagihara</LastName>
        <Affiliation>Iwate University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Akashi</LastName>
        <Affiliation>Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Unsupervised anomaly localization aims to identify anomalous regions that deviate from normal sample patterns. Most recent methods perform feature matching or reconstruction for the target sample with pre-trained deep neural networks. However, they still struggle to address challenging anomalies because the deep embeddings stored in the memory bank can be less powerful and informative. Specifically, prior methods often overly rely on the finite resources stored in the memory bank, which leads to low robustness to unseen targets. In this paper, we propose a novel subspace-guided feature reconstruction framework to pursue adaptive feature approximation for anomaly localization. It first learns to construct low-dimensional subspaces from the given nominal samples, and then learns to reconstruct the given deep target embedding by linearly combining the subspace basis vectors using the self-expressive model. Our core is that, despite the limited resources in the memory bank, the out-of-bank features can be alternatively “mimicked” to adaptively model the target. Moreover, we propose a sampling method that leverages the sparsity of subspaces and allows the feature reconstruction to depend only on a small resource subset, contributing to less memory overhead. Extensive experiments on three benchmark datasets demonstrate that our approach generally achieves state-of-the-art anomaly localization performance.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1347-9032</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Genomic Profiling of Pediatric Solid Tumors With a Dual DNA/RNA Panel: JCCG-TOP2 Study</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kayoko</FirstName>
        <LastName>Tao</LastName>
        <Affiliation>Department of Pediatrics, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takako</FirstName>
        <LastName>Yoshioka</LastName>
        <Affiliation>Department of Pathology, National Center for Child Health and Development</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miho</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Childhood Cancer Data Management, National Center for Child Health and Development</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Komatsu</LastName>
        <Affiliation>Department of Pediatrics, Hamamatsu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Tsujimoto</LastName>
        <Affiliation>Department of Pediatrics, Yokohama City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenichi</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Pediatrics, Shinshu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuki</FirstName>
        <LastName>Tanimura</LastName>
        <Affiliation>Department of Pediatrics, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Minako</FirstName>
        <LastName>Sugiyama</LastName>
        <Affiliation>Department of Pediatrics, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Sekiguchi</LastName>
        <Affiliation>Department of Pediatrics, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiko</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Pediatrics, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Otani</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Yatabe</LastName>
        <Affiliation>Department of Diagnostic Pathology, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Diagnostic Pathology, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hajime</FirstName>
        <LastName>Okita</LastName>
        <Affiliation>Department of Pathology, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Hirato</LastName>
        <Affiliation>Department of Pathology, Public Tomioka General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenichi</FirstName>
        <LastName>Kohashi</LastName>
        <Affiliation>Department of Pathology, Graduate School of Medicine, Osaka Metropolitan University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukichi</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Kanagawa Children's Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Kohsaka</LastName>
        <Affiliation>Division of Cellular Signaling, National Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Kubo</LastName>
        <Affiliation>Department of Clinical Genomics, National Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kuniko</FirstName>
        <LastName>Sunami</LastName>
        <Affiliation>Department of Laboratory Medicine, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Hirata</LastName>
        <Affiliation>Department of Genetic Medicine and Services, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuichi</FirstName>
        <LastName>Tsutsumi</LastName>
        <Affiliation>Genome Science &amp; Medicine Division, Research Center of Advanced Science and Technology, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Aburatani</LastName>
        <Affiliation>Genome Science &amp; Medicine Division, Research Center of Advanced Science and Technology, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyoshi</FirstName>
        <LastName>Koh</LastName>
        <Affiliation>Department of Hematology and Oncology, Saitama Children's Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Hirayama</LastName>
        <Affiliation>Department of Pediatrics, Mie University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuhei</FirstName>
        <LastName>Karakawa</LastName>
        <Affiliation>Department of Pediatrics, Hiroshima University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukayo</FirstName>
        <LastName>Terashita</LastName>
        <Affiliation>Department of Pediatrics, Hokkaido University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Fujisaki</LastName>
        <Affiliation>Department of Pediatric Hematology and Oncology, Osaka City General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Yagi</LastName>
        <Affiliation>Okinawa Prefectural Nanbu Medical Center &amp; Children's Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Yoneda</LastName>
        <Affiliation>Department of Pediatric Surgery, National Center for Child Health and Development</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Mochizuki</LastName>
        <Affiliation>Department of Pediatrics, National Center for Global Health and Medicine, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Shichino</LastName>
        <Affiliation>Department of Pediatrics, National Center for Global Health and Medicine, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Hematology, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Takimoto</LastName>
        <Affiliation>Department of Childhood Cancer Data Management, National Center for Child Health and Development</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Ichimura</LastName>
        <Affiliation>Department of Pathology, Kyorin University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chitose</FirstName>
        <LastName>Ogawa</LastName>
        <Affiliation>Department of Pediatrics, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kimikazu</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Children's Cancer Center National Center for Child Health and Development</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Ichikawa</LastName>
        <Affiliation>Department of Clinical Genomics, National Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motohiro</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Pediatrics, The University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>To develop an optimized genomic medicine platform for pediatric cancers, a nationwide cancer genome profiling project was conducted from January 2022 to February 2023 in collaboration with the Japan Children's Cancer Group. This prospective observational study analyzed matched blood and FFPE tumor samples from patients aged 0–29 years with solid tumors. Genomic analysis used the TOP2 hybrid capture–enrichment system, targeting 737 and 455 genes in the DNA and RNA panels, along with allele-specific genome copy number alterations. A total of 210 patients from 50 institutions were enrolled across Japan (median age, 8 years; range, 0–25). Of these, 154 (77%) were enrolled at diagnosis or during/after initial treatment and 56 (27%) at disease progression or relapse. The TOP2 findings had great benefits in clarifying the diagnosis of pediatric solid tumors. Among the 204 patients with genomic results, 147 (72%) had potentially actionable findings, including diagnostic, prognostic, and therapeutic findings in 111 (54%), 61 (30%), and 64 (31%), respectively. Oncogenic fusions were noted in 45 (23%) patients. A copy number alteration was identified in at least one genomic region in 170 (83%) patients. Two patients exhibited a high tumor mutation burden. Seventeen (8%) patients harbored a germline pathogenic/likely pathogenic variant in cancer-predisposing genes. This study highlighted the feasibility of implementing a nationwide precision medicine platform and the clinical utility of the TOP2 system for pediatric cancers. The results support the integration of genomic data into the standard clinical care of pediatric patients with cancer, both at diagnosis and at relapse.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">genomic medicine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">integrative diagnosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">molecularly targeted therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">multigene panel</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pediatric cancers</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0897-3806</Issn>
      <Volume>38</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Ethical Use of Cadaveric Images in Anatomical Textbooks, Atlases, and Journals: A Consensus Response From Authors and Editors</ArticleTitle>
    <FirstPage LZero="delete">222</FirstPage>
    <LastPage>225</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Joe</FirstName>
        <LastName>Iwanaga</LastName>
        <Affiliation>Department of Neurosurgery, Tulane University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hee‐Jin</FirstName>
        <LastName>Kim</LastName>
        <Affiliation>Division in Anatomy &amp; Development Biology, Department of Oral Biology, Yonsei University College of Dentistry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichi</FirstName>
        <LastName>Akita</LastName>
        <Affiliation>Department of Clinical Anatomy, Tokyo Medical and Dental University (TMDU)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Bari M.</FirstName>
        <LastName>Logan</LastName>
        <Affiliation>UK</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ralph T.</FirstName>
        <LastName>Hutchings</LastName>
        <Affiliation>UK</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nicolás</FirstName>
        <LastName>Ottone</LastName>
        <Affiliation>Department of Integral Adult Dentistry, Center for Research in Dental Sciences (CICO), Dental School, Universidad de La Frontera</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoichi</FirstName>
        <LastName>Nonaka</LastName>
        <Affiliation>Department of Neurosurgery, Tokai University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mahindra</FirstName>
        <LastName>Anand</LastName>
        <Affiliation>Department of Anatomy, Rama Medical College &amp; Research Centre</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Danny</FirstName>
        <LastName>Burns</LastName>
        <Affiliation>Department of Anatomical Sciences, School of Medicine, St. George's University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Vishram</FirstName>
        <LastName>Singh</LastName>
        <Affiliation>Department of Anatomy, Kasturba Medical College Mangalore, Manipal Academy of Higher Education</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maria</FirstName>
        <LastName>Peris‐Celda</LastName>
        <Affiliation>Department of Neurologic Surgery, Mayo Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Francisco</FirstName>
        <LastName>Martinez‐Soriano</LastName>
        <Affiliation>Department of Anatomy, University of Valencia</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nihal</FirstName>
        <LastName>Apaydin</LastName>
        <Affiliation>Department of Anatomy, Faculty of Medicine, Ankara University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Amgad</FirstName>
        <LastName>Hanna</LastName>
        <Affiliation>Department of Neurological Surgery, University of Wisconsin</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobutaka</FirstName>
        <LastName>Yoshioka</LastName>
        <Affiliation>Department of Neuroplastic and Reconstructive Surgery Social Medical Corporation Kotobukikai Tominaga Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Juan</FirstName>
        <LastName>Fernandez‐Miranda</LastName>
        <Affiliation>Department of Neurosurgery, Stanford University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mi‐Sun</FirstName>
        <LastName>Hur</LastName>
        <Affiliation>Department of Anatomy, Daegu Catholic University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mohammadali M.</FirstName>
        <LastName>Shoja</LastName>
        <Affiliation>Department of Medical Education, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University (NSU) </Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Farhood</FirstName>
        <LastName>Saremi</LastName>
        <Affiliation>Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Ronald Reagan UCLA Medical Center </Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Francisco</FirstName>
        <LastName>Reina</LastName>
        <Affiliation>Medical Sciences Department, Faculty of Medicine, Clinical Anatomy, Embryology and Neuroscience Research Group, University of Girona</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoko</FirstName>
        <LastName>Tabira</LastName>
        <Affiliation>Division of Gross and Clinical Anatomy, Department of Anatomy, Kurume University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Anna</FirstName>
        <LastName>Carrera</LastName>
        <Affiliation>Medical Sciences Department, Faculty of Medicine, Clinical Anatomy, Embryology and Neuroscience Research Group, University of Girona</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jonathan D.</FirstName>
        <LastName>Spratt</LastName>
        <Affiliation>University Hospital of North Durham</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">S. Yen</FirstName>
        <LastName>Ho</LastName>
        <Affiliation>Cardiac Morphology, Royal Brompton &amp; Harefield Hospitals</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shumpei</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>University of California Los Angeles (UCLA) Cardiac Arrhythmia Center, Cardiovascular and Interventional Programs, UCLA Health System, David Geffen School of Medicine at UCLA </Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noritaka</FirstName>
        <LastName>Komune</LastName>
        <Affiliation>Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Division of Gross and Clinical Anatomy, Department of Anatomy, Kurume University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Alberto</FirstName>
        <LastName>Prats‐Galino</LastName>
        <Affiliation>Laboratory of Surgical NeuroAnatomy (LSNA), director of the Body Donation and Dissection Rooms Service, Faculty of Medicine and Health of Science, University of Barcelona</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jose</FirstName>
        <LastName>De Andrés</LastName>
        <Affiliation>Surgery Specialties Department, University of Valencia</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miguel Angel</FirstName>
        <LastName>Reina</LastName>
        <Affiliation>CEU‐San‐Pablo University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Peter H.</FirstName>
        <LastName>Abrahams</LastName>
        <Affiliation>Warwick Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Robert H.</FirstName>
        <LastName>Anderson</LastName>
        <Affiliation>Biosciences Institute, Newcastle University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soichiro</FirstName>
        <LastName>Ibaragi</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Marios</FirstName>
        <LastName>Loukas</LastName>
        <Affiliation>Department of Anatomical Sciences, School of Medicine, St. George's University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">R. Shane</FirstName>
        <LastName>Tubbs</LastName>
        <Affiliation>Department of Neurosurgery, Tulane University School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Nowadays, consent to use donor bodies for medical education and research is obtained from the body donors and their families before the donation. Recently, the International Federation of Associations of Anatomists (IFAA) published guidelines that could restrict the appearance of cadaveric images in commercial anatomical resources such as textbooks and other educational products. These guidelines state that the donor must expressly consent to using such images for this purpose. Cadaveric photos and drawings made from dissections of cadavers have been used in anatomy textbooks and atlases for hundreds of years. They are invaluable for anatomy students and clinical/surgical practitioners. The IFAA guidelines should not restrict the use of those older books; to do so would infringe the rights of those seeking knowledge from these resources. As the images in such textbooks and atlases are anonymized and are used for teaching and research, and the donors and their families are informed about this before the donation, we believe no additional consent is needed. It is impossible to separate educational from “commercial” usage entirely in any situation, e.g., publications from publishers and the use of cadavers in medical schools. Therefore, our best efforts to avoid unethical use of cadaveric images by following traditional consent processes are still needed so that more people will reap the benefits from them. As senior textbook/atlas authors/editors from over 10 countries, we believe that using cadaveric images in anatomy textbooks is appropriate, and no additional consent should be necessary. Such usage falls within the good faith of professionals using these invaluable gifts.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">anatomy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cadaver</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">commercial</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">consent</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dissection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">donors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">medical education</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">medical ethics</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">publishing</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Sequential Bilateral Central Retinal Vein Occlusion With Differential Long-Term Outcomes Following Cardiac Surgery</ArticleTitle>
    <FirstPage LZero="delete">e100045</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Ophthalmology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Zenichi</FirstName>
        <LastName>Masuda</LastName>
        <Affiliation>Cardiovascular Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Sugiyama</LastName>
        <Affiliation>Cardiovascular Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazufumi</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Cardiovascular Medicine and Center for Advanced Heart Failure, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Bilateral central retinal vein occlusion (CRVO) is rare and is associated with systemic diseases such as hypertension, diabetes, dyslipidemia, and coagulopathy. In this study, we showed that the sequential development of bilateral CRVO in an elderly patient was related to increased venous pressure in the right heart system. A 71-year-old man developed CRVO in the right eye, and one year later, he developed CRVO in the left eye. He had undergone pacemaker implantation for sick sinus syndrome 10 years earlier and had started hemodialysis three months prior for chronic renal failure, probably caused by hypertensive nephrosclerosis. The right CRVO resulted in neovascular glaucoma and loss of light perception despite intensive treatment with panretinal laser photocoagulation, intravitreal bevacizumab injection, and additional laser therapy. In contrast, the left CRVO remained at an impending stage, was treated only with panretinal laser photocoagulation, and had a favorable outcome for 11 years until his death. In retrospect, half a year after the onset of left CRVO, the patient underwent open-heart surgery to repair aortic, mitral, and tricuspid valve regurgitation through aortic valve replacement, mitral valve annuloplasty, and tricuspid valve annuloplasty, respectively. Based on the temporal sequence of events, elevated venous pressure due to right heart dysfunction may have contributed to the poor outcome of the right CRVO, whereas improvement of venous stasis after cardiac surgery may have led to the better long-term outcome of the left CRVO. Venous stasis in the right heart system should therefore be considered an underlying factor in the development of bilateral CRVO.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">aortic valve regurgitation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">aortic valve replacement</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bevacizumab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bilateral central retinal vein occlusion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">intravitreal injection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mitral valve annuloplasty</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mitral valve regurgitation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">panretinal laser photocoagulation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tricuspid valve annuloplasty</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tricuspid valve regurgitation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2328-9503</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Dorsolateral Cervical Cord T2 Hyperintensity in KIF1C-Related Disease (Spastic Paraplegia 58): Two Long-Duration Cases</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Mitsutake</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masao</FirstName>
        <LastName>Osaki</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miho</FirstName>
        <LastName>Osako</LastName>
        <Affiliation>Department of Neurology, Tokyo Metropolitan Kita Medical and Rehabilitation Center for the Disabled</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chisen</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Department of Neurology, Tokyo Metropolitan Kita Medical and Rehabilitation Center for the Disabled</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Precision Medicine Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Kurokawa</LastName>
        <Affiliation>Department of Radiology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Harushi</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Radiology, School of Medicine, Jichi Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuji</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Institute of Medical Genomics, International University of Health and Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Toda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Pathogenic variants in KIF1C cause Spastic Paraplegia 58 (SPG58), typically presenting with cerebellar ataxia and spastic paraparesis. We report two unrelated patients with spastic paraparesis, cerebellar ataxia, and tremor. Whole-exome sequence analysis identified novel homozygous variants in the motor domain of KIF1C (NM_006612.6): c.921G&gt;A (p.Trp307Ter) and c.607C&gt;T (p.Arg203Trp). In addition to the canonical brain MRI showing leukoencephalopathy with posterior dominance and hyperintensity along the corticospinal tracts, both patients showed symmetric T2 hyperintensity confined to the lateral and dorsal columns of the cervical cord. Given the long disease durations (22 and 51 years), these findings may represent late-emerging or previously overlooked spinal cord involvement and broaden the neuroradiological spectrum of SPG58.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">cerebellar ataxia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hereditary spastic paraplegia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">KIF1C</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">leukoencephalopathy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japanese Society of Internal Medicine</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0918-2918</Issn>
      <Volume>63</Volume>
      <Issue>13</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Activated CD4+ T Cell Proportion in the Peripheral Blood Correlates with the Duration of Cytokine Release Syndrome and Predicts Clinical Outcome after Chimeric Antigen Receptor T Cell Therapy</ArticleTitle>
    <FirstPage LZero="delete">1863</FirstPage>
    <LastPage>1872</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Wataru</FirstName>
        <LastName>Kitamura</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noboru</FirstName>
        <LastName>Asada</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuntaro</FirstName>
        <LastName>Ikegawa</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital, Japan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideaki</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chihiro</FirstName>
        <LastName>Kamoi</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ennishi</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisakazu</FirstName>
        <LastName>Nishimori</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Division of Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuharu</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Division of Blood Transfusion, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken-ichi</FirstName>
        <LastName>Matsuoka</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective Chimeric antigen receptor (CAR) T cell therapy is an emerging and effective therapy for relapsed or refractory diffuse large B cell lymphoma (R/R DLBCL). The characteristic toxicities of CAR T cell therapy include cytokine release syndrome (CRS) and prolonged cytopenia. We investigated the factors associated with these complications after CAR T cell therapy by analyzing lymphocyte subsets following CAR T cell infusion.&lt;br&gt;
Methods We retrospectively analyzed peripheral blood samples on days 7, 14, and 28 after tisagenlecleucel (tisa-cel) infusion by flow cytometry at our institution between June 2020 and September 2022.&lt;br&gt;
Patients Thirty-five patients with R/R DLBCL who received tisa-cel therapy were included.&lt;br&gt;
Results A flow cytometry-based analysis of blood samples from these patients revealed that the proportion of CD4+CD25+CD127+ T cells (hereafter referred to as "activated CD4+ T cells" ) among the total CD4+ T cells on day 7 after tisa-cel infusion correlated with the duration of CRS (r=0.79, p&lt;0.01). In addition, a prognostic analysis of the overall survival (OS) using time-dependent receiver operating characteristic curves indicated a significantly more favorable OS and progression-free survival of patients with a proportion of activated CD4+ T cells among the total CD4+ T cells &lt;0.73 (p=0.01, and p&lt;0.01, respectively).&lt;br&gt;
Conclusion These results suggest that the proportion of activated CD4+ T cells on day 7 after tisa-cel infusion correlates with the CRS duration and predicts clinical outcomes after CAR T cell therapy. Further studies with a larger number of patients are required to validate these observations.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">chimeric antigen receptor T cell therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">diffuse large B cell lymphoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">flow cytometry</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cytokine release syndrome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">prolonged cytopenia</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山大学法学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-3050</Issn>
      <Volume>75</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>職業選択の自由に関する判例法理</ArticleTitle>
    <FirstPage LZero="delete">346</FirstPage>
    <LastPage>141</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">T. </FirstName>
        <LastName>Ito</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1873-9601</Issn>
      <Volume>19</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Interaction between nuclear‐translocated cellular communication network factor 2 and purine‐rich box 1 regulates the expression of fibrosis‐related genes</ArticleTitle>
    <FirstPage LZero="delete">e70051</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Xuan Thi</FirstName>
        <LastName>Nguyen</LastName>
        <Affiliation>Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaharu</FirstName>
        <LastName>Takigawa</LastName>
        <Affiliation>Advanced Research Center for Oral and Craniofacial Sciences, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences  Okayama Japan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Nishida</LastName>
        <Affiliation>Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Cellular communication network factor 2 (CCN2) with a nuclear localization signal-like peptide is known to promote fibrosis. However, translocation of CCN2 into the nucleus and its role in fibrosis remain unclear. We hypothesized that nuclear-translocated CCN2 is associated with purine-rich box 1 (PU.1), which is a transcription factor regulating the differentiation of myofibroblasts. Western blot analysis of the cytoplasmic and nuclear fractions of cell lysate and immunofluorescence analysis revealed that CCN2 was detectable in both the cytoplasm and nuclei of murine fibroblastic NIH3T3 cells. Additionally, chromatin immunoprecipitation (IP)-PCR and an electrophoretic mobility shift assay revealed that recombinant CCN2 protein bound to the regulatory region of Spi1, which encodes PU.1. Furthermore, IP-Western blot analysis showed that CCN2 interacted with PU.1. Finally, the forced expression of both Ccn2 and Spi1 significantly promoted the production of angiotensin II, and increased fibrosis-related molecules, such as Col1a1 and Acta2, at the gene and protein levels. These findings indicate that CCN2 translocated to the nucleus interacts with PU.1 and that the complex promotes the markers of myofibroblast differentiation, suggesting that CCN2 plays an important role in fibrosis via cooperation with PU.1, as a transcription co-factor.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">cellular communication network factor 2 (CCN2)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fibrosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">myofibroblast</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">purine‐rich box 1 (PU.1)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">transcription co‐factor</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Fuji Technology Press Ltd.</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1883-8049</Issn>
      <Volume>37</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Directed Poisoning Attacks on FRIT in Adaptive Cruise Control</ArticleTitle>
    <FirstPage LZero="delete">1392</FirstPage>
    <LastPage>1399</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Taichi</FirstName>
        <LastName>Ikezaki</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Sawada</LastName>
        <Affiliation>Graduate school of Mechanical Engineering, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Kaneko</LastName>
        <Affiliation>Graduate School of Informatics and Engineering, The University of Electro-Communications</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Recent advances in connected-vehicle technologies have enabled the large-scale collection of driving data, facilitating the deployment of data-driven control schemes. Although these methods offer advantages by eliminating the need for explicit modeling, they also introduce vulnerabilities due to their reliance on stored data. This study investigates a class of targeted data poisoning attacks on fictitious reference iterative tuning, a widely used data-driven controller tuning approach. We present a method that allows an adversary to influence closed-loop dynamics by manipulating the training data so that the resulting controller behavior matches a maliciously defined reference response. This strategy differs from conventional poisoning attacks, which aim only to the degrade control performance. Instead, it enables deliberate alteration of control characteristics such as overshoot and convergence time. The proposed attack is formulated as a constrained optimization problem under bounded tampering signals. Through a numerical study involving adaptive cruise control with stop functionality, we show that minor data modifications, indistinguishable from sensor noise, can cause significant degradation in control behavior. These findings highlight the need for robust security mechanisms in data-driven control implementation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">cyberattack</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">data-driven control</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cruise control</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">FRIT</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">poisoning attack</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Ileus Tube-Related Intussusception: A Case Report and Review of 80 Previously Reported Cases</ArticleTitle>
    <FirstPage LZero="delete">469</FirstPage>
    <LastPage>474</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Teruyuki</FirstName>
        <LastName>Tsujii</LastName>
        <Affiliation>Department of Surgery, Matsuda Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuo</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Department of Surgery, Matsuda Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuji</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Surgery, Matsuda Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoichi</FirstName>
        <LastName>Katsube</LastName>
        <Affiliation>Department of Surgery, Matsuda Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hironori</FirstName>
        <LastName>Iwadou</LastName>
        <Affiliation>Department of Surgery, Matsuda Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sadami</FirstName>
        <LastName>Funabiki</LastName>
        <Affiliation>Department of Surgery, Matsuda Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuaki</FirstName>
        <LastName>Kamikawa</LastName>
        <Affiliation>Department of Surgery, Matsuda Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadakazu</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Department of Surgery, Matsuda Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69851</ArticleId>
    </ArticleIdList>
    <Abstract>We report a rare case of ileus tube-related intussusception in an adult. A 56-year-old man with adhesive bowel obstruction was treated with a nasointestinal ileus tube. Although his condition initially improved, persistent abdominal pain led to the diagnosis of intussusception via CT imaging. Manual repositioning of the tube resolved the intussusception without the need for bowel resection. A review of 80 previously reported cases of ileus tube-associated intussusception (total 81 cases, 95 lesions) highlighted the timing of onset, treatment strategies, and precautions. Early detection and diagnosis are crucial to prevent severe complications and preserve bowel function.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">nasointestinal ileus tube</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">intussusception</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">small bowel obstruction</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">enterectomy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">conservative treatment</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>MRI Images of a Case of Adenocarcinoma, Human Papillomavirus-Independent, Mesonephric Type, of the Uterine Cervix</ArticleTitle>
    <FirstPage LZero="delete">463</FirstPage>
    <LastPage>468</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yudai</FirstName>
        <LastName>Asano</LastName>
        <Affiliation>Department of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chika</FirstName>
        <LastName>Nishihara</LastName>
        <Affiliation>Department of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Kitayama</LastName>
        <Affiliation>Department of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nanako</FirstName>
        <LastName>Okawa</LastName>
        <Affiliation>Department of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoko</FirstName>
        <LastName>Makimoto</LastName>
        <Affiliation>Department of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumiyo</FirstName>
        <LastName>Higaki</LastName>
        <Affiliation>Department of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuhide</FirstName>
        <LastName>Kojima</LastName>
        <Affiliation>Department of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hanako</FirstName>
        <LastName>Sugihara</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoyuki</FirstName>
        <LastName>Ida</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Yanai</LastName>
        <Affiliation>Department of Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Hiraki</LastName>
        <Affiliation>Department of Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69850</ArticleId>
    </ArticleIdList>
    <Abstract>We present a case of a woman in her 70s who was diagnosed with mesonephric adenocarcinoma of the uterine cervix, following biopsy and surgery. Preoperative MRI revealed a 7-cm, well-defined circumferential cervical mass with left lateral wall predominance, bulging into the uterine cavity and vagina. The lesion showed intermediate signal intensity on T2-weighted images, diffusion restriction, and early contrast enhancement weaker than that of the myometrium, followed by washout on contrast-enhanced imaging. The circumferential growth pattern with the lateral wall predominance and its imaging characteristics may suggest this rare entity be routinely included in the differential diagnosis of cervical cancers.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">mesonephric adenocarcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cervical cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">MRI imaging characteristics</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">HPV-independent adenocarcinoma</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Exacerbation of Proteinuria in a Patient with Behçet’s Disease and IgA Nephropathy Following Colchicine Discontinuation</ArticleTitle>
    <FirstPage LZero="delete">457</FirstPage>
    <LastPage>461</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tomohiko</FirstName>
        <LastName>Asakawa</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruhito A.</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshimasa</FirstName>
        <LastName>Sakurabu</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Onishi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Natsumi</FirstName>
        <LastName>Matsuoka-Uchiyama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidemi</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoko</FirstName>
        <LastName>Umebayashi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rika</FirstName>
        <LastName>Takemoto</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69849</ArticleId>
    </ArticleIdList>
    <Abstract>This case involves a 23-year-old male who was diagnosed with Behçet’s disease 5 years ago and managed with colchicine. Two months ago, he underwent renal biopsy due to abnormal urinalysis and kidney dysfunction, leading to a diagnosis of IgA nephropathy. He subsequently underwent tonsillectomy followed by glucocorticoid pulse therapy. However, after the tonsillectomy, discontinuing colchicine led to increased proteinuria, despite the glucocorticoid pulse therapy. Upon reintroducing colchicine, urinary protein excretion decreased, achieving incomplete remission. These findings suggest that colchicine may be effective in decreasing proteinuria in patients with Behçet’s disease complicated by IgA nephropathy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Behçet’s disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">IgA nephropathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">colchicine</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Recurrence of FVIII Inhibitor during Surgery in a Patient with Severe Hemophilia A Receiving Emicizumab Prophylaxis</ArticleTitle>
    <FirstPage LZero="delete">451</FirstPage>
    <LastPage>455</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Moe</FirstName>
        <LastName>Hagihara</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Seike</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Hayashino</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Yasuhara</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kyohei</FirstName>
        <LastName>Kin</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichi</FirstName>
        <LastName>Hirata</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wataru</FirstName>
        <LastName>Kitamura</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideaki</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noboru</FirstName>
        <LastName>Asada</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuharu</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Division of Transfusion and Cell Therapy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69848</ArticleId>
    </ArticleIdList>
    <Abstract>Emicizumab, a bispecific monoclonal antibody, benefits patients with severe hemophilia A. It alters laboratory assessments of coagulation activity, requiring anti-idiotype monoclonal antibodies for accurate monitoring. A 64-year-old man, receiving emicizumab regularly, was admitted for laminoplasty. We planned to use FVIII replacement during the perioperative period after confirming the disappearance of inhibitors, monitoring coagulation activity with anti-idiotype monoclonal antibodies. Activated partial thromboplastin time was prolonged on postoperative day 2, prompting an immediate switch to eptacog alfa. The patient recovered without bleeding. This case underscores the necessity of anti-idiotype monoclonal antibodies for accurate monitoring.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">emicizumab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">eptacog alfa</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hemophilia A</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">inhibitor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">anti-idiotype monoclonal antibodies to emicizumab</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Perioperative Team Management Was Beneficially Associated with Prolonged Postoperative Hospital Stays after Long Lower-Abdominal Surgeries</ArticleTitle>
    <FirstPage LZero="delete">445</FirstPage>
    <LastPage>449</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Junya</FirstName>
        <LastName>Matsumi</LastName>
        <Affiliation>Department of Anesthesiology and Intensive Care Medicine, National Cancer Center Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69847</ArticleId>
    </ArticleIdList>
    <Abstract>Our hospital began a PERIO program (perioperative patient management by a multi-disciplinary team from multiple departments) in 2016 to improve patient outcomes. We retrospectively analyzed the clinical effects of the PERIO program regarding the postoperative hospital stay (PHS) in the patients aged ≥ 18 years who underwent long lower-abdominal surgery at our hospital during the period April 2019 to March 2023. We excluded the cases of patients whose general anesthesia use was &lt; 8 h, those for whom another surgery was performed simultaneously at another site, and emergency surgeries. The outcome was prolonged PHS, defined as exceeding the scheduled number of days specified in the patient’s clinical pathway. Among the 480 patients, prolonged PHS was observed for 270 patients (56.3%). In a multivariate logistic regression using advanced age, sex, high-risk general state, surgery requiring colon resection, serious adverse events (SAEs), and PERIO use, the following were associated with prolonged PHS: advance age (odds ratio [OR] 4.91, 95% confidence interval [CI]: 2.68-8.99, p=0.01), surgery requiring colon resection (OR 4.91, 95%CI: 2.68-8.99, p&lt;0.001), SAE (OR 18.7, 95%CI: 7.22-48.2, p&lt;0.001), and PERIO (OR 0.25, 95%CI: 0.13-0.47, p&lt;0.001). The use of the PERIO program was thus beneficially associated with PHS after long lower-abdominal surgery.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">hospital stay</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ERAS</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">perioperative management</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Association of Weekend Admission and In-Hospital Mortality in Adult Patients with Acute Myeloid Leukemia in Japan</ArticleTitle>
    <FirstPage LZero="delete">431</FirstPage>
    <LastPage>436</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Healthcare Management Research Center, Chiba University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyo</FirstName>
        <LastName>Kuwabara</LastName>
        <Affiliation>Healthcare Management Research Center, Chiba University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koh</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Hematology, Yokohama City Minato Red Cross Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69845</ArticleId>
    </ArticleIdList>
    <Abstract>The effect of weekend admission on patient mortality has been investigated in several therapeutic areas, including acute myeloid leukemia (AML), but the investigations’ results are controversial. We evaluated the relationship between in-hospital mortality and weekend admission in adult patients with AML in Japan by conducting a retrospective observational study using administrative data from 144 acute care hospitals from which patients were discharged between April 2014 and March 2019. The primary endpoint was in-hospital mortality, compared between weekend and weekday admissions. Among the 1,340 eligible patients, 11% (150) were admitted during a weekend. The in-hospital mortality rates of the patients admitted during weekends and those admitted on a weekday were 28% (42/150) and 17% (204/1190), respectively. After an adjustment for covariates, weekend admission was associated with a significantly higher risk of in-hospital mortality than weekday admission (HR 1.70, 95%CI: 1.20-2.40; p=0.003). However, such an association was not observed in patients treated in a bio-clean room (HR 1.26, 95%CI: 0.65-2.42). Our results demonstrate that for patients with AML, weekend admission was independently associated with a higher risk of death during hospitalization. An appropriate system is necessary for these patients.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">acute leukemia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">weekend admission</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">in-hospital mortality</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bio-clean room</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effects of Thoron Inhalation and Cyclosporin A Treatment on Dextran Sulfate Sodium-Induced Oxidative Damage in Mice</ArticleTitle>
    <FirstPage LZero="delete">421</FirstPage>
    <LastPage>429</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ayumi</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Graduate School of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>Naoe</LastName>
        <Affiliation>Graduate School of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Reiju</FirstName>
        <LastName>Takenaka</LastName>
        <Affiliation>Graduate School of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norie</FirstName>
        <LastName>Kanzaki</LastName>
        <Affiliation>Ningyo-toge Environmental Engineering Center, Japan Atomic Energy Agency</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Sakoda</LastName>
        <Affiliation>Ningyo-toge Environmental Engineering Center, Japan Atomic Energy Agency</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyonori</FirstName>
        <LastName>Yamaoka</LastName>
        <Affiliation>Faculty of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Kataoka</LastName>
        <Affiliation>Faculty of Health Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69844</ArticleId>
    </ArticleIdList>
    <Abstract>Radon (222Rn; Rn) and thoron (220Rn; Tn) inhalation have been reported to enhance antioxidant activity in various organs. However, the effects of Tn on the colon have not been investigated. This study aimed to clarify the effects of Tn inhalation, alone and in combination with cyclosporin A (CsA), on dextran sulfate sodium (DSS)-induced colitis, and the accompanying oxidative stress, in mice. Male BALB/c mice were subjected to continuous 8-day Tn inhalation (c-Tn, 533±128 Bq/m3) or alternate-day Tn inhalation over the same period (f-Tn, 577±63Bq/m3), followed by treatment with 3% DSS and either CsA or vehicle for 7 days. Although the disease activity index (DAI) decreased significantly by day 2 in the c-Tn group, scores remained significantly higher than those in the f-Tn group. In the c-Tn group, superoxide dismutase and catalase activity in the colon were significantly elevated compared with those in sham controls. Thus, DSS-induced damage was effectively inhibited in the earlier stages by the c-Tn mode of inhalation than by the f-Tn mode. These findings suggest that continuous Tn inhalation more effectively attenuated early colitis symptoms than alternate-day inhalation, potentially through upregulation of antioxidant defenses. Tn and CsA showed no combined effects.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">thoron</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">DSS</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">antioxidant activity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CsA</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">colon</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>COVID-19 and the Risks of Migraine and Headache: A Mendelian Randomization Study</ArticleTitle>
    <FirstPage LZero="delete">413</FirstPage>
    <LastPage>419</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Zhiyun</FirstName>
        <LastName>Jiang</LastName>
        <Affiliation>Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ying</FirstName>
        <LastName>Xi</LastName>
        <Affiliation>Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69843</ArticleId>
    </ArticleIdList>
    <Abstract>Several observational studies suggested that migraine headache attacks were associated with coronavirus disease 2019 (COVID-19). We investigated genetic causal links between COVID-19 phenotypes and the development of headache and migraine, including migraine with aura (MA) and migraine without aura (MO). We conducted a two-sample Mendelian randomization (MR) analysis to estimate the genetic association in European populations. The inverse-variance weighted (IVW) method was used as the main approach in the MR analyses, together with weighted median and MR-Egger methods. We also performed a series of sensitivity tests to assess the robustness of the MR results. The MR results demonstrated that COVID-19 severity, hospitalization, and susceptibility had no causal effect on the risks of headache, migraine, MA, or MO. No horizontal pleiotropy was detected, and the results were robust as supported by the sensitivity analysis findings. Our analyses identified no casual effect of COVID-19 severity, hospitalization, or susceptibility on the risks of headache or migraine in European populations.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">headache</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">migraine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Mendelian randomization</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">COVID-19</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration in Patients Aged 85 or Older</ArticleTitle>
    <FirstPage LZero="delete">405</FirstPage>
    <LastPage>412</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Chihiro</FirstName>
        <LastName>Ouchi</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mio</FirstName>
        <LastName>Morizane Hosokawa</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuhei</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Shiode</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Matoba</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuro</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Morizane</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69842</ArticleId>
    </ArticleIdList>
    <Abstract>We investigated the treatment outcomes of patients aged ≥85 years with neovascular age-related macular degeneration (nAMD) who received anti-vascular endothelial growth factor (anti-VEGF) therapy using either treat-and-extend (TAE) or pro re nata (PRN) regimens for 1 year in real-world clinical practice. Eighty-five eyes from 85 patients were included. Among them, types 1, 2, and 3 macular neovascularization and polypoidal choroidal vasculopathy were present in 27.1%, 17.6%, 18.8%, and 36.5%, respectively. TAE and PRN regimens were used in 43.5% and 56.5% of patients, respectively. At baseline, the PRN group was older and had worse best-corrected visual acuity (BCVA), greater central retinal thickness, and more intraretinal fluid than the TAE group. In the TAE group, the mean number of injections was 7.6, BCVA improved significantly, and all retinal fluid rates decreased. In the PRN group, the mean number of injections was 3.9, BCVA remained unchanged, and the rates of macular fibrosis and atrophy increased. No serious adverse events were observed in either group. Anti-VEGF therapy was safe for patients aged ≥ 85 years with nAMD, and the TAE regimen effectively improved BCVA in this population. BCVA remained unchanged in the PRN-treated patients, with baseline disease severity and/or undertreatment potentially influencing the outcomes.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">anti-vascular endothelial growth factor therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">neovascular age-related macular degeneration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">age</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">treat-and-extend</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pro re nata</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Frontiers Media SA</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1662-453X</Issn>
      <Volume>19</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effects of visual spatial frequency on audiovisual interaction: an event-related potential study</ArticleTitle>
    <FirstPage LZero="delete">1599114</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Fengxia</FirstName>
        <LastName>Wu</LastName>
        <Affiliation>School of Artificial Intelligence, Changchun University of Science and Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yanna</FirstName>
        <LastName>Ren</LastName>
        <Affiliation>Department of Psychology, College of Humanities and Management, Guizhou University of Traditional Chinese Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tengfei</FirstName>
        <LastName>Hao</LastName>
        <Affiliation>School of Artificial Intelligence, Changchun University of Science and Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jingjing</FirstName>
        <LastName>Yang</LastName>
        <Affiliation>School of Artificial Intelligence, Changchun University of Science and Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Qiong</FirstName>
        <LastName>Wu</LastName>
        <Affiliation>Department of Psychology, Suzhou University of Science and Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jiajia</FirstName>
        <LastName>Yang</LastName>
        <Affiliation>Cognitive Neuroscience Laboratory, Graduate School of Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Meng</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>School of Artificial Intelligence, Changchun University of Science and Technology</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Spatial frequency is a fundamental characteristic of visual signals that modulates the audiovisual integration behavior, but the neural mechanisms underlying spatial frequency are not well established. In the present study, the high temporal resolution of event-related potentials was used to investigate how visual spatial frequency modulates audiovisual integration. A visual orientation discrimination task was used, and the spatial frequency of visual stimuli was manipulated under three conditions. Results showed that the influence of visual spatial frequency on audiovisual integration is a dynamic process. The earliest audiovisual integration occurred over the left temporal-occipital regions in the early sensory stage (60–90 ms) for high spatial frequency conditions but was absent for low and middle spatial frequency conditions. In addition, audiovisual integration over fronto-central regions was delayed as spatial frequency increased (from 230–260 ms to 260–320 ms). The integration effect was also observed over parietal and occipital regions at 350–380 ms, and its strength gradually decreased at higher spatial frequencies. These discrepancies in the temporal and spatial distributions of audiovisual integration imply that the role of spatial frequency varies between early sensory and late cognitive stages. The findings of this study offer the first neural demonstration that spatial frequency modulates audiovisual integration, thus providing a basis for studying complex multisensory integration, especially in semantic and emotional domains.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">spatial frequency</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">visual orientation discrimination</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">audiovisual integration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">early sensory stage</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">late cognitive stage</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">event-related potentials</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1341-9625</Issn>
      <Volume>30</Volume>
      <Issue>8</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Phase-Ib dose-finding and pharmacokinetic trial of metformin combined with nivolumab for refractory/recurrent solid tumors</ArticleTitle>
    <FirstPage LZero="delete">1537</FirstPage>
    <LastPage>1544</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshio</FirstName>
        <LastName>Kubo</LastName>
        <Affiliation>Department of Allergy and Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hironari</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Gastroenterology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeru</FirstName>
        <LastName>Horiguchi</LastName>
        <Affiliation>Department of Gastroenterology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Kozuki</LastName>
        <Affiliation>Department of Thoracic Oncology and Medicine, NHO Shikoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akinori</FirstName>
        <LastName>Asagi</LastName>
        <Affiliation>Department of Gastrointestinal Medical Oncology, NHO Shikoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michihiro</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Heiichiro</FirstName>
        <LastName>Udono</LastName>
        <Affiliation>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Kiura</LastName>
        <Affiliation>Department of Allergy and Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Hotta</LastName>
        <Affiliation>Department of Allergy and Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Our previous findings showed that the addition of metformin to nivolumab resulted in remarkable tumor regression and increased the number of tumor-infiltrating T cells in mouse models. Therefore, we conducted a phase Ib study using combination therapy with nivolumab and metformin in patients with refractory/recurrent solid tumors.&lt;br&gt;
Methods This study consisted of two parts: 1, evaluating the maximum tolerated dose (MTD), safety, pharmacokinetics in solid tumors, and 2, principally investigating the safety at the recommended dose limited to thoracic and pancreatic cancers. Metformin and nivolumab were administered orally at doses of 750–2,250 mg/day and biweekly at a fixed intravenous dose of 3 mg/kg, respectively. Dose-limiting toxicity was evaluated within the first 4 weeks. Both metformin and nivolumab were continued until disease progression or discontinued because of toxicity.&lt;br&gt;
Results In total, 17 and 24 patients were enrolled in parts 1 and 2, respectively. One patient experienced increased pancreatic enzyme levels (grade 4) and lactic acidosis (grade 3). No Grade 5 adverse events were observed. MTD was not reached up to 2,250 mg/day of metformin, 2,250 mg/day was selected for part 2. An objective response was observed in 4 of 41 patients. One-year progression-free and overall survival rates were 9.8% and 56.8%, respectively. Two patients remained alive without disease progression for more than three years.&lt;br&gt;
Conclusions Nivolumab and metformin combination therapy was well-tolerated and showed preliminary signals of efficacy in a subset of patients. Further verification of the underlying mechanism in cases where treatment is effective is required.&lt;br&gt;
Trial registration numbers UMIN registration number 000028405 https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031915.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Pancreatic cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Thoracic tumors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Phase Ib</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Anti-PD-1 antibody</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nivolumab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Metformin</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1433-7851</Issn>
      <Volume>64</Volume>
      <Issue>13</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Conduction Band and Defect Engineering for the Prominent Visible‐Light Responsive Photocatalysts</ArticleTitle>
    <FirstPage LZero="delete">e202419624</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Yamakata</LastName>
        <Affiliation>Graduate School of Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosaku</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Graduate School of Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Ogawa</LastName>
        <Affiliation>Nanostructures Research Laboratory, Japan Fine Ceramics Center </Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kanta</FirstName>
        <LastName>Ogawa</LastName>
        <Affiliation>Department of Energy and Hydrocarbon Chemistry Graduate School of Engineering, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Ogawa</LastName>
        <Affiliation>Department of Energy and Hydrocarbon Chemistry Graduate School of Engineering, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daichi</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Energy and Hydrocarbon Chemistry Graduate School of Engineering, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chengchao</FirstName>
        <LastName>Zhong</LastName>
        <Affiliation>Department of Energy and Hydrocarbon Chemistry Graduate School of Engineering, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihide</FirstName>
        <LastName>Kuwabara</LastName>
        <Affiliation>Nanostructures Research Laboratory, Japan Fine Ceramics Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryu</FirstName>
        <LastName>Abe</LastName>
        <Affiliation>Department of Energy and Hydrocarbon Chemistry Graduate School of Engineering, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Kageyama</LastName>
        <Affiliation>Department of Energy and Hydrocarbon Chemistry Graduate School of Engineering, Kyoto University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Controlling trap depth is crucial to improve photocatalytic activity, but designing such crystal structures has been challenging. In this study, we discovered that in 2D materials like BiOCl and Bi4NbO8Cl, composed of interleaved [Bi2O2]2+ and Cl- slabs, the trap depth can be controlled by manipulating the slab stacking structure. In BiOCl, oxygen vacancies (VO) create deep electron traps, while chlorine vacancies (VCl) produce shallow traps. The depth is determined by the coordination around anion vacancies: VO forms strong σ bonds with Bi-6p dangling bonds below the conduction band minimum (CBM), while those around Cl are parallel, forming weak π-bonding. The strong re-hybridization makes the trap depth deeper. In Bi4NbO8Cl, VCl also creates shallow traps, but VO does not produce deep traps although Bi-6p orbitals are also forming strong σ bonding. This difference is attributed to the difference of the energy level of CBM. In both cases, the CBM consists of Bi-6p orbitals extending into the Cl layers. However, these orbitals are isolated in BiOCl, but those in Bi4NbO8Cl are bonded with each other between neighboring [Bi2O2]2+ layers. This unique bonding-based CBM prevents the formation of deep electron traps, and significantly enhances H2 evolution activity by prolonging the lifetime of highly reactive free electrons.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">photocatalysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">defects</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">charge trapping</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">recombination</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">time-resolved spectroscopy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1479-5876</Issn>
      <Volume>23</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Tumor marker–guided precision BNCT for CA19-9–positive cancers: a new paradigm in molecularly targeted chemoradiation therapy</ArticleTitle>
    <FirstPage LZero="delete">1387</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Noriyuki</FirstName>
        <LastName>Kanehira</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fuminori</FirstName>
        <LastName>Teraishi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyuki</FirstName>
        <LastName>Tajima</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsunori</FirstName>
        <LastName>Osone</LastName>
        <Affiliation>Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyoshi</FirstName>
        <LastName>Gotoh</LastName>
        <Affiliation>Department of Medical Laboratory Science, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Fujimoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Sakurai</LastName>
        <Affiliation>Institute for Integrated Radiation and Nuclear Science, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Natsuko</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Institute for Integrated Radiation and Nuclear Science, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Narikazu</FirstName>
        <LastName>Nagahisa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaoru</FirstName>
        <LastName>Kamei</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taiga</FirstName>
        <LastName>Fujita</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Morihara</LastName>
        <Affiliation>Graduate School of Environmental, Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yutaka</FirstName>
        <LastName>Takaguchi</LastName>
        <Affiliation>Faculty of Sustainable Design, Department of Material Design and Engineering, University of Toyama</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mizuki</FirstName>
        <LastName>Kitamatsu</LastName>
        <Affiliation>Department of Applied Chemistry, Kindai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Takarada</LastName>
        <Affiliation>Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunitoshi</FirstName>
        <LastName>Shigeyasu</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Minoru</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Institute for Integrated Radiation and Nuclear Science, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Michiue</LastName>
        <Affiliation>Neutron Therapy Research Center, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Boron neutron capture therapy (BNCT) is a molecularly targeted chemoradiation modality that relies on boron delivery agents such as p-borophenylalanine (BPA), which require LAT1 (L-type amino acid transporter 1) for tumor uptake. However, the limited efficacy of BPA in LAT1-low tumors restricts its therapeutic scope. To address this limitation, we developed a tumor marker–guided BNCT strategy targeting cancers overexpressing the clinically validated glycan biomarker CA19-9.&lt;br&gt;
Methods: We conducted transcriptomic analyses using The Cancer Genome Atlas (TCGA) datasets to identify LAT1-low cancers with high CA19-9 expression. These analyses revealed elevated expression of fucosyltransferase 3 (FUT3), which underlies CA19-9 biosynthesis, in pancreatic, biliary, and ovarian malignancies. Based on this, we synthesized a novel boron compound, fucose-BSH, designed to selectively accumulate in CA19-9–positive tumors. We evaluated its physicochemical properties, pharmacokinetics, biodistribution, and antitumor efficacy in cell lines and xenograft models, comparing its performance to that of BPA.&lt;br&gt;
Results: Fucose-BSH demonstrated significantly greater boron uptake in CA19-9–positive cell lines (AsPC-1, Panc 04.03, HuCCT-1, HSKTC, OVISE) compared to CA19-9–negative PANC-1. In HuCCT-1 xenografts, boron accumulation reached 36.2 ppm with a tumor/normal tissue ratio of 2.1, outperforming BPA. Upon neutron irradiation, fucose-BSH–mediated BNCT achieved &gt; 80% tumor growth inhibition. Notably, fucose-BSH retained therapeutic efficacy in LAT1-deficient models where BPA was ineffective, confirming LAT1-independent targeting.&lt;br&gt;
Conclusions: This study establishes a novel precision BNCT approach by leveraging CA19-9 as a tumor-selective glycan marker for boron delivery. Fucose-BSH offers a promising platform for expanding BNCT to previously inaccessible LAT1-low malignancies, including pancreatic, biliary, and ovarian cancers. These findings provide a clinically actionable strategy for tumor marker–driven chemoradiation and lay the foundation for translational application in BNCT. This strategy has the potential to support companion diagnostic development and precision stratification in ongoing and future BNCT clinical trials.&lt;br&gt;
Translational Relevance: Malignancies with elevated CA19-9 expression, such as pancreatic, biliary, and ovarian cancers, are associated with poor prognosis and limited response to current therapies. This study presents a tumor marker–guided strategy for boron neutron capture therapy (BNCT) by leveraging CA19-9 glycan biology to enable selective tumor targeting via fucose-BSH, a novel boron compound. Through transcriptomic data mining and preclinical validation, fucose-BSH demonstrated LAT1-independent boron delivery, potent BNCT-mediated cytotoxicity, and tumor-specific accumulation in CA19-9–positive models. These findings support a precision chemoradiation approach that addresses a critical gap in BNCT applicability, offering a clinically actionable pathway for patient stratification and therapeutic development in CA19-9–expressing cancers.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Boron neutron capture therapy (BNCT)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Precision BNCT</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Fucose-conjugated medicine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CA19-9</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Drug discovery</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2304-6767</Issn>
      <Volume>13</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effects of miR-128-3p on Renal Inflammation in a Rat Periodontitis Model</ArticleTitle>
    <FirstPage LZero="delete">577</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Mohammad</FirstName>
        <LastName>Nurhamim</LastName>
        <Affiliation>Department of Preventive Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yixuan</FirstName>
        <LastName>Zhang</LastName>
        <Affiliation>Department of Preventive Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Momoko</FirstName>
        <LastName>Nakahara</LastName>
        <Affiliation>Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daiki</FirstName>
        <LastName>Fukuhara</LastName>
        <Affiliation>Department of Preventive Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosei</FirstName>
        <LastName>Nagashima</LastName>
        <Affiliation>Department of Preventive Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Maruyama</LastName>
        <Affiliation>Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manabu</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of Oral Health, Takarazuka University of Medical and Health Care</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ekuni</LastName>
        <Affiliation>Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives: The study aim was to investigate the effects of extracellular vesicles (EVs) derived miR-128-3p on renal inflammation using a rat periodontitis model. Methods: Ten-week-old male Wistar rats were divided into two groups: a control (n = 8) and a lipopolysaccharides (LPS) group (n = 8). The LPS group received LPS (Porphyromonas gingivalis) injection in the gingiva for 7 days. At the end of the experiment, plasma, gingival tissue, and kidney samples were collected. Hematoxylin and eosin staining was performed to evaluate the glomerular tissue injury score. Bioinformatic analysis was conducted to identify potential target genes of miR-128-3p. The reverse transcription-quantitative polymerase chain reaction was performed to evaluate miR-128-3p, inflammatory, pro-inflammatory cytokine, chemokine and predicting gene’s expression. The control and LPS groups were compared using Welch’s t-test. p-values &lt; 0.05 were considered to indicate statistical significance. Results: The kidney glomerular tissue injury score was significantly higher in the LPS than in the control group. miR-128-3p expression in the LPS group was significantly higher in the gingival tissue and plasma. mRNAs (interleukin [IL]-1β, tumor necrosis factor [TNF]-α, C-X3-C motif chemokine ligand 1 [CX3CL1], and C-X-C motif chemokine ligand 7 [CXCL7]) expression was higher in the kidney of the LPS group. The potential target genes of activin A receptor type I (Acvr1), ribosomal protein S6 kinase B1 (Rps6kb1), and transforming growth factor beta receptor type 1 (Tgfbr1) were significantly lower in the kidneys of the LPS group. Conclusions: EVs-derived miR-128-3p in LPS induced periodontitis may cause kidney inflammation which may be mediated by, Rps6kb1, Tgfbr1, and Acvr1.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">extracellular vesicles</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">miR-128-3p</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mRNA</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">inflammation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">periodontitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">renal inflammation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lipopolysaccharide</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2692-4609</Issn>
      <Volume>6</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Japanese Multi‐Institution Study of Success Rates of Wire‐Guided Biliary Cannulation During Endoscopic Retrograde Cholangiopancreatography in Relation to Guidewire tip Length (JMIT Study) (With Video)</ArticleTitle>
    <FirstPage LZero="delete">e70144</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Ogura</LastName>
        <Affiliation>Endoscopy Center, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Tanisaka</LastName>
        <Affiliation>Gastroenterology, Saitama Medical University International Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanari</FirstName>
        <LastName>Sekine</LastName>
        <Affiliation>Department of Gastroenterology Jichi Medical University, Saitama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsumasa</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Department of Gastroenterology, Tokyo Metropolitan Bokutoh Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirotsugu</FirstName>
        <LastName>Maruyama</LastName>
        <Affiliation>Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Hirai</LastName>
        <Affiliation>Department of Medicine, Division of Gastroenterology, Kurume University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideyuki</FirstName>
        <LastName>Shiomi</LastName>
        <Affiliation>Department of Gastroenterology, Division of Hepatobiliary and Pancreatic Diseases, Hyogo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Minoru</FirstName>
        <LastName>Shigekawa</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Kuwatani</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Hokkaido University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Ikezawa</LastName>
        <Affiliation>Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Itonaga</LastName>
        <Affiliation>Second Department of Internal Medicine, Wakayama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mamoru</FirstName>
        <LastName>Takenaka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Faculty of Medicine, Kindai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Susumu</FirstName>
        <LastName>Hijioka</LastName>
        <Affiliation>Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsukasa</FirstName>
        <LastName>Ikeura</LastName>
        <Affiliation>Third Department of Internal Medicine, Kansai Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinpei</FirstName>
        <LastName>Doi</LastName>
        <Affiliation>Department of Gastroenterology, Teikyo University Mizonokuchi Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nao</FirstName>
        <LastName>Fujimori</LastName>
        <Affiliation>Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Koizumi</LastName>
        <Affiliation>Department of Gastroenterology, Medicine Center, Shonan Kamakura General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yousuke</FirstName>
        <LastName>Nakai</LastName>
        <Affiliation>Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadahisa</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Gastroenterology, Aichi Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuntaro</FirstName>
        <LastName>Mukai</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Tokyo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuki</FirstName>
        <LastName>Minami</LastName>
        <Affiliation>Department of Gastroenterology, Tenri Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichiro</FirstName>
        <LastName>Mandai</LastName>
        <Affiliation>Department of Gastroenterology, Kyoto Second Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsuhiro</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Department of Internal Medicine, Toyama Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuji</FirstName>
        <LastName>Iwashita</LastName>
        <Affiliation>First Department of Internal Medicine, Gifu University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Kawashima</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Itoi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Tokyo Medical University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective: Wire-guided cannulation (WGC) reportedly increases the successful biliary cannulation rate and reduces the risk of post-endoscopic retrograde cholangiopancreatography pancreatitis. Currently, various types of guidewires are available. However, the effect of the length of flexible-tip guidewires on the success rate of biliary cannulation under WGC and the rate of adverse events, especially post-endoscopic retrograde cholangiopancreatography pancreatitis, is unclear. The aim of this study was to compare the influence of long-tapered and short-tapered tips of a 0.025-inch guidewire on outcomes in primary selective biliary cannulation.&lt;br&gt;
Methods: Consecutive patients who underwent biliary access under endoscopic retrograde cholangiopancreatography guidance using WGC at 27 high-volume centers in Japan were enrolled in this prospective registration study. The primary outcome was the technical success rate of biliary cannulation. The secondary outcomes were the rates of adverse events, biliary cannulation time, and number of guidewire insertions into the pancreatic duct.&lt;br&gt;
Results: A total of 530 patients underwent biliary cannulation for biliary disease with native papilla between April 2021 and December 2023. The technical success rate of biliary cannulation was 86.1% (161/187) in the long-tip group and 84.3% (289/343) in the short-tip group, indicating no significant differences between the two groups. Although the frequency of post-endoscopic retrograde cholangiopancreatography was not significantly different, the successful biliary cannulation rate without guidewire mis-insertion into the main pancreatic duct was significantly higher in the long tip group (64.7%, 121/187) compared with the short tip group (54.2%, 186/343p = 0.02).&lt;br&gt;
Conclusions: In conclusion, WGC using long-tip guidewires might reduce the risk of guidewire insertion into the main pancreatic duct.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">ERCP</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">guidewire</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pancreatitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">post-ERCP pancreatitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">wire-guided cannulation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0915-5635</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>EUS-Guided Versus Percutaneous Transhepatic Drainage of Liver Abscesses: A Multicenter Endohepatology Study in Western Japan (EPIC-LA Study)</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Ogura</LastName>
        <Affiliation>Pancreatobiliary Advanced Medical Center, Osaka Medical and Pharmaceutical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taira</FirstName>
        <LastName>Kuroda</LastName>
        <Affiliation>Gastroenterology Center, Ehime Prefectural Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takanori</FirstName>
        <LastName>Matsuura</LastName>
        <Affiliation>Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Kitadai</LastName>
        <Affiliation>Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koh</FirstName>
        <LastName>Kitagawa</LastName>
        <Affiliation>Department of Gastroenterology, Nara Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Itonaga</LastName>
        <Affiliation>Second Department of Internal Medicine, Wakayama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kotaro</FirstName>
        <LastName>Takeshita</LastName>
        <Affiliation>Department of Gastroenterology, Tane General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Matsumori</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoya</FirstName>
        <LastName>Emori</LastName>
        <Affiliation>Department of Gastroenterology, Wakayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mamoru</FirstName>
        <LastName>Takenaka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine Graduate School of Medical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hajime</FirstName>
        <LastName>Imai</LastName>
        <Affiliation>Department of Gastroenterology, Okanami General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichiro</FirstName>
        <LastName>Mandai</LastName>
        <Affiliation>Department of Gastroenterology, Kyoto Second Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuhei</FirstName>
        <LastName>Shintani</LastName>
        <Affiliation>Department of Gastroenterology, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nao</FirstName>
        <LastName>Fujimori</LastName>
        <Affiliation>Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideyuki</FirstName>
        <LastName>Shiomi</LastName>
        <Affiliation>Division of Hepatobiliary and Pancreatic Diseases, Department of Gastroenterology, Hyogo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Asada</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Japanese Red Cross Osaka Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryota</FirstName>
        <LastName>Sagami</LastName>
        <Affiliation>Department of Gastroenterology, Faculty of Medicine, Oita University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirotsugu</FirstName>
        <LastName>Maruyama</LastName>
        <Affiliation>Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsukasa</FirstName>
        <LastName>Ikeura</LastName>
        <Affiliation>Division of Gastroenterology and Hepatology, Kansai Medical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaaki</FirstName>
        <LastName>Shimatani</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Kansai Medical University Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidefumi</FirstName>
        <LastName>Nishikiori</LastName>
        <Affiliation>Department of Gastroenterology, Oita San-ai Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Endoscopy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahito</FirstName>
        <LastName>Kokubu</LastName>
        <Affiliation>Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Kamada</LastName>
        <Affiliation>Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Ishida</LastName>
        <Affiliation>Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akitoshi</FirstName>
        <LastName>Hakoda</LastName>
        <Affiliation>2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayuki</FirstName>
        <LastName>Kitano</LastName>
        <Affiliation>Second Department of Internal Medicine, Wakayama Medical University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective: Percutaneous transhepatic liver abscess drainage (PTAD) and endoscopic ultrasound-guided liver abscess drainage (EUS-LAD) have several limitations. Recently, because of technical improvements in echoendoscope maneuvers, EUS-guided access for the right hepatic lobe has been reported. The aim of this multicenter, retrospective study was to compare clinical outcomes of PTAD and EUS-LAD including the right hepatic lobe in West Japan.&lt;br&gt;
Method: This retrospective, multicenter study included consecutive patients with liver abscesses between January 2019 and November 2024. The primary outcome in this study was the clinical success rate compared between EUS-LAD and PTAD.&lt;br&gt;
Results: During the study period, 1012 consecutive patients developed liver abscesses. Of them, 734 patients were excluded, 43 underwent EUS-LAD and 235 patients underwent PTAD. After propensity score-matched analysis, the clinical success rate was significantly higher in the EUS-LAD group (97.7%, 42/43) than in the PTAD group (79.1%, 34/43) (p = 0.007). After a propensity score-matched analysis, 25 patients were included in each group. The clinical success rate was significantly higher in the EUS-LAD group (100%, 25/25) than in the PTAD group (84%, 21/25) (p = 0.037). Adverse events were also significantly higher in the PTAD group (16%, 5/25) than in the EUS-LAD group (p = 0.025). In addition, the median length of hospital stay was significantly shorter in the EUS-LAD group (15 days) than in the PTAD group (22 days) (p = 0.005).&lt;br&gt;
Conclusions: EUS-LAD using a metal stent might be one of the options, but further randomized, controlled trials are needed.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">drainage</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">endoscopic ultrasound-guided liver abscess drainage</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">EUS</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">liver abscess</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">percutaneous transhepatic liver abscess drainage</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0944-1174</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryotaro</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Division of Gastroenterology, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Kikuta</LastName>
        <Affiliation>Division of Gastroenterology, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Takikawa</LastName>
        <Affiliation>Division of Gastroenterology, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yousuke</FirstName>
        <LastName>Nakai</LastName>
        <Affiliation>Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mamoru</FirstName>
        <LastName>Takenaka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Oki</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Kurashiki Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eizaburo</FirstName>
        <LastName>Ohno</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Fujita Health University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Division of Gastroenterology and Hepatology, Toho University Omori Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nao</FirstName>
        <LastName>Fujimori</LastName>
        <Affiliation>Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akio</FirstName>
        <LastName>Katanuma</LastName>
        <Affiliation>Center for Gastroenterology, Teine-Keijinkai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsuhiro</FirstName>
        <LastName>Masuda</LastName>
        <Affiliation>Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuki</FirstName>
        <LastName>Hori</LastName>
        <Affiliation>Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsukasa</FirstName>
        <LastName>Ikeura</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Kansai Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rei</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Gastroenterology, Fukushima Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Gastroenterology, Fujita Health University Bantane Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshio</FirstName>
        <LastName>Sogame</LastName>
        <Affiliation>Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Kawashima</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuhide</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Neuroendocrine Tumor Centre, Fukuoka Sanno Hospital, International University of Health and Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosuke</FirstName>
        <LastName>Okuwaki</LastName>
        <Affiliation>Department of Gastroenterology, Kitasato University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Itoi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Tokyo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukiko</FirstName>
        <LastName>Takayama</LastName>
        <Affiliation>Department of Internal Medicine, Institute of Gastroenterology, Tokyo Women’s Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuji</FirstName>
        <LastName>Terai</LastName>
        <Affiliation>Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Kuwatani</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Hokkaido University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Kishiwada</LastName>
        <Affiliation>Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Minoru</FirstName>
        <LastName>Shigekawa</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Matsumori</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Inatomi</LastName>
        <Affiliation>Department of Medicine, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Waku</FirstName>
        <LastName>Hatta</LastName>
        <Affiliation>Division of Gastroenterology, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Irisawa</LastName>
        <Affiliation>Department of Gastroenterology, Dokkyo Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michiaki</FirstName>
        <LastName>Unno</LastName>
        <Affiliation>Department of Surgery, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshifumi</FirstName>
        <LastName>Takeyama</LastName>
        <Affiliation>Department of Surgery, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Masamune</LastName>
        <Affiliation>Division of Gastroenterology, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>Japan Pancreatitis Study Group for Chronic Pancreatitis</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Objective: Since the 2010s, Japan’s national health insurance system has covered key management for chronic pancreatitis (CP), including pancreatic enzyme replacement therapy. These therapies are expected to improve long-term prognosis; however, recent data are lacking. This study aimed to clarify the updated cancer risk and mortality among patients with CP in Japan.&lt;br&gt;
Methods: We conducted a multicenter, retrospective cohort study on 1,110 patients with CP treated at 28 institutions in 2011. Standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs) were calculated for comorbidities. Factors associated with the development of malignancy and overall survival were analyzed.&lt;br&gt;
Results: Patients with CP had an elevated SIR of 1.62 (95% confidence interval [CI], 1.43–1.83) for malignancy, with the highest risk observed for pancreatic cancer (SIR = 6.44 [95% CI, 4.64–8.90]). During follow-up, 143 patients (12.9%) died, most frequently from malignancy (47.5%). The SMR was elevated in all patients with CP (SMR = 1.20 [95% CI, 1.01–1.42]) and in those with alcohol-related CP (SMR = 1.49 [95% CI, 1.23–1.81]) but not in those with alcohol-unrelated CP. Pancreatic cancer was identified as the strongest factor associated with overall survival (hazard ratio, 48.92 in multivariate analysis). Overall survival of the patients with pancreatic cancer was significantly longer in those who underwent regular examinations for CP at least every three months (P = 0.011).&lt;br&gt;
Conclusions: Patients with alcohol-related CP have higher mortality than the general population in Japan. Pancreatic cancer remains a crucial prognostic factor in patients with CP. Regular surveillance for pancreatic cancer is important to improve their prognosis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Alcohol</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Chronic pancreatitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pancreatic cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pancreatitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Smoking</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2073-4344</Issn>
      <Volume>14</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Photocatalytic Ammonia Decomposition Using Dye-Encapsulated Single-Walled Carbon Nanotubes</ArticleTitle>
    <FirstPage LZero="delete">715</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tomoyuki</FirstName>
        <LastName>Tajima</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kotone</FirstName>
        <LastName>Yano</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazushi</FirstName>
        <LastName>Mukai</LastName>
        <Affiliation>Department of Materials Design and Engineering, University of Toyama</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yutaka</FirstName>
        <LastName>Takaguchi</LastName>
        <Affiliation>Department of Materials Design and Engineering, University of Toyama</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The photocatalytic decomposition of ammonia to produce N2 and H2 was achieved using single-walled carbon nanotube (SWCNT) nanohybrids. The physical modification of ferrocene-dye-encapsulated CNTs by amphiphilic C60-dendron yielded nanohybrids with a dye/CNT/C60 coaxial heterojunction. Upon irradiation with visible light, an aqueous solution of NH3 and dye@CNT/C60-dendron nanohybrids produced both N2 and H2 in a stoichiometric ratio of 1/3. The action spectra of this reaction clearly demonstrated that the encapsulated dye acted as the photosensitizer, exhibiting an apparent quantum yield (AQY) of 0.22% at 510 nm (the λmax of the dye). This study reports the first example of dye-sensitized ammonia decomposition and provides a new avenue for developing efficient and sustainable photocatalytic hydrogen production systems.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">photocatalyst</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ammonia decomposition</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dye sensitization</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hydrogen evolution</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">carbon nanotube</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fullerene</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1078-8174</Issn>
      <Volume>32</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Optimization of the reconstruction kernel for temporal bone imaging using photon-counting detector CT: A combined physical and visual evaluation</ArticleTitle>
    <FirstPage LZero="delete">103274</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">S.</FirstName>
        <LastName>Nishii</LastName>
        <Affiliation>Graduate School of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Asahara</LastName>
        <Affiliation>Department of Radiological Technology, Faculty of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Y.</FirstName>
        <LastName>Morimitsu</LastName>
        <Affiliation>Division of Radiological Technology, Medical Support Department, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">S.</FirstName>
        <LastName>Kajisaki</LastName>
        <Affiliation>Division of Radiological Technology, Medical Support Department, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">N.</FirstName>
        <LastName>Akagi</LastName>
        <Affiliation>Division of Radiological Technology, Medical Support Department, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">M.</FirstName>
        <LastName>Honda</LastName>
        <Affiliation>Division of Radiological Technology, Medical Support Department, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">H.</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>College of Transdisciplinary Sciences for Innovation, Kanazawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">A.</FirstName>
        <LastName>Sugaya</LastName>
        <Affiliation>Department of Otolaryngology, Head &amp; Neck Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">K.</FirstName>
        <LastName>Munetomo</LastName>
        <Affiliation>Department of Radiology, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">F.</FirstName>
        <LastName>Higaki</LastName>
        <Affiliation>Department of Radiology, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Hiraki</LastName>
        <Affiliation>Department of Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Iguchi</LastName>
        <Affiliation>Department of Radiological Technology, Faculty of Health Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: Photon-counting detector CT (PCD-CT) offers superior spatial resolution and noise characteristics compared to conventional CT. However, optimal reconstruction parameters for temporal bone imaging, especially kernel selection, remain unclear. This study aimed to identify the optimal reconstruction kernel using both objective physical image quality metrics and subjective expert assessments.&lt;br&gt;
Methods: In phantom experiments, the system performance function (SPF) based on the task-based transfer function (TTF) and noise power spectrum (NPS) was calculated across 11 reconstruction kernels (Hr60–Hr98). Based on the results of the physical evaluation and clinical considerations from clinical practice, a subset of kernels was selected for visual assessment. For clinical images, two diagnostic radiologists evaluated three fine anatomical structures (i.e., stapes footplate, incudomalleolar joint, and cochlea) and overall image quality using both a ranking method and a 5-point Likert scale.&lt;br&gt;
Results: TTF analysis indicated that Hr96 had the highest spatial resolution, while Hr60 showed the lowest noise in the NPS. SPF analysis identified Hr72 as providing the optimal balance between resolution and noise. Visual assessment using four reconstruction kernels (Hr60, Hr72, Hr76, and Hr84) showed that Hr76 consistently received the highest preference for overall image quality and visualization of fine structures. Statistically significant differences were observed among the kernels, with Hr60 consistently rated the lowest (p &lt; 0.05).&lt;br&gt;
Conclusion: The kernel Hr76 was found suitable for middle and inner ear diagnoses using PCD-CT, providing a good balance between spatial resolution and image noise. This finding provides a foundation for standardized reconstruction protocols in high-resolution temporal bone imaging.&lt;br&gt;
Implications for practice: These findings support the use of Hr76 as a standard kernel for high-resolution temporal bone imaging and may contribute to protocol optimization in clinical PCD-CT practice.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Photon-counting CT</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Temporal bone imaging</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Reconstruction kernel</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Image quality</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>AME Publishing Company</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2790-8852</Issn>
      <Volume>3</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Airway management during sedation for dental treatment in people with intellectual disabilities: a review</ArticleTitle>
    <FirstPage LZero="delete">28</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Higuchi</LastName>
        <Affiliation>Department of Dental Anesthesiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukiko</FirstName>
        <LastName>Nishioka</LastName>
        <Affiliation>Department of Dental Anesthesiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Saki</FirstName>
        <LastName>Miyake</LastName>
        <Affiliation>Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Miyawaki</LastName>
        <Affiliation>Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The oral health of people with intellectual disabilities remains poor due to a complex combination of physical and social problems, and often requires invasive dental treatment. However, it can be difficult to obtain their cooperation for dental treatment because they may not fully understand the need for treatment or may experience high levels of anxiety due to lack of understanding and/or sensory aversions to stimuli present in the dental environment, and behavioral management is often necessary during such treatment. Sedation is a very useful patient management method for dental treatment for people with intellectual disabilities; however, the dental treatment-related sedation of people with intellectual disabilities has different characteristics to the dental treatment-related sedation of others or other procedure-related sedation. For example, deep sedation is required for behavioral management; drug interactions between the patient’s regular medications, such as antiepileptic and antipsychotic drugs, and anesthetics may make the depth of sedation deeper; and the prevalence rate of obesity is higher among people with intellectual disabilities. The fact that the patient is in the supine position with their mouth open also makes airway management during sedation for dental treatment more difficult. It is therefore imperative that airway management during dental treatment for people with intellectual disabilities be conducted with the utmost precision and vigilance. Various attempts have been made to improve airway management during such sedation, and new technologies, such as capnography, nasal high-flow systems, and acoustic respiration monitors, may help. The objective of this review is to enhance comprehension of the attributes of airway management in dental sedation for people with intellectual disabilities and to properly understand the usefulness of the techniques that have been attempted thus far to ensure safer and more secure airway management for this population. The ultimate goal is to provide them with safe and secure medical care and improve their health outcomes.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Dentistry</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">sedation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">airway management</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">people with intellectual disabilities</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2073-4344</Issn>
      <Volume>15</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Palladium-Catalyzed Decarbonylative Nucleophilic Halogenation of Acid Anhydrides</ArticleTitle>
    <FirstPage LZero="delete">191</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tian</FirstName>
        <LastName>Tian</LastName>
        <Affiliation>Graduate School of Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuhei</FirstName>
        <LastName>Uei</LastName>
        <Affiliation>Department of Chemistry, Faculty of Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Weidan</FirstName>
        <LastName>Yan</LastName>
        <Affiliation>Graduate School of Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Nishihara</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science (RIIS), Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>In this study, we developed a palladium-catalyzed decarbonylative nucleophilic halogenation reaction using inexpensive and readily available acid anhydrides as substrates. This approach effectively circumvents the instability of acyl chlorides and the low reactivity of acyl fluorides. The Pd/Xantphos catalyst system exhibited excellent compatibility with the thermodynamically and kinetically challenging reductive elimination of C–X bonds (X = I, Br, and Cl) from Pd(II) intermediates. Notably, for electron-donating substrates, adopting an open system significantly improved the reaction efficiency. The positive effect of the open system may be due to the reversible nature of CO insertion and deinsertion, which helps direct the reaction toward the desired pathway by allowing the generated CO to exit the reaction system. Mechanistic studies suggest that the reaction proceeds through a highly reactive acyl halide intermediate, followed by a unimolecular fragment coupling (UFC) pathway via decarbonylation or an alternative pathway involving the formation of an activated anionic palladate complex in the presence of lithium halide.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">reductive elimination of C–X bond</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">nucleophilic halogenation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">unimolecular fragment coupling (UFC)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">acid anhydrides</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">aryl halides</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1616-301X</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Biologically-Architected Wear and Damage-Resistant Nanoparticle Coating From the Radular Teeth of Cryptochiton stelleri</ArticleTitle>
    <FirstPage LZero="delete">e21664</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Taifeng</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Department of Materials Science and Engineering, University of California</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Chen</LastName>
        <Affiliation>Lyles School of Civil and Construction Engineering, Purdue University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ezra</FirstName>
        <LastName>Sarmiento</LastName>
        <Affiliation>Department of Materials Science and Engineering, University of California</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taige</FirstName>
        <LastName>Hao</LastName>
        <Affiliation>Materials and Manufacturing Technologies Program, University of California</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Arakaki</LastName>
        <Affiliation>Division of Biotechnology and Life Science, Institute of Engineering, Tokyo University of Agriculture and Technology </Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michiko</FirstName>
        <LastName>Nemoto</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Pablo</FirstName>
        <LastName>Zavattieri</LastName>
        <Affiliation>Lyles School of Civil and Construction Engineering, Purdue University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">David</FirstName>
        <LastName>Kisailus</LastName>
        <Affiliation>Department of Materials Science and Engineering, University of California</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Nature utilizes simple building blocks to construct mechanically robust materials that demonstrate superior performance under extreme conditions. These exquisite structures result from the controlled synthesis and hierarchical assembly of nanoscale organic and mineral components that have provided critical evolutionary advantages to ensure survival. One such example is the ultrahard radular teeth found in mollusks, which are used to scrape against rock to feed on algae. Here, it is reported that the leading edges of these teeth consist of a wear-resistant coating that is comprised of densely packed ≈65 nm magnetic nanoparticles integrated within an organic matrix of chitin and protein. These mesocrystalline magnetite-based structures are assembled from smaller, highly aligned nanocrystals with inter/intracrystalline organics introduced during the crystallization process. Nanomechanical testing reveals that this multi-scale, nano-architected coating has a combination of increased hardness and a slight decrease in modulus versus geologic magnetite provides the surface of the chiton tooth with superior abrasion resistance. The mesocrystalline structures fracture at primary domain interfaces, corroborated by computational models, providing significant toughening to the tooth under extreme contact stresses. The design features revealed provide insight for the design and fabrication of next-generation advanced wear- and impact-resistant coatings for tooling, machinery, wind turbines, armor, etc.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">biomineralization</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">coatings</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">damage tolerance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">magnetite</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mesocrystals</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Public Library of Science</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1932-6203</Issn>
      <Volume>20</Volume>
      <Issue>8</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Risk stratification for the prediction of skeletal-related events in patients with castration-resistant prostate cancer with bone metastases</ArticleTitle>
    <FirstPage LZero="delete">e0328792</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Hamada</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiji</FirstName>
        <LastName>Nakata</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuichi</FirstName>
        <LastName>Nakahara</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinsuke</FirstName>
        <LastName>Sugihara</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruyoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuto</FirstName>
        <LastName>Itano</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>Takihira</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiteru</FirstName>
        <LastName>Akezaki</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Skeletal-related events (SREs) are common in patients with bone metastases from castration-resistant prostate cancer (CRPC). Despite advances in prostate cancer treatment, clinically validated predictive models for SREs in CRPC patients with bone metastases remain elusive. This gap in prognostic tools hinders optimal patient management and treatment planning for this high-risk population. This study aimed to develop a prediction model for SRE by investigating potential risk factors and classifying them into different groups. This model can be used to identify patients at high risk of SREs who need close follow-up. Between 2004 and 2013, 68 male patients with bone metastases from CRPC who were treated at our institute were evaluated for survival without SREs and survival without SREs of the spinal cord. The study analyzed clinical data at enrollment to identify risk factors for initial and spinal SREs. Multivariate analysis revealed that a high count of metastatic vertebrae, along with visceral or lymph node metastases, were significant risk factors. Patients were categorized into four subgroups based on the number of vertebral metastases and presence of visceral or lymph node metastases: 1) extensive vertebral and both types of metastases, 2) extensive vertebral without additional metastases, 3) some vertebral with other metastases, 4) some vertebral without additional metastases. The first SRE and spinal SRE occurred significantly sooner in the first subgroup compared to others. Incidence rates at 12 months for the first SRE were 56%, 40%, 27%, and 5%, and for the first spinal SRE were 47%, 40%, 27%, and 0% respectively. Patients with extensive vertebral and additional metastases require vigilant monitoring to mitigate SREs.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Association of Use of GRADE, Protocol Registration, and Journal Impact Factor With Reporting and Methodological Quality of Systematic Reviews Published in Rehabilitation Journals: A Meta-Epidemiological Study</ArticleTitle>
    <FirstPage LZero="delete">e95695</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Tsuge</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norio</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Systematic Reviewers, Scientific Research WorkS Peer Support Group (SRWS-PSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Tomita</LastName>
        <Affiliation>Physical Therapy, Faculty of Health Care, Takasaki University of Health and Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akikazu</FirstName>
        <LastName>Hagiyama</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daijo</FirstName>
        <LastName>Shiratsuchi</LastName>
        <Affiliation>Physical Therapy, School of Health Sciences, Faculty of Medicine, Kagoshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masatsugu</FirstName>
        <LastName>Okamura</LastName>
        <Affiliation>Systematic Reviewers, Scientific Research WorkS Peer Support Group (SRWS-PSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Kaneko</LastName>
        <Affiliation>Rehabilitation, Yamagata Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosuke</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Rehabilitation, Yamagata Saisei Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Nakashima</LastName>
        <Affiliation>Systematic Reviewers, Scientific Research WorkS Peer Support Group (SRWS-PSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Taito</LastName>
        <Affiliation>Systematic Reviewers, Scientific Research WorkS Peer Support Group (SRWS-PSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yorifuji</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>This study aimed to identify factors associated with the reporting and methodological quality of systematic reviews (SRs) published in rehabilitation journals. We conducted a meta-epidemiological study as a secondary analysis of a previous study. The study protocol was registered in the Open Science Framework. We analyzed 219 SRs from rehabilitation journals published since 2020. We assessed reporting quality using the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) 2020 and methodological quality using A MeaSurement Tool to Assess systematic Reviews (AMSTAR) 2. Multiple linear regression and Spearman's correlation were used to identify factors associated with quality, including Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach and the Journal Impact Factor (JIF). Multivariate analysis revealed PRISMA 2020 adherence was significantly associated with use of GRADE (β = 4.33; 95% confidence interval (CI): 3.24-5.42), protocol registration (β = 3.40; 95% CI: 2.32-4.47), and the JIF (2023) (β = 0.69; 95% CI: 0.42-0.95). AMSTAR 2 adherence was also significantly associated with use of GRADE (β = 2.52; 95% CI: 1.88-3.17), protocol registration (β = 2.07; 95% CI: 1.44-2.70), and the JIF (2023) (β = 0.29; 95% CI: 0.14-0.45). Weak positive correlations were observed between the JIF (2023) and both PRISMA 2020 and AMSTAR 2 adherence (ρ = 0.27 and ρ = 0.22, respectively; both P &lt; 0.01). It should be noted that these findings reflect associations and do not imply causality. To enhance the quality of SRs in rehabilitation, researchers should prioritize adherence to PRISMA 2020, particularly the use of GRADE and protocol registration, which this study identified as key associated factors.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">citation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">grade</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">journal impact factor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">methodological and reporting quality</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">prisma</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Society for Microbiology</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2379-5042</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Analysis of the drug target of the anti-tuberculosis compound OCT313: phosphotransacetylase is a potential drug target for anti-mycobacterial agents</ArticleTitle>
    <FirstPage LZero="delete">e00463-25</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takemasa</FirstName>
        <LastName>Takii</LastName>
        <Affiliation>Department of Mycobacterium Reference and Research, the Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Hasegawa</LastName>
        <Affiliation>Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Saotomo</FirstName>
        <LastName>Itoh</LastName>
        <Affiliation>Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Graduate School of Pharmaceutical Sciences, Hokkaido University of Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Microbiology, Graduate School of Human Life and Ecology, Osaka Metropolitan University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Horita</LastName>
        <Affiliation>Department of Clinical Pharmaceutics, Graduate School of Medical Sciences, Nagoya City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihito</FirstName>
        <LastName>Nishiyama</LastName>
        <Affiliation>Department of Bacteriology, Niigata University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sohkichi</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Bacteriology, Niigata University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoya</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Oral Microbiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aoi</FirstName>
        <LastName>Kimishima</LastName>
        <Affiliation>Laboratory of Applied Microbial Chemistry, Ōmura Satoshi Memorial Institute, Kitasato University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukihiro</FirstName>
        <LastName>Asami</LastName>
        <Affiliation>Laboratory of Applied Microbial Chemistry, Ōmura Satoshi Memorial Institute, Kitasato University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeaki</FirstName>
        <LastName>Hida</LastName>
        <Affiliation>Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kikuo</FirstName>
        <LastName>Onozaki</LastName>
        <Affiliation>Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Tuberculosis (TB) is one of the most common infectious diseases caused by bacteria worldwide. The increasing prevalence of multidrug-resistant TB (MDR-TB) and latent TB infection (LTBI) has intensified the global TB burden. Therefore, the development of new drugs for MDR-TB and LTBI is urgently required. We have reported that the derivative of dithiocarbamate sugar derivative, 2-acetamido-2-deoxy-β-D-glucopyranosyl N,N-dimethyldithiocarbamate (OCT313), exhibits anti-mycobacterial activity against MDR-MTB. Here, we identified the target of OCT313. In experimentally generated OCT313-resistant bacteria, adenine at position 1,092 in the metabolic enzyme phosphotransacetylase (PTA) gene was replaced with cytosine. This mutation is a nonsynonymous mutation that converts methionine to leucine at position 365 in the PTA protein. OCT313 inhibited the enzymatic activity of recombinant wild-type PTA, but not of the mutant PTA (M365L). PTA is an enzyme that produces acetyl-coenzyme A (acetyl-CoA) from acetyl phosphate and CoA and is involved in metabolic pathways; therefore, it was expected to also be active against dormant Mycobacterium tuberculosis bacilli. OCT313 exhibits antibacterial activity in the Wayne model of dormancy using Mycobacterium bovis BCG, and overexpression of PTA in OCT313-resistant bacilli restored sensitivity to OCT313. Collectively, the target of OCT313 is PTA, and OCT313 is a promising antimicrobial candidate for MDR-TB and LTBI.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">phosphotransacetylase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">acetyl coenzyme A</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dithiocarbamate</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">N-acetyl glucosamine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">anti-mycobacterial agents</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">latent tuberculosis infection</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Long intervals between repetitive concussions reduce risk of cognitive impairment and limit microglial activation, astrogliosis, and tauopathy in adolescent rats</ArticleTitle>
    <FirstPage LZero="delete">40522</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuichi</FirstName>
        <LastName>Hirata</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kyohei</FirstName>
        <LastName>Kin</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Nagase</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Sasaki</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Susumu</FirstName>
        <LastName>Sasada</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chiaki</FirstName>
        <LastName>Sugahara</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Hirayama</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shun</FirstName>
        <LastName>Tanimoto</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hayato</FirstName>
        <LastName>Miyake</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoya</FirstName>
        <LastName>Saijo</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromichi</FirstName>
        <LastName>Naito</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaori</FirstName>
        <LastName>Masai</LastName>
        <Affiliation>Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Yasuhara</LastName>
        <Affiliation>Yasuhara Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Although previous studies have demonstrated the effects of concussions do not accumulate as the time interval between injuries increases, little is known about the relationship between this interval and the effects of repetitive concussions. The objective of this study is to explore the relationship between the time interval and changes in behavior and histology following repetitive concussions. Male adolescent rats received concussions by weight drop and were randomly assigned to one of five experimental groups, receiving concussions three times either daily, every other day, once per week, once every 2 weeks, or receiving sham procedures. Only rats that received daily concussions exhibited cognitive impairment, while the other groups did not. No groups showed motor or anxiety-like impairments. Histological analysis revealed accumulation of microglia, as well as astrogliosis, in the prefrontal cortex, corpus callosum, dentate gyrus, and cornu Ammonis 1 region of the hippocampus in rats subjected to daily concussions. Accumulation of phosphorylated tau was also observed in the prefrontal cortex and cornu Ammonis 1. Longer intervals between concussions may reduce the risk of cognitive impairment and limit microglial activation, astrogliosis, and phosphorylated tau accumulation. These findings may help guide decisions on the appropriate timing for return to play in humans.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Concussion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Return to play</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Sports-related head injury</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Microglia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Astrocyte</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tauopathy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1478-6362</Issn>
      <Volume>27</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Does perioperative discontinuation of anti-rheumatic drugs increase postoperative complications in orthopedic surgery for rheumatoid arthritis?</ArticleTitle>
    <FirstPage LZero="delete">219</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiromu</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kurashiki Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hajime</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Department of Rheumatology, Niigata Rheumatic Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeyoshi</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Osaka Minami Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Nakayama</LastName>
        <Affiliation>Department of Orthopaedic Surgery, International University of Health and Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Nishida</LastName>
        <Affiliation>Locomotive Pain Center, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Mochizuki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kamagaya General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosuke</FirstName>
        <LastName>Ebina</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Osaka University Faculty of Medicine Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihisa</FirstName>
        <LastName>Kojima</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Nagoya University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takumi</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Orthopaedic Surgery, University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayako</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Toho University Omori Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Arata</FirstName>
        <LastName>Nakajima</LastName>
        <Affiliation>Department of Orthopaedic Surgery and Rehabilitation, Toho University Sakura Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Kaneko</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Nagoya Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Isao</FirstName>
        <LastName>Matsushita</LastName>
        <Affiliation>Department of Rehabilitation Medicine, Kanazawa Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryota</FirstName>
        <LastName>Hara</LastName>
        <Affiliation>The Center for Rheumatic Diseases, Nara Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Sakuraba</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kyushu Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukio</FirstName>
        <LastName>Akasaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsukasa</FirstName>
        <LastName>Matsubara</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Matsubara Mayflower Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichi</FirstName>
        <LastName>Mochida</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Yokohama City University Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuaki</FirstName>
        <LastName>Kanbe</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Nippori Orthopaedics and Rheumatic Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Natsuko</FirstName>
        <LastName>Nakagawa</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kakogawa Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Murata</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeki</FirstName>
        <LastName>Momohara</LastName>
        <Affiliation>Endowed Course for Advanced Therapy for Musculoskeletal Disorders, Keio University School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective This study aimed to investigate whether discontinuation of biological or targeted synthetic antirheumatic disease-modifying drugs (bDMARDs or tsDMARDs) influences the incidence of postoperative complications in patients with rheumatoid arthritis (RA) undergoing orthopedic surgery.&lt;br&gt;
Methods A retrospective multicenter cohort study including patients receiving bDMARDs or tsDMARDs who underwent orthopedic surgery was conducted. Data collected encompassed the duration of drug discontinuation and postoperative adverse events, such as delayed wound healing, surgical site infection (SSI), disease flare-ups, and mortality. The association between drug discontinuation and these outcomes was analyzed. Multivariate analyses were conducted to identify potential risk factors for these events.&lt;br&gt;
Results A total of 2,060 cases were initially enrolled. After applying inclusion and exclusion criteria, data from 1,953 patients were analyzed. No significant differences were observed between the groups regarding delayed wound healing, SSI, or mortality. However, the incidence of disease flare-ups was substantially higher in the drug discontinuation group and in the interleukin (IL)-6 inhibitor group. Multivariate analysis identified that tumor necrosis factor α and IL-6 inhibitor use was associated with a higher risk of delayed wound healing relative to T-cell function modifiers.&lt;br&gt;
Conclusion In orthopedic surgery for patients with RA, maintaining the standard or the half of administration interval of bDMARD appears safe in the preoperative period. However, the drug discontinuation may increase the risk of postoperative flare-ups, particularly with IL-6 inhibitors. In addition, T-cell function modifiers may be associated with a lower risk of delayed wound healing, suggesting their safety profile in this context.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Rheumatoid arthritis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Orthopaedic surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">DMARD</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Perioperative complications</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1422-0067</Issn>
      <Volume>26</Volume>
      <Issue>19</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Critical Requirement of Senescence-Associated CCN3 Expression in CD44-Positive Stem Cells for Osteoarthritis Progression</ArticleTitle>
    <FirstPage LZero="delete">9630</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Janvier</FirstName>
        <LastName>Habumugisha</LastName>
        <Affiliation>Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuichiro</FirstName>
        <LastName>Okuda</LastName>
        <Affiliation>Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuki</FirstName>
        <LastName>Hirose</LastName>
        <Affiliation>Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miho</FirstName>
        <LastName>Kuwahara</LastName>
        <Affiliation>Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ziyi</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Department of Molecular Biology and Biochemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuaki</FirstName>
        <LastName>Ono</LastName>
        <Affiliation>Department of Oral Rehabilitation and Regenerative Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Kamioka</LastName>
        <Affiliation>Department of Orthodontics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takako</FirstName>
        <LastName>Hattori</LastName>
        <Affiliation>Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Osteoarthritis (OA) is a degenerative joint disease characterized by progressive cartilage breakdown, synovial inflammation, and subchondral bone remodeling. Previous studies have shown that cellular communication network factor 3 (CCN3) expression increases with age in cartilage, and its overexpression promotes OA-like changes by inducing senescence-associated secretory phenotypes. This study aimed to investigate the effect of Ccn3 knockout (KO) on OA development using a murine OA model. Destabilization of the medial meniscus (DMM) surgery was performed in wild-type (WT) and Ccn3-KO mice. Histological scoring and staining were used to assess cartilage degeneration and proteoglycan loss. Gene and protein expressions of catabolic enzyme (Mmp9), hypertrophic chondrocyte marker (Col10a1), senescence marker, and cyclin-dependent kinase inhibitor 1A (Cdkn1a) were evaluated. Single-cell RNA sequencing (scRNA-seq) data from WT and Sox9-deficient cartilage were reanalyzed to identify Ccn3+ progenitor populations. Immunofluorescence staining assessed CD44 and Ki67 expression in articular cartilage. The effects of Ccn3 knockdown on IL-1β-induced Mmp13 and Adamts5 expression in chondrocytes were examined in vitro. Ccn3 KO mice exhibited reduced cartilage degradation and catabolic gene expression compared with WT mice post-DMM. scRNA-seq revealed enriched Ccn3-Cd44 double-positive cells in osteoblast progenitor, synovial mesenchymal stem cell, and mesenchymal stem cell clusters. Immunofluorescence showed increased CCN3+/CD44+ cells in femoral and tibial cartilage and meniscus. Ki67+ cells were significantly increased in DMM-treated Ccn3 KO cartilage, mostly CD44+. In vitro Ccn3 knockdown attenuated IL-1β-induced Mmp13 and Adamts5 expressions in chondrocytes. Ccn3 contributes to OA pathogenesis by promoting matrix degradation, inducing hypertrophic changes, and restricting progenitor cell proliferation, highlighting Ccn3 as a potential therapeutic target for OA.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">articular</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cartilage</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mesenchymal stem cells</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">nephroblastoma overexpressed protein</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">osteoarthritis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2076-3921</Issn>
      <Volume>14</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Roles of ROS and NO in Plant Responses to Individual and Combined Salt Stress and Waterlogging</ArticleTitle>
    <FirstPage LZero="delete">1455</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Taufika Islam</FirstName>
        <LastName>Anee</LastName>
        <Affiliation>Department of Materials and Life Sciences, Faculty of Science and Technology, Sophia University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nasser A.</FirstName>
        <LastName>Sewelam</LastName>
        <Affiliation>Botany Department, Faculty of Science, Tanta University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nonnatus S.</FirstName>
        <LastName>Bautista</LastName>
        <Affiliation>Institute of Biological Sciences, College of Arts and Sciences, University of the Philippines Los Baños</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Hirayama</LastName>
        <Affiliation>Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuhiro</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Materials and Life Sciences, Faculty of Science and Technology, Sophia University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>During the climate change era, plants are increasingly exposed to multiple environmental challenges occurring simultaneously or sequentially. Among these, salt stress and waterlogging are two major factors that severely constrain crop productivity worldwide and often occur together. To survive under such conditions, plants have evolved sophisticated systems to scavenge harmful levels of reactive oxygen species (ROS). Despite their cytotoxic potential, ROS also act as key signaling molecules that interact with nitric oxide (NO), Ca2+, protein kinases, ion homeostasis pathways, and plant hormones. These signaling and acclimatory mechanisms are closely associated with the functions of energy-regulating organelles—chloroplasts and mitochondria—which are major sources of ROS under both individual and combined stresses. While many of these responses are shared between salt stress, waterlogging and their combination, it is likely that specific signaling mechanisms are uniquely activated when both stresses occur together—mechanisms that cannot be inferred from responses to each stress alone. Such specificity may depend on precise coordination among organelle-derived signals and the tight regulation of their cross-communication. Within this network, ROS and NO likely serve as central hubs, fine-tuning the integration of multiple signaling pathways that enable plants to adapt to complex and fluctuating stress environments.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">chloroplasts</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mitochondria</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">nitric oxide (NO)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">reactive oxygen species (ROS)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">salt stress</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">stress combination waterlogging</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1865-7257</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Avoiding splenectomy in splenic sclerosing angiomatoid nodular transformation through endoscopic ultrasound-guided tissue acquisition: a 36-month follow-up case report</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takaki</FirstName>
        <LastName>Okuyama</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosaku</FirstName>
        <LastName>Morimoto</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shogo</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayoshi</FirstName>
        <LastName>Miyake</LastName>
        <Affiliation>Department of Pathology, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Satomi</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Takei</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shogo</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuta</FirstName>
        <LastName>Takenaka</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>A 48-mm splenic mass was incidentally discovered in a 78-year-old man upon computed tomography. Follow-up imaging at 12 months revealed enlargement to 60 mm, prompting endoscopic ultrasound-guided tissue acquisition with a 22-gauge needle. Histopathological analysis confirmed that it was a sclerosing angiomatoid nodular transformation. The patient was asymptomatic and had no hematologic abnormalities; therefore, splenectomy was not performed. After biopsy, the lesion regressed from 60 mm to 46 mm, possibly owing to hematoma formation or vascular disruption, and remained stable during 36 months of follow-up. Although splenectomy has been performed in most reported cases of sclerosing angiomatoid nodular transformation because of diagnostic uncertainty, a few recent reports have demonstrated that sclerosing angiomatoid nodular transformation can be diagnosed by endoscopic ultrasound-guided tissue acquisition, thereby avoiding splenectomy. This case highlights the diagnostic utility of endoscopic ultrasound-guided tissue acquisition and supports spleen-preserving management for biopsy-proven sclerosing angiomatoid nodular transformation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Sclerosing angiomatoid nodular transformation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Spleen</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Endoscopic ultrasound-guided tissue acquisition</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Conservative management</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Biopsy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1473-0502</Issn>
      <Volume>64</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Novel leukocytapheresis method using highly concentrated sodium citrate solution for the manufacturing of tisagenlecleucel</ArticleTitle>
    <FirstPage LZero="delete">104265</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Wataru</FirstName>
        <LastName>Kitamura</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Abe</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Ikeuchi</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kana</FirstName>
        <LastName>Washio</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumio</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Division of Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuharu</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>For the manufacturing of tisagenlecleucel (tisa-cel) requires the non-mobilized mononuclear cell collection (MNC). CD3+ cell collection is performed using the same protocol as autologous peripheral blood stem cell harvest (auto-PBSCH), but this procedure necessitates the same target CD3+ cell yields regardless of age or body weight, which may take several days especially in pediatric and small female patients with low white blood cell counts. We previously demonstrated a novel method using highly concentration sodium citrate (HSC), which reduced the need for an anticoagulant (AC) solution and shortened the procedure time in auto-PBSCH. This novel method was expected to offer advantages for smaller patients, prompting us to investigate its application in leukocytapheresis for the manufacturing of tisa-cel. We retrospectively analyzed consecutive leukocytapheresis data obtained using Spectra Optia continuous MNC mode between November 2022 and June 2024 at our institution (n = 9). In six of nine patients, pre-leukocytapheresis CD3+ cell counts were less than 500 /μL, but all could obtain the target CD3+ cell yields in one day upon processing blood volume adjustment. When we compared patients who had received CD3+ cell collection using normal-concentration sodium citrate (NSC) as our previously reported using propensity score-matched pair analysis, the total AC solution volume was significantly lower (1168 vs. 316 mL, p &lt; 0.001) and procedure time was significantly shorter (254 vs. 228 min, p = 0.04) in the HSC group compared to the NSC group. In conclusion, this procedure was also useful for non-mobilized MNC. Our findings warrant validation in a larger patient cohort.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Chimeric antigen receptor T cell therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Anticoagulant</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Acid citrate dextrose solution A</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Highly concentrated sodium citrate</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>8</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Conversion to Hip Arthroplasty After Internal Fixation Failure in an Intertrochanteric Femoral Fracture: A Case Report</ArticleTitle>
    <FirstPage LZero="delete">e90112</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shiro</FirstName>
        <LastName>Fukuoka</LastName>
        <Affiliation>Department of Orthopedics, Kagawa Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoo</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Orthopedics, Kagawa Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoki</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Orthopedics, Kagawa Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Kawasaki</LastName>
        <Affiliation>Department of Orthopedic Surgery, Kagawa Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Intertrochanteric femoral fractures are mainly managed by internal fixation. However, failures such as over-telescoping, cut-out, nonunion, or implant failure can occur, especially in osteoporotic elderly patients. We report the case of a patient in whom we performed artificial hip replacement surgery after fixation failure following internal fixation of an intertrochanteric femoral fracture. We report the case of an 85-year-old woman who sustained a left intertrochanteric femoral fracture treated with a dynamic hip screw (DHS). One week postoperatively, radiographs revealed over-telescoping of the lag screw. The patient did not complain of pain, but she underwent conversion to cemented bipolar hemiarthroplasty under general anesthesia. One possible cause of over-telescoping of the lag screw after surgery was that the longitudinal fracture line in the calcar of the proximal bone fragment, as seen in the initial CT image, may have extended horizontally at the neck level. During surgery, a fracture at the same site caused the anterior medial fragment to fail, resulting in a coronal shear fracture and fixation failure. When a longitudinal fracture line is observed in the calcar of the proximal fragment, it is necessary to keep in mind that it may extend horizontally at the neck level.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">arthroplasty</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">coronal shear fracture</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">double jaws sign</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fixation failure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">intertrochanteric femoral fracture</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Case of Charcot Spine Arthropathy at the Lumbosacral Level in a Patient With Ankylosis of the Spine</ArticleTitle>
    <FirstPage LZero="delete">e80656</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yoshiaki</FirstName>
        <LastName>Oda</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Uotani</LastName>
        <Affiliation>Department of Musculoskeletal Traumatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Tetsunaga</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Shinohara</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopedic Surgery, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Charcot spinal arthropathy, a rare refractory progressive disease, is characterized by symptoms such as pain, deformity, and neurological impairment, which can significantly reduce functional ability, quality of life, and life expectancy. We report a case of Charcot spine at the L5/S1 level with long segment ankylosis to the L5 vertebra. We first performed thorough debridement via a posterior approach. We used antibiotic-containing cement as a spacer to fill the dead space, facilitating the second surgery approach. In the second surgery, transdiscal screws, which have a low profile and strong force, were used as anchors, and bulk bone harvested from both iliac bones was grafted to the intervertebral space. The lumbosacral alignment was kyphotic, and the patient could sit and move independently. Disimpaction was impossible, and a stoma had to be created.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">ankylosing spine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">charcot spine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">charcot spine arthropathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lumbosacral segment</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">paraplegia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">transdiscal screw</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Mid-term Clinical and Radiographic Outcomes of the Actis Total Hip System: A Retrospective Study</ArticleTitle>
    <FirstPage LZero="delete">e77632</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yasutaka</FirstName>
        <LastName>Masada</LastName>
        <Affiliation>Department of Medical Materials for Musculoskeletal Reconstruction, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomonori</FirstName>
        <LastName>Tetsunaga</LastName>
        <Affiliation>Department of Musculoskeletal Health Promotion, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuki</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Medical Materials for Musculoskeletal Reconstruction, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Koura</LastName>
        <Affiliation>Department of Medical Materials for Musculoskeletal Reconstruction, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Medical Materials for Musculoskeletal Reconstruction, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuichiro</FirstName>
        <LastName>Okuda</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Tetsunaga</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Yokoyama</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Okazaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction&lt;br&gt;
Implant technology for total hip arthroplasty (THA) was developed to improve hip function and patient satisfaction. Actis (DePuy Synthes, Warsaw, IN, USA) is a short fit-and-fill titanium stem, with a medial-collared and triple-taper (MCTT) geometry, that is fully coated with hydroxyapatite (HA). We evaluated the radiographic and clinical outcomes of the Actis Total Hip System during a mean follow-up of five years.&lt;br&gt;
Patients and methods&lt;br&gt;
We retrospectively analyzed data from 80 patients (14 male and 66 female, mean age: 65 ± 8.4 years) who underwent primary THA using Actis stems (anterolateral approach, 60 hips; posterior approach, 20 hips). Radiographs were obtained postoperatively and at the time of the final examination. Radiographic assessments included the alignment of the femoral stem, spot welds, stress shielding, cortical hypertrophy, subsidence (&gt;2 mm), radiolucent line, pedestal formation, Dorr type, canal fill ratio (CFR), and stem fixation. Clinical evaluation included the Japanese Orthopaedic Association Hip-Disease Evaluation Questionnaire (JHEQ) and Harris Hip Score (HHS).&lt;br&gt;
Results&lt;br&gt;
The mean follow-up period was 64.0 ± 6.0 months. No significant differences were observed in the alignment of the femoral components between approaches. Of the 80 hips, 53 (66.3%) showed radiographic signs of stem osseointegration, predominantly in the mid-distal region of the stem at the final follow-up. Multiple logistic regression analysis revealed that younger age and a higher CFR (20 mm proximal to the lesser trochanter) were associated with the presence of spot welds. Mild stress shielding occurred in 25 hips (31.3%), and no patient experienced severe stress shielding. All stems were fixed by bone on growth. The JHEQ and HHS significantly improved at the final assessment.&lt;br&gt;
Conclusion&lt;br&gt;
At the five-year follow-up, patients who received the Actis Total Hip System during THA had good radiographic and clinical outcomes.&lt;br&gt;</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">actis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hydroxyapatite</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mid-term outcome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">spot welds</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">stem</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">total hip arthroplasty</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1434-3916</Issn>
      <Volume>145</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Changes in the anatomical positions of the femoral nerve and artery in the lateral and supine positions: a multicenter retrospective study</ArticleTitle>
    <FirstPage LZero="delete">373</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryuichiro</FirstName>
        <LastName>Okuda</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomonori</FirstName>
        <LastName>Tetsunaga</LastName>
        <Affiliation>Department of Musculoskeletal Health Promotion, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuki</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Medical Materials for Musculoskeletal Reconstruction, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Tetsunaga</LastName>
        <Affiliation>Department of Sports Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Koura</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasutaka</FirstName>
        <LastName>Masada</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisanori</FirstName>
        <LastName>Ikuma</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kagawa Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Komatsubara</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Okazaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction Femoral nerve palsy and femoral artery injury are serious complications of total hip arthroplasty. However, few studies have compared the anatomical positions of these structures in different patient positions. This study aimed to compare the anatomical positions of the femoral nerve and artery in the lateral and supine positions.&lt;br&gt;
Materials and methods This multicenter retrospective study included 111 patients who underwent lateral and supine computed tomography (CT) from 2016 to 2023. CT images were reconstructed in the anterior pelvic plane. The horizontal distance from the anterior margin of the acetabulum to the femoral nerve (Distance N) and femoral artery (Distance A) was measured. The difference in Distance N between the two positions (ΔLateral–supine Distance N) was calculated by subtracting the supine value from the lateral value.&lt;br&gt;
Results The average Distance N was 26.5 ± 5.1 mm in the lateral position and 21.1 ± 4.4 mm in the supine position, with the nerve located significantly closer to the acetabulum in the supine position (P &lt; 0.001). Similarly, the average Distance A was 26.8 ± 5.4 mm in the lateral position and 20.4 ± 4.9 mm in the supine position (P &lt; 0.001). Multiple regression analysis showed that Distance N in the lateral position was significantly shorter in female patients and those with low body weight. In addition, low body weight correlated with a smaller ΔLateral–supine Distance N.&lt;br&gt;
Conclusions The femoral nerve and artery are located closer to the anterior margin of the acetabulum in the supine position than in the lateral position. Low body weight was an independent predictor of shorter Distance N in both positions and a smaller ΔLateral–supine Distance N. These findings underscore the importance of considering patient positioning during total hip arthroplasty, particularly in patients with low body weight, to reduce neurovascular risks.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Total hip arthroplasty</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Femoral artery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Femoral nerve</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Computed tomography</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Lateral position</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Supine position</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Vesicular Glutamate Transporter 3 Is Involved in Glutamatergic Signalling in Podocytes</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Naoko</FirstName>
        <LastName>NISHII</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Studies on the functional roles of γδ T cells in the early phase of acute avian coccidiosis</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>LE VIET QUAN</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The X-ray induced quenching of the thorium-229 isomer states in a CaF2 crystal host</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ming</FirstName>
        <LastName>Guan</LastName>
        <Affiliation>Graduate School of Natural Science and Technology, Okayama university</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Co-precipitating calcium phosphate as oral detoxification of cadmium</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">AHMAD</FirstName>
        <LastName>BIKHARUDIN</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Clinical Prediction Models for Upper Airway Volume Based on Soft Palate and Airway Lumen Dimensions in Adults With Varying Vertical Skeletal Patterns</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>HABUMUGISHA JANVIER</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Impacts of Dental Follicle Cells and Periodontal Ligament Cells on the Bone Invasion of Well-Differentiated Oral Squamous Cell Carcinoma</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">ANQI</FirstName>
        <LastName>CHANG</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Importance of Blood Glucose Measurement for Predicting the Prognosis of Long COVID：A Retrospective Study in Japan</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sho</FirstName>
        <LastName>YOKOYAMA</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Examination of yield, bacteriolytic activity and cold storage of linker deletion mutants based on endolysin S6_ORF93 derived from Staphylococcus giant bacteriophage S6</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sosuke</FirstName>
        <LastName>MUNETOMO</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>High Antigenicity for Treg Cells Confers Resistance to PD-1 Blockade Therapy via High PD-1 Expression in Treg Cells</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiroaki</FirstName>
        <LastName>MATSUURA</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Somatic mutations in tumor-infiltrating lymphocytes impact on antitumor immunity </ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Fumiaki</FirstName>
        <LastName>MUKOHARA</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Genomic landscape and clinical impact of homologous recombination repair gene mutation in small bowel adenocarcinoma</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshiki</FirstName>
        <LastName>OZATO</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Tumor microvessels with specific morphology as a prognostic factor in esophageal squamous cell carcinoma</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>HNIN THIDA TUN</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Alteration of perineuronal nets and parvalbumin interneurons in prefrontal cortex and hippocampus, and correlation with blood corticosterone in activity-based anorexia model mice</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>NGUYEN DUY HOANG</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Cancer‑associated fibroblasts promote pro‑tumor functions of neutrophils in pancreatic cancer via IL‑8: potential suppression by pirfenidon</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tomohiko</FirstName>
        <LastName>YAGI</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>ADAR1-high tumor-associated macrophages induce drug resistance and are therapeutic targets in colorectal cancer</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hibiki</FirstName>
        <LastName>OTSUKI (UMEDA)</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Efficacy of amivantamab, a bi-specific antibody targeting EGFR and MET, in ALK-rearranged non-small-cell lung cancer cell lines</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>NISHI</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>HIF‐PH inhibitors induce pseudohypoxia in T cells and suppress the growth of microsatellite stable colorectal cancer by enhancing antitumor immune responses</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">YUEHUA</FirstName>
        <LastName>CHEN</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Application of intratympanic steroid injection as salvage therapy for idiopathic sudden sensorineural hearing loss</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yasutoshi</FirstName>
        <LastName>KOMATSUBARA</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Novel treatment strategy targeting interleukin-6 induced by cancer associated fibroblasts for peritoneal metastasis of gastric cancer</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ema</FirstName>
        <LastName>MITSUI</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>KOBAYASHI</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Evaluation and processing of physical properties of anti-calcified glutaraldehyde-treated three-dimensional cultured cartilage tissues</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yohei</FirstName>
        <LastName>KITAGUCHI</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Efficient diagnosis for endoscopic remission in Crohn’s diseases by the combination of three non-invasive markers</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>TAKEI</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Induction Therapy With Oral Tacrolimus Provides Long-Term Benefit in Thiopurine-Naïve Refractory Ulcerative Colitis Patients Despite Low Serum Albumin Levels</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shoko</FirstName>
        <LastName>IGAWA</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Osteosarcoma cell–derived CCL2 facilitates lung metastasis via accumulation of tumor-associated macrophages</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiroya</FirstName>
        <LastName>KONDO</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Changes in body mass index during early childhood on school-age asthma prevalence classified by phenotypes and sex</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>YABUUCHI</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Grafting Islets to a Prevascularized Subcutaneous Site to Improve Transplant Survival and Function: A Mouse Model</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>OKADA</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Exploring factors influencing the hearing test and hearing aid adoption among Japanese older adults: Implications of recognizing the hearing loss–dementia relationship</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ichiro</FirstName>
        <LastName>FUKUMASU</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>LRP4 and Agrin Are Modulated by Cartilage Degeneration and Involved in β-Catenin Signaling in Human Articular Chondrocytes</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shuichi</FirstName>
        <LastName>NANIWA</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Impact of Birth Order on Paediatric Allergic Diseases: A National Birth Cohort in Japan</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Mitsuro</FirstName>
        <LastName>KOBAYASHI</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Changes of leucine-rich alpha 2 glycoprotein could be a marker of changes of endoscopic and histologic activity of ulcerative colitis</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>AOYAMA</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Repeated non-hemorrhagic and non-contusional mild traumatic brain injury in rats elicits behavioral impairment with microglial activation, astrogliosis, and tauopathy: Reproducible and quantitative model of chronic traumatic encephalopathy</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Chiaki</FirstName>
        <LastName>SUGAHARA</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1648-9144</Issn>
      <Volume>61</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Accuracy Verification of a Computed Tomography-Based Navigation System for Total Hip Arthroplasty in Severe Hip Dysplasia: A Simulation Study Using 3D-Printed Bone Models of Crowe Types II, III, and IV</ArticleTitle>
    <FirstPage LZero="delete">973</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryuichiro</FirstName>
        <LastName>Okuda</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomonori</FirstName>
        <LastName>Tetsunaga</LastName>
        <Affiliation>Department of Musculoskeletal Health Promotion, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuki</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Tetsunaga</LastName>
        <Affiliation>Department of Sports Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Koura</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasutaka</FirstName>
        <LastName>Masada</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Okazaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background and Objective: The use of computed tomography (CT)-based navigation systems has been shown to improve surgical accuracy in total hip arthroplasty. However, there is limited literature available about the application of CT-based navigation systems in severe hip dysplasia. This study aimed to evaluate the accuracy of a CT-based navigation system in patients with severe hip dysplasia using three-dimensional (3D)-printed bone models. Methods: 3D-printed bone models were generated from CT data of patients with severe hip dysplasia (Crowe type II, 10 hips; type III, 10 hips; and type IV, 10 hips). The accuracy of automatic segmentation, success rate, point-matching accuracy across different registration methods, and deviation values at reference points after registration were assessed. Results: For the combined cohort of Crowe II, III, and IV cases (n = 30), the Dice Similarity Coefficient and Jaccard Index were 0.99 ± 0.01 and 0.98 ± 0.02, respectively. These values indicate a high level of segmentation accuracy. The “Matching with true and false acetabulum + iliac crest” method achieved a 100% success rate across all groups, with mean deviations of 0.08 ± 0.28 mm in the Crowe II group, 0.12 ± 0.33 mm in the Crowe III group, and 0.14 ± 0.50 mm in the Crowe IV group (p = 0.572). In the Crowe IV group, the anterior superior iliac spine deviation was significantly lower using the “Matching with true and false acetabulum + iliac crest” method compared to the “Matching with true and false acetabulum” method (0.28 ± 0.49 mm vs. 3.29 ± 2.56 mm, p &lt; 0.05). Conclusions: This study demonstrated the high accuracy of automatic AI-based segmentation, with a Dice Similarity Coefficient of 0.99 ± 0.01 and a Jaccard Index of 0.98 ± 0.02 in the combined cohort of Crowe type II, III, and IV cases (n = 30). The matching success rate was 100%, with additional points on the iliac crest, which improved matching accuracy and reduced deviations, depending on the case.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">total hip arthroplasty</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CT-based navigation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bone model</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">artificial intelligence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Ortoma Treatment Solution</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Subcutaneous and Periorbital Emphysema Following a Dental Procedure</ArticleTitle>
    <FirstPage LZero="delete">e83089</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Obara</LastName>
        <Affiliation>Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Nojima</LastName>
        <Affiliation>Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuki</FirstName>
        <LastName>Nakatsuji</LastName>
        <Affiliation>Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Hongo</LastName>
        <Affiliation>Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Yumoto</LastName>
        <Affiliation>Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsunori</FirstName>
        <LastName>Nakao</LastName>
        <Affiliation>Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Subcutaneous emphysema following dental procedures is rare. We present the case of a young, healthy woman who was transferred from a dental clinic to our emergency department due to sudden swelling of the left orbit immediately after a dental procedure involving the use of the dental air and water syringe. The diagnosis of subcutaneous facial emphysema was made based on the patient's history, physical examination, and computed tomography imaging. The patient received prophylactic amoxicillin, and the lesion resolved completely in one week. Prompt clinical suspicion and a thorough evaluation of the signs and symptoms, including a detailed clinical history, are crucial for diagnosing subcutaneous emphysema following a dental procedure.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">air pressure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">antibiotic prophylaxis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dental procedures</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">operative</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">subcutaneous emphysema</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2040-1116</Issn>
      <Volume>16</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Relation between obesity and health disorders as revealed by the J-ORBIT clinical information collection system directly linked to electronic medical records (J-ORBIT 1)</ArticleTitle>
    <FirstPage LZero="delete">1100</FirstPage>
    <LastPage>1111</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Seiji</FirstName>
        <LastName>Nishikage</LastName>
        <Affiliation>Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yushi</FirstName>
        <LastName>Hirota</LastName>
        <Affiliation>Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Nakagawa</LastName>
        <Affiliation>Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masamichi</FirstName>
        <LastName>Ishii</LastName>
        <Affiliation>Center for Medical Informatics Intelligence, National Center for Global Health and Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuru</FirstName>
        <LastName>Ohsugi</LastName>
        <Affiliation>Diabetes and Metabolism Information Center, Research Institute, National Center for Global Health and Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiichi</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Division of Medical Informatics, Department of Internal Medicine, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kai</FirstName>
        <LastName>Yoshimura</LastName>
        <Affiliation>Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akane</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomofumi</FirstName>
        <LastName>Takayoshi</LastName>
        <Affiliation>Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Diabetes, Endocrinology, and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Yabe</LastName>
        <Affiliation>Department of Diabetes, Endocrinology, and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Munehide</FirstName>
        <LastName>Matsuhisa</LastName>
        <Affiliation>Diabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Eguchi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukihiro</FirstName>
        <LastName>Fujita</LastName>
        <Affiliation>Department of Medicine, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Kume</LastName>
        <Affiliation>Department of Medicine, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Maegawa</LastName>
        <Affiliation>Department of Medicine, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kana</FirstName>
        <LastName>Miyake</LastName>
        <Affiliation>Department of Diabetes and Metabolic Disease, The University of Tokyo Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuhiro</FirstName>
        <LastName>Shojima</LastName>
        <Affiliation>Department of Diabetes and Metabolic Disease, The University of Tokyo Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshimasa</FirstName>
        <LastName>Yamauchi</LastName>
        <Affiliation>Department of Diabetes and Metabolic Disease, The University of Tokyo Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koutaro</FirstName>
        <LastName>Yokote</LastName>
        <Affiliation>Chiba University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohjiro</FirstName>
        <LastName>Ueki</LastName>
        <Affiliation>Diabetes Research Center, Research Institute, National Center for Global Health and Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kengo</FirstName>
        <LastName>Miyo</LastName>
        <Affiliation>Center for Medical Informatics Intelligence, National Center for Global Health and Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wataru</FirstName>
        <LastName>Ogawa</LastName>
        <Affiliation>Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Aims/Introduction: Obesity triggers various health disorders, but information on these disorders in real-world settings remains limited. To address this knowledge gap, we developed a database directly linked to electronic medical records (EMRs). We here present the baseline data for this database, designated Japan Obesity Research Based on electronIc healTh Records (J-ORBIT).&lt;br&gt;
Materials and Methods: Individuals with obesity disease diagnosed according to the criteria of the Japan Society for the Study of Obesity were registered in J-ORBIT from seven medical centers in Japan. We analyzed the relationship between body mass index (BMI), clinical characteristics, and the prevalence of obesity-related health disorders in this cohort.&lt;br&gt;
Results: Data were obtained from 1,169 individuals, with a mean (±SD) age of 56.9 ± 15.3 years and a BMI of 31.4 ± 6.1 kg/m2. The prevalence of health disorders varied substantially across BMI categories, with a higher BMI being associated with an increased prevalence of hyperuricemia or gout, obstructive sleep apnea syndrome or obesity hypoventilation syndrome, musculoskeletal disorders, and obesity-related kidney disease, as well as with a higher frequency of both a family history of obesity and of a history of childhood obesity. Among individuals with a BMI of ≥25 kg/m2, the prevalence of hypertension and dyslipidemia did not increase with BMI, whereas that of glucose intolerance decreased with increasing BMI.&lt;br&gt;
Conclusions: The J-ORBIT system, which collects clinical data in real time directly from EMRs, has the potential to provide insight into obesity and its associated health conditions, thereby contributing to improved care of affected individuals.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Body mass index</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Electronic medical records</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Obesity</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Hypoglycemia and hyperinsulinemia induced by phenolic uremic toxins in CKD and DKD patients</ArticleTitle>
    <FirstPage LZero="delete">5762</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yoshiyasu</FirstName>
        <LastName>Tongu</LastName>
        <Affiliation>Tohoku University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Kasahara</LastName>
        <Affiliation>Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasutoshi</FirstName>
        <LastName>Akiyama</LastName>
        <Affiliation>Laboratory of Oncology, Pharmacy Practice and Sciences, Tohoku University Graduate School of Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hsin-Jung</FirstName>
        <LastName>Ho</LastName>
        <Affiliation>Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yotaro</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Laboratory of Oncology, Pharmacy Practice and Sciences, Tohoku University Graduate School of Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryota</FirstName>
        <LastName>Kujirai</LastName>
        <Affiliation>Laboratory of Oncology, Pharmacy Practice and Sciences, Tohoku University Graduate School of Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Kikuchi</LastName>
        <Affiliation>Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Nata</LastName>
        <Affiliation>Department of Medical Biochemistry, School of Pharmacy, Iwate Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Kanzaki</LastName>
        <Affiliation>Department of Biomedical Engineering, Tohoku University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenshin</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Tohoku University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shun</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chiharu</FirstName>
        <LastName>Kawabe</LastName>
        <Affiliation>Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yui</FirstName>
        <LastName>Miyata</LastName>
        <Affiliation>Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shun</FirstName>
        <LastName>Itai</LastName>
        <Affiliation>Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Toyohara</LastName>
        <Affiliation>Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chitose</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuhiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Division of Nephrology, Endocrinology, and Vascular Medicine, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihisa</FirstName>
        <LastName>Tomioka</LastName>
        <Affiliation>Laboratory of Oncology, Pharmacy Practice and Sciences, Tohoku University Graduate School of Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takaaki</FirstName>
        <LastName>Abe</LastName>
        <Affiliation>Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Patients with end-stage renal disease have lower fasting plasma glucose and HbA1c levels, with significantly higher insulin levels. For a long time, it has been believed that this higher insulin level in renal failure is due to decreased insulin clearance caused by reduced renal function. However, here we reported that accumulation of the gut microbiota-derived uremic toxin, phenyl sulfate (PS) in the renal failure, increased insulin secretion from the pancreas by enhanced glucose-stimulated insulin secretion. Other endogenous sulfides compounds which accumulated as in the renal failure also increased glucose-stimulated insulin secretion from β﻿-cell. With RNA-seq analyses and gene knock down, we demonstrated that insulin secretion evoked by PS was mediated by Ddah2. In addition, we also found that PS increased insulin resistance through lncRNA expression and Erk phosphorylation in the adipocytes. To confirm the relationship between PS and glucose metabolism in human, we recruited 2 clinical cohort studies (DKD and CKD) including 462 patients, and found that there was a weak negative correlation between PS and HbA1c. Because these trials did not measure fasting insulin level, we alternatively used the urinary C-peptide/creatinine ratio (UCPCR) as an indicator of insulin resistance. We found that PS may induce insulin resistance in patients with eGFR &lt; 60 mL/min/1.73 m2. These data suggest that the accumulation of uremic toxins modulates glucose metabolism and induced insulin resistance in CKD and DKD patients. Considering HbA1c as a reflection of chronic hyperglycemia and UCPCR as a reflection of chronic hyperinsulinemia, our findings indicate that PS is negatively associated with hyperglycemia independent of CKD, and positively associated with hyperinsulinemia in DKD patients.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">CKD, DKD, Phenyl sulfate, Uremic toxin, Insulin secretion, Insulin resistance, Gut microbiota</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Frontiers Media SA</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1664-3224</Issn>
      <Volume>16</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A pilot transcriptomic study of a novel multitargeted BRT regimen for anti–MDA5 antibody-positive dermatomyositis: improving survival over conventional therapy</ArticleTitle>
    <FirstPage LZero="delete">1568338</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Moe</FirstName>
        <LastName>Tokunaga</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Nakai</LastName>
        <Affiliation>Division of Rheumatology, Center for Autoimmune Diseases, Japanese Red Cross Okayama Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiharu</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>DNA Chip Research Inc., Medical Laboratory</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitori</FirstName>
        <LastName>Hiratsuka</LastName>
        <Affiliation>DNA Chip Research Inc., Medical Laboratory</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Nakatsue</LastName>
        <Affiliation>Division of Rheumatology and Nephrology, Department of Internal Medicine, Nagaoka Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takako</FirstName>
        <LastName>Saeki</LastName>
        <Affiliation>Division of Rheumatology and Nephrology, Department of Internal Medicine, Nagaoka Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takatsune</FirstName>
        <LastName>Umayahara</LastName>
        <Affiliation>Division of Dermatology, Center for Autoimmune Diseases, Japanese Red Cross Okayama Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Koyama</LastName>
        <Affiliation>Division of Rheumatology, Center for Autoimmune Diseases, Japanese Red Cross Okayama Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis (MDA5-DM) is associated with severe outcomes, primarily due to rapidly progressive interstitial lung disease (RP-ILD), which is often refractory to standard therapies such as calcineurin inhibitors (e.g., tacrolimus) combined with cyclophosphamide (TC-Tx). This study evaluated the efficacy of a novel multitargeted regimen combining baricitinib, rituximab, and tacrolimus (BRT-Tx) in improving survival outcomes for MDA5-DM patients with poor prognostic factors.&lt;br&gt;
Methods: Fourteen MDA5-DM patients with multiple adverse prognostic factors were studied. Seven received the BRT-Tx regimen, and the remaining seven, previously treated with TC-Tx, served as historical controls. Twelve-month survival was assessed. Transcriptome analysis was performed for six patients (BRT=3, TC=3), beginning with cluster analysis to evaluate whether changes in peripheral blood gene expression varied according to treatment or prognosis. Gene ontology analysis characterized expression profiles in survivors and distinguished treatment effects. Alterations in the type I, II, and III interferon signatures were also assessed.&lt;br&gt;
Results: In the TC-Tx group, four of seven patients succumbed to RP-ILD, whereas all seven BRT-Tx patients survived the 12-month observation period. Only one BRT-Tx patient required combined rescue therapies, including plasma exchange, and one case of unexplained limbic encephalitis (LE) occurred. Cytomegalovirus reactivation was observed in both groups (BRT: 5/7; TC: 6/7). Transcriptomic analysis revealed no treatment-specific clustering of differentially expressed genes (DEGs) before and after therapy. However, survivors and nonsurvivors formed distinct clusters, with survivors showing significant posttreatment suppression of B-cell-related gene expression. Moreover, interferon signature scores were significantly lower after treatment in survivors than in nonsurvivors. BRT-Tx effectively suppressed B-cell-mediated immune responses and maintained a low interferon signature, while TC-Tx resulted in nonspecific gene suppression, and in nonsurvivors, an elevated interferon signature was observed.&lt;br&gt;
Conclusion: BRT-Tx has the potential to improve survival in MDA5-DM patients by effectively targeting hyperactive immune pathways. The combination of rituximab and tacrolimus is expected to disrupt B-cell–T-cell interactions and reduce autoantibody production, whereas baricitinib may suppress both IFN and GM-CSF signaling, regulating excessive autoimmunity mediated by cells such as macrophages. Unlike TC-Tx, BRT-Tx avoids cyclophosphamide-associated risks such as infertility and secondary malignancies. Future randomized controlled trials are warranted to validate its efficacy and safety.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">anti-MDA5 antibody-positive dermatomyositis (MDA5-DM)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">JAK inhibitor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">baricitinib</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">rituximab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">multitargeted treatment</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">IFN signature</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">transcriptome analysis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>14</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Association between proteinuria and mineral metabolism disorders in chronic kidney disease: the Japan chronic kidney disease database extension (J-CKD-DB-Ex)</ArticleTitle>
    <FirstPage LZero="delete">27481</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sho</FirstName>
        <LastName>Shimamoto</LastName>
        <Affiliation>Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takako</FirstName>
        <LastName>Nakahara</LastName>
        <Affiliation>Department of Medical Technology, Faculty of Health Science and Technology, Kawasaki University of Medical Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hajime</FirstName>
        <LastName>Nagasu</LastName>
        <Affiliation>Department of Nephrology and Hypertension, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiji</FirstName>
        <LastName>Kishi</LastName>
        <Affiliation>Department of Nephrology and Hypertension, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Nakashima</LastName>
        <Affiliation>Department of Medical Informatics, Graduate School of Medical Science, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Tsuruya</LastName>
        <Affiliation>Department of Nephrology, Nara Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirokazu</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Department of Nephrology, Faculty of Medicine, Saitama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kouichi</FirstName>
        <LastName>Tamura</LastName>
        <Affiliation>Department of Medical Science and Cardiorenal Medicine, Graduate School of Medicine, Yokohama City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ichiei</FirstName>
        <LastName>Narita</LastName>
        <Affiliation>Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoichi</FirstName>
        <LastName>Maruyama</LastName>
        <Affiliation>Department of Nephrology, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichiro</FirstName>
        <LastName>Yano</LastName>
        <Affiliation>Department of General Medicine, Juntendo University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yokoo</LastName>
        <Affiliation>Division of Kidney and Hypertension, Department of Internal Medicine, Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology and Rheumatology, Kanazawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiichiro</FirstName>
        <LastName>Kanda</LastName>
        <Affiliation>Department of Health Data Science, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromi</FirstName>
        <LastName>Kataoka</LastName>
        <Affiliation>Department of Medical Technology, Faculty of Health Science and Technology, Kawasaki University of Medical Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaomi</FirstName>
        <LastName>Nangaku</LastName>
        <Affiliation>Division of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Kashihara</LastName>
        <Affiliation>Department of Nephrology and Hypertension, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Chronic kidney disease-mineral and bone disorder (CKD-MBD) are recognized as a systemic disease affecting the prognosis of patients with CKD. Proper management of CKD-MBD is important to improve the prognosis of patients with CKD. Although proteinuria is recognized as a poor prognostic factor in these patients, few reports have examined its association with CKD-MBD. We examined the association between proteinuria and CKD-MBD using data from the Japan Chronic Kidney Disease Database Extension (J-CKD-DB-Ex). Among the patients registered in the J-CKD-DB-Ex, 30,977 with CKD stages G2–G5 who had serum creatinine, albumin, calcium, and phosphate concentrations measured at least once and urinalysis performed were included. The patients were divided into four groups (negative, 1+, 2+, and 3+) according to the degree of proteinuria. The association between proteinuria and CKD-MBD was examined by a logistic regression analysis. In a model adjusted for age, sex, diabetes, and the estimated glomerular filtration rate (eGFR), the odds ratio of the 3 + group compared with the negative group significantly increased to 2.67 (95% confidence interval, 2.29–3.13) for hyperphosphatemia, 2.68 (1.94–3.71) for hypocalcemia, and 1.56 (1.24–1.98) for hypomagnesemia. Proteinuria is associated with hyperphosphatemia, hypocalcemia, and hypomagnesemia in patients with CKD independently of eGFR.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">CKD-MBD</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Proteinuria</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hyperphosphatemia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hypocalcemia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hypomagnesemia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">J-CKD-DB-Ex</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
</ArticleSet>
